id
stringlengths 1
5
| document_id
stringlengths 5
8
| passages
list | entities
list | events
sequence | coreferences
sequence | relations
sequence |
|---|---|---|---|---|---|---|
72845 | 26527417 | [
{
"id": "72846",
"type": "document",
"text": [
"The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation . BACKGROUND Reabsorption of bile acids from the intestine by ileal bile acid transporter is pivotal for the enterohepatic circulation of BAs and sterol homoeostasis . AIM To assess tolerability and study , bile acid metabolism in a phase 1 trial with the selective ileal bile acid transporter inhibitor A4250 . METHODS A randomised double-blind , single-ascending dose ( SAD ) and multiple-ascending-dose study consisting of five cohorts comprising 40 individuals with a single administration of A4250 ( 0.1 , 0.3 , 1 , 3 , or 10 mg ) or placebo and three cohorts comprising 24 individuals with a 1-week administration of A4250 ( 1 or 3 mg once daily or 1.5 mg twice daily ) or placebo . For the multiple-ascending-dose study , bile acids were measured by HPLC-MS in plasma and faeces , and fibroblast growth factor 19 ( FGF19 ) and 7α-hydroxy-4-cholesten-3-one ( C4 ) were measured in plasma . RESULTS No serious adverse events occurred and all participants finished the trial per protocol . At the end of the multiple-ascending-dose study , plasma total bile acids and FGF19 decreased by 47 % and 76 % , respectively , at 3 mg/day ( P < 0.01 ) , and by 15 % and 16 % , respectively , at 1.5 mg twice daily ( P < 0.05 ) . Plasma C4 and faecal bile acids increased at all dose regimens , by 555 % , 664 % , 292 % and 338 % , 421 % , 420 % , respectively ( P < 0.01-0.05 ) . The primary bile acids cholic and chenodeoxycholic acids constituted the majority of faecal bile acids in the A4250-treated groups . CONCLUSIONS A4250 is well tolerated . By blocking ileal bile acid transporter in the terminal ileum , it highly efficiently interrupts the enterohepatic circulation of BAs , and should be of benefit to patients with cholestatic liver diseases . Clinical Trial registration EudraCT 2013-001175-21 ."
],
"offsets": [
[
0,
1926
]
]
}
] | [
{
"id": "72847",
"type": "Intervention_Pharmacological",
"text": [
"ileal bile acid transporter inhibitor A4250"
],
"offsets": [
[
4,
47
]
],
"normalized": []
},
{
"id": "72848",
"type": "Intervention_Pharmacological",
"text": [
"A4250"
],
"offsets": [
[
42,
47
]
],
"normalized": []
},
{
"id": "72849",
"type": "Outcome_Physical",
"text": [
"serum bile acids"
],
"offsets": [
[
58,
74
]
],
"normalized": []
},
{
"id": "72850",
"type": "Outcome_Other",
"text": [
"tolerability"
],
"offsets": [
[
303,
315
]
],
"normalized": []
},
{
"id": "72851",
"type": "Outcome_Physical",
"text": [
"bile acid metabolism"
],
"offsets": [
[
328,
348
]
],
"normalized": []
},
{
"id": "72852",
"type": "Participant_Sample-size",
"text": [
"40"
],
"offsets": [
[
571,
573
]
],
"normalized": []
},
{
"id": "72853",
"type": "Participant_Sample-size",
"text": [
"24"
],
"offsets": [
[
697,
699
]
],
"normalized": []
},
{
"id": "72854",
"type": "Participant_Condition",
"text": [
"cholestatic liver"
],
"offsets": [
[
1845,
1862
]
],
"normalized": []
}
] | [] | [] | [] |
72855 | 26529471 | [
{
"id": "72856",
"type": "document",
"text": [
"Reducing Sitting Time After Stroke : A Phase II Safety and Feasibility Randomized Controlled Trial . OBJECTIVE To test the safety , feasibility , and effectiveness of reducing sitting time in stroke survivors . DESIGN Randomized controlled trial with attention-matched controls and blinded assessments . SETTING Community . PARTICIPANTS Stroke survivors ( N=35 ; 22 men ; mean age , 66.9±12.7y ) . INTERVENTIONS Four counseling sessions over 7 weeks with a message of sit less and move more ( intervention group ) or calcium for bone health ( attention-matched control group ) . MAIN OUTCOME MEASURES Measures included safety ( adverse events , increases in pain , spasticity , or fatigue ) and feasibility ( adherence to trial protocol ) . Secondary measures included time spent sitting ( including in prolonged bouts ≥30min ) , standing , and stepping as measured by the thigh-worn inclinometer ( 7d , 24h/d protocol ) and time spent in physical activity of at least moderate intensity as measured by a triaxial accelerometer . The Multimedia Activity Recall for Children and Adults was used to describe changes in use of time . RESULTS Thirty-three participants completed the full protocol . Four participants reported falls during the intervention period with no other adverse events . From a baseline average of 640.7±99.6min/d , daily sitting time reduced on average by 30±50.6min/d ( 95 % confidence interval [ CI ] , 5.8-54.6 ) in the intervention group and 40.4±92.5min/d in the control group ( 95 % CI , 13.0-93.8 ) . Participants in both groups also reduced their time spent in prolonged sitting bouts ( ≥30min ) and increased time spent standing and stepping . CONCLUSIONS Our protocol was both safe and feasible . Participants in both groups spent less time sitting and more time standing and stepping postintervention , but outcomes were not superior for intervention participants . Attention matching is desirable in clinical trials and may have contributed to the positive outcomes for control participants ."
],
"offsets": [
[
0,
2024
]
]
}
] | [
{
"id": "72857",
"type": "Intervention_Physical",
"text": [
"reducing sitting time in stroke survivors"
],
"offsets": [
[
167,
208
]
],
"normalized": []
},
{
"id": "72858",
"type": "Outcome_Adverse-effects",
"text": [
"adverse events"
],
"offsets": [
[
628,
642
]
],
"normalized": []
},
{
"id": "72859",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
658,
662
]
],
"normalized": []
},
{
"id": "72860",
"type": "Outcome_Physical",
"text": [
"spasticity , or fatigue )"
],
"offsets": [
[
665,
690
]
],
"normalized": []
},
{
"id": "72861",
"type": "Outcome_Mental",
"text": [
"feasibility ( adherence to trial protocol"
],
"offsets": [
[
695,
736
]
],
"normalized": []
},
{
"id": "72862",
"type": "Outcome_Mental",
"text": [
"spent sitting ( including in prolonged bouts ≥30min )"
],
"offsets": [
[
774,
827
]
],
"normalized": []
},
{
"id": "72863",
"type": "Outcome_Mental",
"text": [
"standing"
],
"offsets": [
[
830,
838
]
],
"normalized": []
},
{
"id": "72864",
"type": "Outcome_Physical",
"text": [
"and"
],
"offsets": [
[
55,
58
]
],
"normalized": []
},
{
"id": "72865",
"type": "Outcome_Mental",
"text": [
"time spent in physical activity"
],
"offsets": [
[
925,
956
]
],
"normalized": []
},
{
"id": "72866",
"type": "Outcome_Mental",
"text": [
"The Multimedia Activity Recall for Children and Adults"
],
"offsets": [
[
1030,
1084
]
],
"normalized": []
},
{
"id": "72867",
"type": "Outcome_Adverse-effects",
"text": [
"reported falls"
],
"offsets": [
[
1213,
1227
]
],
"normalized": []
},
{
"id": "72868",
"type": "Outcome_Adverse-effects",
"text": [
"other adverse events"
],
"offsets": [
[
1267,
1287
]
],
"normalized": []
},
{
"id": "72869",
"type": "Outcome_Mental",
"text": [
"sitting time"
],
"offsets": [
[
176,
188
]
],
"normalized": []
},
{
"id": "72870",
"type": "Outcome_Mental",
"text": [
"time spent in prolonged sitting"
],
"offsets": [
[
1575,
1606
]
],
"normalized": []
},
{
"id": "72871",
"type": "Outcome_Mental",
"text": [
"spent standing and stepping"
],
"offsets": [
[
1643,
1670
]
],
"normalized": []
}
] | [] | [] | [] |
72872 | 2653041 | [
{
"id": "72873",
"type": "document",
"text": [
"Treatments of preterm premature rupture of the membranes : a meta-analysis . The objective of this overview was to critically evaluate published randomized controlled trials on treatments in preterm premature rupture of the membranes . The Oxford data base on perinatal trials , MEDLINE , Excerpta Medica , and Index Medicus were searched . Through primary and secondary review with preset inclusion criteria , two independent judges identified 27 randomized controlled trials , of which 13 met inclusion criteria . The quality of these randomized controlled trials was scored . Five randomized controlled trials regarding antenatal use of corticosteroids to prevent respiratory distress syndrome could be combined meta-analytically and showed a reduction in respiratory distress syndrome in the treatment group ( p = 0.001 ) . However , no significant reduction in respiratory distress syndrome ( p = 0.286 ) was found after one study , with the lowest quality score , was excluded . A significant increase in endometritis and a trend toward an increase in neonatal infections and cesarean section rates were noted with treatment . Tocolysis , prophylactic antibiotics , and other interventions studied were not found to be of proved benefit and therefore should not be used outside of a randomized controlled trial ."
],
"offsets": [
[
0,
1318
]
]
}
] | [
{
"id": "72874",
"type": "Intervention_Pharmacological",
"text": [
"corticosteroids"
],
"offsets": [
[
640,
655
]
],
"normalized": []
},
{
"id": "72875",
"type": "Intervention_Pharmacological",
"text": [
"Tocolysis , prophylactic antibiotics"
],
"offsets": [
[
1133,
1169
]
],
"normalized": []
},
{
"id": "72876",
"type": "Outcome_Physical",
"text": [
"respiratory distress syndrome"
],
"offsets": [
[
667,
696
]
],
"normalized": []
},
{
"id": "72877",
"type": "Outcome_Physical",
"text": [
"respiratory distress syndrome"
],
"offsets": [
[
667,
696
]
],
"normalized": []
},
{
"id": "72878",
"type": "Outcome_Physical",
"text": [
"respiratory distress syndrome"
],
"offsets": [
[
667,
696
]
],
"normalized": []
},
{
"id": "72879",
"type": "Outcome_Physical",
"text": [
"endometritis"
],
"offsets": [
[
1011,
1023
]
],
"normalized": []
},
{
"id": "72880",
"type": "Outcome_Physical",
"text": [
"neonatal infections and cesarean section rates"
],
"offsets": [
[
1058,
1104
]
],
"normalized": []
},
{
"id": "72881",
"type": "Participant_Condition",
"text": [
"preterm premature rupture of the membranes :"
],
"offsets": [
[
14,
58
]
],
"normalized": []
},
{
"id": "72882",
"type": "Participant_Condition",
"text": [
"preterm premature rupture of the membranes ."
],
"offsets": [
[
191,
235
]
],
"normalized": []
}
] | [] | [] | [] |
72883 | 26551184 | [
{
"id": "72884",
"type": "document",
"text": [
"Elective Induction of Labor Compared With Expectant Management of Nulliparous Women at 39 Weeks of Gestation : A Randomized Controlled Trial . OBJECTIVE To evaluate whether the elective induction of labor in nulliparous women with an unfavorable cervix affects the cesarean delivery rate . METHODS We conducted a randomized controlled trial at a tertiary care medical center . Nulliparous woman between 38 0/7 and 38 6/7 weeks of gestation who were least 18 years of age with a singleton gestation and a Bishop score of 5 or less were randomized to elective induction of labor or expectant management . The induction of labor group was induced within 1 week of enrollment but not before 39 0/7 weeks of gestation . The control group continued routine prenatal care with admission for labor or obstetric indication . The primary outcome was cesarean delivery . Assuming a 20 % rate in women in a control group , 80 % power , and a goal to detect a twofold increase to 40 % in the induction of labor group , 162 patients were needed . RESULTS From March 2010 to February 2014 , 82 patients were randomly allocated to induction of labor and 80 to expectant management . Baseline characteristics were similar between groups . The cesarean delivery rate in the induction of labor group was 30.5 % ( 25/82 ) compared with 17.7 % ( 14/79 ) in the expectant management group ( relative risk 1.72 , 95 % confidence interval 0.96-3.06 ) . CONCLUSION In nulliparous women with a Bishop score of 5 or less , elective induction after 39 0/7 weeks of gestation compared with expectant management of pregnancy did not double the rate of cesarean delivery . CLINICAL TRIAL REGISTRACTION ClinicalTrials.gov , www.clinicaltrials.gov , NCT01076062 . LEVEL OF EVIDENCE I ."
],
"offsets": [
[
0,
1752
]
]
}
] | [
{
"id": "72885",
"type": "Intervention_Physical",
"text": [
"Elective Induction of Labor"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "72886",
"type": "Intervention_Physical",
"text": [
"Expectant Management of Nulliparous Women"
],
"offsets": [
[
42,
83
]
],
"normalized": []
},
{
"id": "72887",
"type": "Intervention_Physical",
"text": [
"elective induction of labor"
],
"offsets": [
[
177,
204
]
],
"normalized": []
},
{
"id": "72888",
"type": "Intervention_Physical",
"text": [
"elective induction of labor"
],
"offsets": [
[
177,
204
]
],
"normalized": []
},
{
"id": "72889",
"type": "Intervention_Physical",
"text": [
"expectant management"
],
"offsets": [
[
580,
600
]
],
"normalized": []
},
{
"id": "72890",
"type": "Intervention_Physical",
"text": [
"induction of labor"
],
"offsets": [
[
186,
204
]
],
"normalized": []
},
{
"id": "72891",
"type": "Intervention_Control",
"text": [
"prenatal care with admission for labor"
],
"offsets": [
[
751,
789
]
],
"normalized": []
},
{
"id": "72892",
"type": "Intervention_Control",
"text": [
"obstetric indication"
],
"offsets": [
[
793,
813
]
],
"normalized": []
},
{
"id": "72893",
"type": "Intervention_Physical",
"text": [
"elective induction"
],
"offsets": [
[
177,
195
]
],
"normalized": []
},
{
"id": "72894",
"type": "Intervention_Physical",
"text": [
"expectant management of pregnancy"
],
"offsets": [
[
1561,
1594
]
],
"normalized": []
},
{
"id": "72895",
"type": "Outcome_Physical",
"text": [
"cesarean delivery rate"
],
"offsets": [
[
265,
287
]
],
"normalized": []
},
{
"id": "72896",
"type": "Participant_Sex",
"text": [
"Women"
],
"offsets": [
[
78,
83
]
],
"normalized": []
},
{
"id": "72897",
"type": "Participant_Condition",
"text": [
"Gestation"
],
"offsets": [
[
99,
108
]
],
"normalized": []
},
{
"id": "72898",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
220,
225
]
],
"normalized": []
},
{
"id": "72899",
"type": "Participant_Condition",
"text": [
"unfavorable cervix"
],
"offsets": [
[
234,
252
]
],
"normalized": []
},
{
"id": "72900",
"type": "Participant_Age",
"text": [
"18 years of age"
],
"offsets": [
[
455,
470
]
],
"normalized": []
},
{
"id": "72901",
"type": "Participant_Sample-size",
"text": [
"82 patients"
],
"offsets": [
[
1076,
1087
]
],
"normalized": []
}
] | [] | [] | [] |
72902 | 26551748 | [
{
"id": "72903",
"type": "document",
"text": [
"Effects of therapeutic horse riding on gait cycle parameters and some aspects of behavior of children with autism . We studied effects of therapeutic riding on the development of children with autism . Experiments in walking is appropriate for assessing the coordination of movement and for following the changes . We found that therapeutic riding should be considered as a new form of rehabilitation . Twenty-six pupils ( 12 boys and 14 girls ) of a special needs school participated in therapeutic riding . We analyzed walking twice during a school-term : full body analyses each time before and after one-month therapy . The research included a non-riding control group . All together 104 analyses were performed . We measured mental skills using Pedagogical Analysis and Curriculum ( PAC ) test consisting of four parts being communication , self care , motor skills and socialization . The Gait Cycle Analysis consists of the time-series analysis , the analysis of part of the gait cycle and the measurement of joint angles in each plane . We found significant differences between before and after the therapy in the length of the gait cycle that became more stable in the sagital plane and concluded that our results proved that horse therapy may be successfully used as an additional therapy for children with autism , and it may be a form of rehabilitation in cases when other therapies are not successful ."
],
"offsets": [
[
0,
1415
]
]
}
] | [
{
"id": "72904",
"type": "Intervention_Physical",
"text": [
"therapeutic horse riding"
],
"offsets": [
[
11,
35
]
],
"normalized": []
},
{
"id": "72905",
"type": "Intervention_Physical",
"text": [
"therapeutic riding"
],
"offsets": [
[
138,
156
]
],
"normalized": []
},
{
"id": "72906",
"type": "Intervention_Physical",
"text": [
"therapeutic riding"
],
"offsets": [
[
138,
156
]
],
"normalized": []
},
{
"id": "72907",
"type": "Intervention_Physical",
"text": [
"therapeutic riding"
],
"offsets": [
[
138,
156
]
],
"normalized": []
},
{
"id": "72908",
"type": "Intervention_Physical",
"text": [
"full body analyses"
],
"offsets": [
[
558,
576
]
],
"normalized": []
},
{
"id": "72909",
"type": "Intervention_Physical",
"text": [
"one-month therapy"
],
"offsets": [
[
604,
621
]
],
"normalized": []
},
{
"id": "72910",
"type": "Intervention_Control",
"text": [
"non-riding control group"
],
"offsets": [
[
648,
672
]
],
"normalized": []
},
{
"id": "72911",
"type": "Intervention_Psychological",
"text": [
"."
],
"offsets": [
[
114,
115
]
],
"normalized": []
},
{
"id": "72912",
"type": "Outcome_Physical",
"text": [
"gait cycle parameters"
],
"offsets": [
[
39,
60
]
],
"normalized": []
},
{
"id": "72913",
"type": "Outcome_Mental",
"text": [
"aspects of behavior"
],
"offsets": [
[
70,
89
]
],
"normalized": []
},
{
"id": "72914",
"type": "Outcome_Mental",
"text": [
"communication , self care , motor skills"
],
"offsets": [
[
830,
870
]
],
"normalized": []
},
{
"id": "72915",
"type": "Outcome_Mental",
"text": [
"socialization ."
],
"offsets": [
[
875,
890
]
],
"normalized": []
},
{
"id": "72916",
"type": "Outcome_Physical",
"text": [
"length of the gait cycle"
],
"offsets": [
[
1122,
1146
]
],
"normalized": []
},
{
"id": "72917",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
107,
113
]
],
"normalized": []
},
{
"id": "72918",
"type": "Participant_Condition",
"text": [
"autism ."
],
"offsets": [
[
107,
115
]
],
"normalized": []
},
{
"id": "72919",
"type": "Participant_Sample-size",
"text": [
"Twenty-six"
],
"offsets": [
[
403,
413
]
],
"normalized": []
},
{
"id": "72920",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
423,
425
]
],
"normalized": []
},
{
"id": "72921",
"type": "Participant_Sex",
"text": [
"boys"
],
"offsets": [
[
426,
430
]
],
"normalized": []
},
{
"id": "72922",
"type": "Participant_Sample-size",
"text": [
"14"
],
"offsets": [
[
435,
437
]
],
"normalized": []
},
{
"id": "72923",
"type": "Participant_Sex",
"text": [
"girls"
],
"offsets": [
[
438,
443
]
],
"normalized": []
},
{
"id": "72924",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
93,
101
]
],
"normalized": []
}
] | [] | [] | [] |
72925 | 26554619 | [
{
"id": "72926",
"type": "document",
"text": [
"The role of routinely given hyoscine-N-butylbromide in colonoscopy : a double-blind , randomized , placebo-controlled , clinical trial . OBJECTIVE Hyoscine-N-butylbromide ( HBB ) has been proposed to ease colonoscopy and improve mucosal visualization , yet the results from previous studies are conflicting . In our prospective , double-blind , placebo-controlled , randomized study we aimed at evaluating whether routine administration of HBB , before and during colonoscopy , ease the procedure or increase the detection rate for polyps . MATERIAL AND METHODS One hundred fifty outpatients scheduled for an elective colonoscopy were randomized to receive intravenous injections of either 10 mg hyoscine-N-butylbromide or saline before insertion and at cecum . Patient tolerance and technical ease of colonoscopy were evaluated by visual analogue scale ( VAS ) . Procedure times were recorded . Number of detected polyps per patient was evaluated as well . Heart rate was monitored with a pulse oximetry . RESULTS HBB did not improve patient tolerance or technically ease the procedure as evaluated by VAS . However , HBB led to faster ileal intubation ( 1.5 vs 2.0 min , p < 0.001 ) and shorter total procedure time ( 22.0 vs 24.0 min , p = 0.03 ) . Patients who received HBB also needed less often external abdominal pressure ( 48.6 vs 66.7 % , p = 0.03 ) . HBB did not improve polyp detection rate ( 0.89 vs 0.91 , p = 0.90 ) . HBB induced a significant rise in heart rate ( p < 0.001 ) and more often tachycardia ( 17.6 vs 0 % , p < 0.001 ) . CONCLUSIONS Routine administration of HBB before and during colonoscopy yields only limited improvement in the technical performance of the examination compromised by high incidence of tachycardia ."
],
"offsets": [
[
0,
1746
]
]
}
] | [
{
"id": "72927",
"type": "Intervention_Pharmacological",
"text": [
"hyoscine-N-butylbromide"
],
"offsets": [
[
28,
51
]
],
"normalized": []
},
{
"id": "72928",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
99,
117
]
],
"normalized": []
},
{
"id": "72929",
"type": "Intervention_Pharmacological",
"text": [
"Hyoscine-N-butylbromide ( HBB )"
],
"offsets": [
[
147,
178
]
],
"normalized": []
},
{
"id": "72930",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
99,
117
]
],
"normalized": []
},
{
"id": "72931",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72932",
"type": "Intervention_Pharmacological",
"text": [
"hyoscine-N-butylbromide or saline before"
],
"offsets": [
[
696,
736
]
],
"normalized": []
},
{
"id": "72933",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72934",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72935",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72936",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72937",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72938",
"type": "Intervention_Pharmacological",
"text": [
"HBB"
],
"offsets": [
[
173,
176
]
],
"normalized": []
},
{
"id": "72939",
"type": "Outcome_Other",
"text": [
"ease the procedure"
],
"offsets": [
[
478,
496
]
],
"normalized": []
},
{
"id": "72940",
"type": "Outcome_Other",
"text": [
"increase the detection rate for polyps"
],
"offsets": [
[
500,
538
]
],
"normalized": []
},
{
"id": "72941",
"type": "Outcome_Other",
"text": [
"Patient tolerance"
],
"offsets": [
[
762,
779
]
],
"normalized": []
},
{
"id": "72942",
"type": "Outcome_Other",
"text": [
"technical ease of colonoscopy"
],
"offsets": [
[
784,
813
]
],
"normalized": []
},
{
"id": "72943",
"type": "Outcome_Other",
"text": [
"Procedure times"
],
"offsets": [
[
864,
879
]
],
"normalized": []
},
{
"id": "72944",
"type": "Outcome_Other",
"text": [
"Number of detected polyps per patient"
],
"offsets": [
[
896,
933
]
],
"normalized": []
},
{
"id": "72945",
"type": "Outcome_Physical",
"text": [
"Heart rate"
],
"offsets": [
[
958,
968
]
],
"normalized": []
},
{
"id": "72946",
"type": "Outcome_Other",
"text": [
"patient tolerance"
],
"offsets": [
[
1035,
1052
]
],
"normalized": []
},
{
"id": "72947",
"type": "Outcome_Other",
"text": [
"technically ease the procedure"
],
"offsets": [
[
1056,
1086
]
],
"normalized": []
},
{
"id": "72948",
"type": "Outcome_Other",
"text": [
"total procedure time"
],
"offsets": [
[
1197,
1217
]
],
"normalized": []
},
{
"id": "72949",
"type": "Outcome_Physical",
"text": [
"external abdominal pressure"
],
"offsets": [
[
1301,
1328
]
],
"normalized": []
},
{
"id": "72950",
"type": "Outcome_Other",
"text": [
"polyp detection rate"
],
"offsets": [
[
1381,
1401
]
],
"normalized": []
},
{
"id": "72951",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
1466,
1476
]
],
"normalized": []
},
{
"id": "72952",
"type": "Outcome_Physical",
"text": [
"tachycardia"
],
"offsets": [
[
1506,
1517
]
],
"normalized": []
},
{
"id": "72953",
"type": "Outcome_Other",
"text": [
"technical performance of the examination"
],
"offsets": [
[
1659,
1699
]
],
"normalized": []
},
{
"id": "72954",
"type": "Outcome_Physical",
"text": [
"tachycardia ."
],
"offsets": [
[
1733,
1746
]
],
"normalized": []
},
{
"id": "72955",
"type": "Participant_Condition",
"text": [
"colonoscopy :"
],
"offsets": [
[
55,
68
]
],
"normalized": []
},
{
"id": "72956",
"type": "Participant_Sample-size",
"text": [
"One hundred fifty"
],
"offsets": [
[
562,
579
]
],
"normalized": []
},
{
"id": "72957",
"type": "Participant_Condition",
"text": [
"elective colonoscopy"
],
"offsets": [
[
609,
629
]
],
"normalized": []
}
] | [] | [] | [] |
72958 | 26573368 | [
{
"id": "72959",
"type": "document",
"text": [
"A randomised double-blind placebo-controlled trial investigating the behavioural effects of vitamin , mineral and n-3 fatty acid supplementation in typically developing adolescent schoolchildren . Nutrient deficiencies have been implicated in anti-social behaviour in schoolchildren ; hence , correcting them may improve sociability . We therefore tested the effects of vitamin , mineral and n-3 supplementation on behaviour in a 12-week double-blind randomised placebo-controlled trial in typically developing UK adolescents aged 13-16 years ( n 196 ) . Changes in erythrocyte n-3 and 6 fatty acids and some mineral and vitamin levels were measured and compared with behavioural changes , using Conners ' teacher ratings and school disciplinary records . At baseline , the children 's PUFA ( n-3 and n-6 ) , vitamin and mineral levels were low , but they improved significantly in the group treated with n-3 , vitamins and minerals ( P=0·0005 ) . On the Conners disruptive behaviour scale , the group given the active supplements improved , whereas the placebo group worsened ( F=5·555 , d=0·35 ; P=0·02 ) . The general level of disciplinary infringements was low , thus making it difficult to obtain improvements . However , throughout the school term school disciplinary infringements increased significantly ( by 25 % ; Bayes factor=115 ) in both the treated and untreated groups . However , when the subjects were split into high and low baseline infringements , the low subset increased their offences , whereas the high-misbehaviour subset appeared to improve after treatment . But it was not possible to determine whether this was merely a statistical artifact . Thus , when assessed using the validated and standardised Conners teacher tests ( but less clearly when using school discipline records in a school where misbehaviour was infrequent ) , supplementary nutrition might have a protective effect against worsening behaviour ."
],
"offsets": [
[
0,
1941
]
]
}
] | [
{
"id": "72960",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "72961",
"type": "Intervention_Pharmacological",
"text": [
"vitamin , mineral and n-3 fatty acid supplementation"
],
"offsets": [
[
92,
144
]
],
"normalized": []
},
{
"id": "72962",
"type": "Intervention_Pharmacological",
"text": [
"vitamin , mineral and n-3 supplementation"
],
"offsets": [
[
370,
411
]
],
"normalized": []
},
{
"id": "72963",
"type": "Intervention_Pharmacological",
"text": [
"vitamin"
],
"offsets": [
[
92,
99
]
],
"normalized": []
},
{
"id": "72964",
"type": "Intervention_Pharmacological",
"text": [
"mineral"
],
"offsets": [
[
102,
109
]
],
"normalized": []
},
{
"id": "72965",
"type": "Intervention_Pharmacological",
"text": [
"vitamins and minerals"
],
"offsets": [
[
911,
932
]
],
"normalized": []
},
{
"id": "72966",
"type": "Outcome_Physical",
"text": [
"vitamin and mineral levels"
],
"offsets": [
[
809,
835
]
],
"normalized": []
},
{
"id": "72967",
"type": "Outcome_Mental",
"text": [
"the Conners disruptive behaviour scale"
],
"offsets": [
[
951,
989
]
],
"normalized": []
},
{
"id": "72968",
"type": "Outcome_Other",
"text": [
"The general level of disciplinary infringements"
],
"offsets": [
[
1109,
1156
]
],
"normalized": []
},
{
"id": "72969",
"type": "Outcome_Other",
"text": [
"term school disciplinary infringements"
],
"offsets": [
[
1249,
1287
]
],
"normalized": []
},
{
"id": "72970",
"type": "Participant_Age",
"text": [
"adolescent schoolchildren"
],
"offsets": [
[
169,
194
]
],
"normalized": []
},
{
"id": "72971",
"type": "Participant_Age",
"text": [
"adolescents aged 13-16 years"
],
"offsets": [
[
514,
542
]
],
"normalized": []
},
{
"id": "72972",
"type": "Participant_Sample-size",
"text": [
"n 196"
],
"offsets": [
[
545,
550
]
],
"normalized": []
}
] | [] | [] | [] |
72973 | 26606872 | [
{
"id": "72974",
"type": "document",
"text": [
"Effectiveness of Neuromuscular Electrical Stimulation on Patients With Dysphagia With Medullary Infarction . OBJECTIVE To evaluate and compare the effects of neuromuscular electrical stimulation ( NMES ) acting on the sensory input or motor muscle in treating patients with dysphagia with medullary infarction . DESIGN Prospective randomized controlled study . SETTING Department of physical medicine and rehabilitation . PARTICIPANTS Patients with dysphagia with medullary infarction ( N=82 ) . INTERVENTIONS Participants were randomized over 3 intervention groups : traditional swallowing therapy , sensory approach combined with traditional swallowing therapy , and motor approach combined with traditional swallowing therapy . Electrical stimulation sessions were for 20 minutes , twice a day , for 5d/wk , over a 4-week period . MAIN OUTCOME MEASURES Swallowing function was evaluated by the water swallow test and Standardized Swallowing Assessment , oral intake was evaluated by the Functional Oral Intake Scale , quality of life was evaluated by the Swallowing-Related Quality of Life ( SWAL-QOL ) Scale , and cognition was evaluated by the Mini-Mental State Examination ( MMSE ) . RESULTS There were no statistically significant differences between the groups in age , sex , duration , MMSE score , or severity of the swallowing disorder ( P > .05 ) . All groups showed improved swallowing function ( P≤.01 ) ; the sensory approach combined with traditional swallowing therapy group showed significantly greater improvement than the other 2 groups , and the motor approach combined with traditional swallowing therapy group showed greater improvement than the traditional swallowing therapy group ( P < .05 ) . SWAL-QOL Scale scores increased more significantly in the sensory approach combined with traditional swallowing therapy and motor approach combined with traditional swallowing therapy groups than in the traditional swallowing therapy group , and the sensory approach combined with traditional swallowing therapy and motor approach combined with traditional swallowing therapy groups showed statistically significant differences ( P=.04 ) . CONCLUSIONS NMES that targets either sensory input or motor muscle coupled with traditional therapy is conducive to recovery from dysphagia and improves quality of life for patients with dysphagia with medullary infarction . A sensory approach appears to be better than a motor approach ."
],
"offsets": [
[
0,
2448
]
]
}
] | [
{
"id": "72975",
"type": "Intervention_Physical",
"text": [
"Neuromuscular Electrical Stimulation"
],
"offsets": [
[
17,
53
]
],
"normalized": []
},
{
"id": "72976",
"type": "Intervention_Physical",
"text": [
"neuromuscular electrical stimulation ( NMES )"
],
"offsets": [
[
158,
203
]
],
"normalized": []
},
{
"id": "72977",
"type": "Intervention_Physical",
"text": [
"traditional swallowing therapy , sensory approach combined with traditional swallowing therapy , and motor approach combined with traditional swallowing therapy"
],
"offsets": [
[
568,
728
]
],
"normalized": []
},
{
"id": "72978",
"type": "Outcome_Physical",
"text": [
"Swallowing function"
],
"offsets": [
[
856,
875
]
],
"normalized": []
},
{
"id": "72979",
"type": "Outcome_Physical",
"text": [
"water swallow test and Standardized Swallowing Assessment , oral intake"
],
"offsets": [
[
897,
968
]
],
"normalized": []
},
{
"id": "72980",
"type": "Outcome_Physical",
"text": [
"Functional Oral Intake Scale , quality of life"
],
"offsets": [
[
990,
1036
]
],
"normalized": []
},
{
"id": "72981",
"type": "Outcome_Physical",
"text": [
"Swallowing-Related Quality of Life ( SWAL-QOL ) Scale"
],
"offsets": [
[
1058,
1111
]
],
"normalized": []
},
{
"id": "72982",
"type": "Outcome_Mental",
"text": [
"Mini-Mental State Examination ( MMSE ) ."
],
"offsets": [
[
1149,
1189
]
],
"normalized": []
},
{
"id": "72983",
"type": "Outcome_Mental",
"text": [
"MMSE score , or severity of the swallowing disorder"
],
"offsets": [
[
1295,
1346
]
],
"normalized": []
},
{
"id": "72984",
"type": "Outcome_Physical",
"text": [
"swallowing function"
],
"offsets": [
[
1388,
1407
]
],
"normalized": []
},
{
"id": "72985",
"type": "Participant_Condition",
"text": [
"Dysphagia With Medullary Infarction"
],
"offsets": [
[
71,
106
]
],
"normalized": []
},
{
"id": "72986",
"type": "Participant_Condition",
"text": [
"dysphagia with medullary infarction"
],
"offsets": [
[
274,
309
]
],
"normalized": []
},
{
"id": "72987",
"type": "Participant_Condition",
"text": [
"dysphagia with medullary infarction"
],
"offsets": [
[
274,
309
]
],
"normalized": []
},
{
"id": "72988",
"type": "Participant_Sample-size",
"text": [
"N=82"
],
"offsets": [
[
487,
491
]
],
"normalized": []
},
{
"id": "72989",
"type": "Participant_Condition",
"text": [
"for patients with dysphagia with medullary infarction"
],
"offsets": [
[
2329,
2382
]
],
"normalized": []
}
] | [] | [] | [] |
72990 | 26609668 | [
{
"id": "72991",
"type": "document",
"text": [
"Socio-demographic , anthropometric , and psychosocial predictors of attrition across behavioral weight-loss trials . Preventing attrition is a major concern in behavioral weight loss intervention studies . The purpose of this analysis was to identify baseline and six-month predictors associated with participant attrition across three independent clinical trials of behavioral weight loss interventions ( PREFER , SELF , and SMART ) that were conducted over 10 years . Baseline measures included body mass index , Barriers to Healthy Eating , Beck Depression Inventory-II ( BDI ) , Hunger Satiety Scale ( HSS ) , Binge Eating Scale ( BES ) , Medical Outcome Study Short Form ( MOS SF-36 v2 ) and Weight Efficacy Lifestyle Questionnaire ( WEL ) . We also examined early weight loss and attendance at group sessions during the first 6 months . Attrition was recorded at the end of the trials . Participants included 504 overweight and obese adults seeking weight loss treatment . The sample was 84.92 % female and 73.61 % white , with a mean ( ± SD ) age of 47.35 ± 9.75 years . After controlling for the specific trial , for every one unit increase in BMI , the odds of attrition increased by 11 % . For every year increase in education , the odds of attrition decreased by 10 % . Additional predictors of attrition included previous attempts to lose 50-79 lbs , age , not possessing health insurance , and BES , BDI , and HSS scores . At 6 months , the odds of attrition increased by 10 % with reduced group session attendance . There was also an interaction between percent weight change and trial ( p < .001 ) . Multivariate analysis of the three trials showed education , age , BMI , and BES scores were independently associated with attrition ( ps ≤ .01 ) . These findings may inform the development of more robust strategies for reducing attrition ."
],
"offsets": [
[
0,
1855
]
]
}
] | [
{
"id": "72992",
"type": "Intervention_Psychological",
"text": [
"("
],
"offsets": [
[
404,
405
]
],
"normalized": []
},
{
"id": "72993",
"type": "Intervention_Educational",
"text": [
"PREFER , SELF"
],
"offsets": [
[
406,
419
]
],
"normalized": []
},
{
"id": "72994",
"type": "Intervention_Educational",
"text": [
"SMART )"
],
"offsets": [
[
426,
433
]
],
"normalized": []
},
{
"id": "72995",
"type": "Intervention_Physical",
"text": [
"Baseline measures included body mass index"
],
"offsets": [
[
470,
512
]
],
"normalized": []
},
{
"id": "72996",
"type": "Intervention_Physical",
"text": [
"Barriers to Healthy Eating"
],
"offsets": [
[
515,
541
]
],
"normalized": []
},
{
"id": "72997",
"type": "Intervention_Educational",
"text": [
"Beck Depression Inventory-II ( BDI )"
],
"offsets": [
[
544,
580
]
],
"normalized": []
},
{
"id": "72998",
"type": "Intervention_Physical",
"text": [
"Hunger Satiety Scale ( HSS"
],
"offsets": [
[
583,
609
]
],
"normalized": []
},
{
"id": "72999",
"type": "Intervention_Physical",
"text": [
"Binge Eating Scale ( BES )"
],
"offsets": [
[
614,
640
]
],
"normalized": []
},
{
"id": "73000",
"type": "Intervention_Educational",
"text": [
"Medical Outcome Study Short Form ( MOS SF-36 v2"
],
"offsets": [
[
643,
690
]
],
"normalized": []
},
{
"id": "73001",
"type": "Intervention_Educational",
"text": [
"Weight Efficacy Lifestyle Questionnaire ( WEL )"
],
"offsets": [
[
697,
744
]
],
"normalized": []
},
{
"id": "73002",
"type": "Intervention_Educational",
"text": [
"early weight loss and attendance at group sessions during the first 6 months ."
],
"offsets": [
[
764,
842
]
],
"normalized": []
},
{
"id": "73003",
"type": "Outcome_Physical",
"text": [
"body mass index"
],
"offsets": [
[
497,
512
]
],
"normalized": []
},
{
"id": "73004",
"type": "Outcome_Physical",
"text": [
"Barriers to Healthy Eating"
],
"offsets": [
[
515,
541
]
],
"normalized": []
},
{
"id": "73005",
"type": "Outcome_Other",
"text": [
"Beck Depression Inventory-II ( BDI )"
],
"offsets": [
[
544,
580
]
],
"normalized": []
},
{
"id": "73006",
"type": "Outcome_Other",
"text": [
"Hunger Satiety Scale ( HSS )"
],
"offsets": [
[
583,
611
]
],
"normalized": []
},
{
"id": "73007",
"type": "Outcome_Other",
"text": [
"Binge Eating Scale ( BES )"
],
"offsets": [
[
614,
640
]
],
"normalized": []
},
{
"id": "73008",
"type": "Outcome_Other",
"text": [
"Medical Outcome Study Short Form ( MOS SF-36 v2 )"
],
"offsets": [
[
643,
692
]
],
"normalized": []
},
{
"id": "73009",
"type": "Outcome_Other",
"text": [
"Weight Efficacy Lifestyle Questionnaire ( WEL )"
],
"offsets": [
[
697,
744
]
],
"normalized": []
},
{
"id": "73010",
"type": "Outcome_Physical",
"text": [
"early weight loss"
],
"offsets": [
[
764,
781
]
],
"normalized": []
},
{
"id": "73011",
"type": "Outcome_Physical",
"text": [
"attendance"
],
"offsets": [
[
786,
796
]
],
"normalized": []
},
{
"id": "73012",
"type": "Outcome_Physical",
"text": [
"Attrition"
],
"offsets": [
[
843,
852
]
],
"normalized": []
},
{
"id": "73013",
"type": "Outcome_Physical",
"text": [
"in BMI"
],
"offsets": [
[
1149,
1155
]
],
"normalized": []
},
{
"id": "73014",
"type": "Outcome_Physical",
"text": [
"year increase in education"
],
"offsets": [
[
1210,
1236
]
],
"normalized": []
},
{
"id": "73015",
"type": "Outcome_Other",
"text": [
"possessing health insurance , and BES , BDI , and HSS scores"
],
"offsets": [
[
1373,
1433
]
],
"normalized": []
},
{
"id": "73016",
"type": "Outcome_Physical",
"text": [
"of attrition"
],
"offsets": [
[
65,
77
]
],
"normalized": []
},
{
"id": "73017",
"type": "Participant_Sample-size",
"text": [
"504"
],
"offsets": [
[
915,
918
]
],
"normalized": []
},
{
"id": "73018",
"type": "Participant_Condition",
"text": [
"overweight and obese"
],
"offsets": [
[
919,
939
]
],
"normalized": []
},
{
"id": "73019",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
940,
946
]
],
"normalized": []
},
{
"id": "73020",
"type": "Participant_Sample-size",
"text": [
"84.92 %"
],
"offsets": [
[
994,
1001
]
],
"normalized": []
},
{
"id": "73021",
"type": "Participant_Sex",
"text": [
"female"
],
"offsets": [
[
1002,
1008
]
],
"normalized": []
},
{
"id": "73022",
"type": "Participant_Sample-size",
"text": [
"73.61 %"
],
"offsets": [
[
1013,
1020
]
],
"normalized": []
},
{
"id": "73023",
"type": "Participant_Age",
"text": [
"age of 47.35 ± 9.75 years"
],
"offsets": [
[
1050,
1075
]
],
"normalized": []
},
{
"id": "73024",
"type": "Participant_Condition",
"text": [
"previous attempts to lose 50-79 lbs"
],
"offsets": [
[
1325,
1360
]
],
"normalized": []
},
{
"id": "73025",
"type": "Participant_Condition",
"text": [
"not possessing health insurance"
],
"offsets": [
[
1369,
1400
]
],
"normalized": []
}
] | [] | [] | [] |
73026 | 26628383 | [
{
"id": "73027",
"type": "document",
"text": [
"Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation : The AMADEUS Trial . BACKGROUND AND PURPOSE Obesity has been associated with increased cardiovascular risk in atrial fibrillation , but little is known in elderly patients with atrial fibrillation . METHODS Post hoc analysis of data from the AMADEUS ( Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation ) trial . RESULTS We studied 1588 elderly patients , who were categorized as normal body mass index ( BMI , 18.5-25 kg/m ( 2 ) ; n=515 [ 32.4 % ] ) , overweight ( BMI , 25-30 kg/m ( 2 ) ; n=711 [ 44.8 % ] ) , and obese ( BMI≥30 kg/m ( 2 ) ; n=362 [ 22.8 % ] ) . There was a significant reduction in the composite outcome of cardiovascular death and stroke/systemic embolism with increasing BMI category , being 5.0 % , 3.2 % , and 1.5 % per 100 patient-years , respectively ( P for trend=0.01 ) . Cox proportional hazards analysis found obesity to be associated with a lower risk of the primary composite outcome ( hazard ratio , 0.29 ; 95 % confidence interval , 0.11-0.77 ; P=0.01 ) . In the warfarin arm ( n=814 ) , multivariate logistic regression analysis demonstrated that obesity was independently related to higher odds of time in therapeutic range ≥60 % ( odds ratio , 1.84 ; 95 % confidence interval , 1.21-2.80 ; P=0.004 ) . CONCLUSION Obesity was associated with a lower stroke and mortality rate in elderly anticoagulated atrial fibrillation patients . Obesity was related to good quality anticoagulation control ."
],
"offsets": [
[
0,
1567
]
]
}
] | [
{
"id": "73028",
"type": "Intervention_Pharmacological",
"text": [
"Warfarin"
],
"offsets": [
[
377,
385
]
],
"normalized": []
},
{
"id": "73029",
"type": "Intervention_Pharmacological",
"text": [
"Acenocoumarol"
],
"offsets": [
[
389,
402
]
],
"normalized": []
},
{
"id": "73030",
"type": "Outcome_Mortality",
"text": [
"cardiovascular death"
],
"offsets": [
[
764,
784
]
],
"normalized": []
},
{
"id": "73031",
"type": "Outcome_Physical",
"text": [
"stroke/systemic embolism"
],
"offsets": [
[
789,
813
]
],
"normalized": []
},
{
"id": "73032",
"type": "Outcome_Physical",
"text": [
"lower stroke"
],
"offsets": [
[
1417,
1429
]
],
"normalized": []
},
{
"id": "73033",
"type": "Outcome_Mortality",
"text": [
"mortality rate"
],
"offsets": [
[
1434,
1448
]
],
"normalized": []
},
{
"id": "73034",
"type": "Participant_Age",
"text": [
"Elderly"
],
"offsets": [
[
40,
47
]
],
"normalized": []
},
{
"id": "73035",
"type": "Participant_Condition",
"text": [
"Atrial Fibrillation"
],
"offsets": [
[
62,
81
]
],
"normalized": []
},
{
"id": "73036",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
238,
245
]
],
"normalized": []
},
{
"id": "73037",
"type": "Participant_Condition",
"text": [
"atrial fibrillation"
],
"offsets": [
[
193,
212
]
],
"normalized": []
},
{
"id": "73038",
"type": "Participant_Condition",
"text": [
"Atrial Fibrillation"
],
"offsets": [
[
62,
81
]
],
"normalized": []
},
{
"id": "73039",
"type": "Participant_Sample-size",
"text": [
"1588"
],
"offsets": [
[
469,
473
]
],
"normalized": []
},
{
"id": "73040",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
238,
245
]
],
"normalized": []
},
{
"id": "73041",
"type": "Participant_Sample-size",
"text": [
"n=515"
],
"offsets": [
[
569,
574
]
],
"normalized": []
},
{
"id": "73042",
"type": "Participant_Sample-size",
"text": [
"n=711"
],
"offsets": [
[
628,
633
]
],
"normalized": []
},
{
"id": "73043",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
238,
245
]
],
"normalized": []
},
{
"id": "73044",
"type": "Participant_Condition",
"text": [
"anticoagulated atrial fibrillation"
],
"offsets": [
[
1460,
1494
]
],
"normalized": []
}
] | [] | [] | [] |
73045 | 2663585 | [
{
"id": "73046",
"type": "document",
"text": [
"Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure . A double-blind multicentre study . Ibopamine is a dopaminergic and adrenergic receptor agonist , which is active in the treatment of congestive heart failure . Since the long-term prognosis for patients with congestive heart failure remains very poor and the incidence of arrhythmic death is high , every new drug to be employed against this disease should be thoroughly tested in order to rule out any possible arrhythmogenic action . This multicentre study was designed to evaluate the effect of ibopamine versus placebo in double-blind conditions on heart rate , rhythm and electrical safety . Ibopamine was employed at a dose of 100 mg t.i.d . in 97 patients ( aged 31-83 years ) belonging to NYHA class II and III with congestive heart failure of different aetiology , but without any complex ventricular arrhythmias in basal conditions ( couplets with R'-R \" less than or equal to 400 msec , ventricular tachycardia , R on T phenomena ) . Using a random cross-over design the patients were submitted to 48 hr . Holter recordings in basal conditions and following 7 days of ibopamine and placebo treatment . No influence on heart rhythm was noted . No significant variations in maximum heart rate ( ibopamine 117.7 +/- 20.9 ; placebo 118.1 +/- 20.7 ) , medium heart rate ( ibopamine 71.8 +/- 10.2 ; placebo 72.6 +/- 10.1 ) or minimum heart rate ( ibopamine 55.3 +/- 11.7 ; placebo 54.6 +/- 10.6 ) were observed . The mean number/hr . of ectopic supraventricular beats was 26.1 +/- 61.9 after ibopamine and 21.7 +/- 35.8 after placebo ( p = ns ) . The complexity of ectopic supraventricular beats did not change . The mean number/hr . of ectopic ventricular beats was 31.1 +/- 52.5 after ibopamine and 30.4 +/- 57.8 after placebo ( p = ns ) . Neither the distribution of the patients among Lown classification nor the Final Score of the Italian Lown Classification ( 26.1 +/- 18.0 and 26.6 +/- 17.9 in the 1st and 2nd day of monitoring after ibopamine and 25.7 +/- 18.6 and 25.7 +/- 18.8 after placebo ; p = ns ) showed any difference between active treatment and placebo . Similar results were achieved when the patients were sub-divided into subgroups according to sequences of treatment ( basal -- -- ibopamine -- -- placebo and basal -- -- placebo -- -- ibopamine ) , NYHA class II or III , aetiology of congestive heart failure ( dilatative cardiomyopathy , ischemic cardiomyopathy and other aetiologies ) , associated treatment with digitalis or diuretics and the number and complexity of base ectopic ventricular beats . None of the patients experienced sustained ventricular tachycardia . ( ABSTRACT TRUNCATED AT 400 WORDS )"
],
"offsets": [
[
0,
2740
]
]
}
] | [
{
"id": "73047",
"type": "Intervention_Pharmacological",
"text": [
"ibopamine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "73048",
"type": "Intervention_Pharmacological",
"text": [
"Ibopamine"
],
"offsets": [
[
139,
148
]
],
"normalized": []
},
{
"id": "73049",
"type": "Intervention_Pharmacological",
"text": [
"ibopamine"
],
"offsets": [
[
13,
22
]
],
"normalized": []
},
{
"id": "73050",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
619,
626
]
],
"normalized": []
},
{
"id": "73051",
"type": "Intervention_Pharmacological",
"text": [
"Ibopamine was employed at a dose of 100 mg t.i.d ."
],
"offsets": [
[
701,
751
]
],
"normalized": []
},
{
"id": "73052",
"type": "Intervention_Physical",
"text": [
"in 97 patients ( aged 31-83 years ) belonging to NYHA class II and III with congestive heart failure of different aetiology"
],
"offsets": [
[
752,
875
]
],
"normalized": []
},
{
"id": "73053",
"type": "Intervention_Physical",
"text": [
"but without any complex ventricular arrhythmias in basal conditions ( couplets with R'-R \" less than or equal to 400 msec , ventricular tachycardia"
],
"offsets": [
[
878,
1025
]
],
"normalized": []
},
{
"id": "73054",
"type": "Intervention_Other",
"text": [
"R on T phenomena"
],
"offsets": [
[
1028,
1044
]
],
"normalized": []
},
{
"id": "73055",
"type": "Intervention_Pharmacological",
"text": [
"Holter recordings in basal conditions and following 7 days of ibopamine"
],
"offsets": [
[
1121,
1192
]
],
"normalized": []
},
{
"id": "73056",
"type": "Outcome_Physical",
"text": [
"heart rate and arrhythmic pattern"
],
"offsets": [
[
26,
59
]
],
"normalized": []
},
{
"id": "73057",
"type": "Outcome_Physical",
"text": [
"arrhythmogenic action"
],
"offsets": [
[
516,
537
]
],
"normalized": []
},
{
"id": "73058",
"type": "Outcome_Physical",
"text": [
"heart rate , rhythm and"
],
"offsets": [
[
657,
680
]
],
"normalized": []
},
{
"id": "73059",
"type": "Outcome_Other",
"text": [
"electrical safety"
],
"offsets": [
[
681,
698
]
],
"normalized": []
},
{
"id": "73060",
"type": "Outcome_Other",
"text": [
"Holter recordings"
],
"offsets": [
[
1121,
1138
]
],
"normalized": []
},
{
"id": "73061",
"type": "Outcome_Physical",
"text": [
"heart rhythm"
],
"offsets": [
[
1233,
1245
]
],
"normalized": []
},
{
"id": "73062",
"type": "Outcome_Physical",
"text": [
"maximum heart rate"
],
"offsets": [
[
1287,
1305
]
],
"normalized": []
},
{
"id": "73063",
"type": "Outcome_Physical",
"text": [
"medium heart rate"
],
"offsets": [
[
1362,
1379
]
],
"normalized": []
},
{
"id": "73064",
"type": "Outcome_Physical",
"text": [
"minimum heart rate"
],
"offsets": [
[
1435,
1453
]
],
"normalized": []
},
{
"id": "73065",
"type": "Outcome_Physical",
"text": [
"ectopic supraventricular beats"
],
"offsets": [
[
1546,
1576
]
],
"normalized": []
},
{
"id": "73066",
"type": "Outcome_Physical",
"text": [
"ectopic supraventricular beats"
],
"offsets": [
[
1546,
1576
]
],
"normalized": []
},
{
"id": "73067",
"type": "Outcome_Physical",
"text": [
"ectopic ventricular beats"
],
"offsets": [
[
1746,
1771
]
],
"normalized": []
},
{
"id": "73068",
"type": "Outcome_Physical",
"text": [
"Lown classification nor the Final Score of the Italian Lown Classification"
],
"offsets": [
[
1898,
1972
]
],
"normalized": []
},
{
"id": "73069",
"type": "Participant_Condition",
"text": [
"patients with congestive heart failure ."
],
"offsets": [
[
63,
103
]
],
"normalized": []
}
] | [] | [] | [] |
73070 | 2663834 | [
{
"id": "73071",
"type": "document",
"text": [
"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children . This double-blind and placebo-controlled clinical trial in autistic children had three objectives : ( a ) to replicate earlier findings that haloperidol administration is associated with a significant reduction of behavioral symptoms ; ( b ) to further assess its safety when given on a short-term basis ; and ( c ) to assess whether it has an effect on discrimination learning . Forty-five children , 2.02 to 7.58 years old ( M = 4.49 ) , completed this crossover design , with random assignment to treatment sequences . Haloperidol was shown to be a powerful therapeutic agent when administered for 4 weeks and free of side effects ; at doses ranging from 0.25 to 4.0 mg/day ( M = 0.844 ) , there was a clinically and statistically significant reduction of a variety of symptoms . Under the given conditions , the children failed to learn on either haloperidol or placebo ."
],
"offsets": [
[
0,
976
]
]
}
] | [
{
"id": "73072",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "73073",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
123,
141
]
],
"normalized": []
},
{
"id": "73074",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "73075",
"type": "Intervention_Pharmacological",
"text": [
"Haloperidol"
],
"offsets": [
[
623,
634
]
],
"normalized": []
},
{
"id": "73076",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "73077",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
123,
130
]
],
"normalized": []
},
{
"id": "73078",
"type": "Outcome_Mental",
"text": [
"discrimination learning and behavioral symptoms"
],
"offsets": [
[
30,
77
]
],
"normalized": []
},
{
"id": "73079",
"type": "Outcome_Mental",
"text": [
"behavioral symptoms"
],
"offsets": [
[
58,
77
]
],
"normalized": []
},
{
"id": "73080",
"type": "Outcome_Other",
"text": [
"safety"
],
"offsets": [
[
365,
371
]
],
"normalized": []
},
{
"id": "73081",
"type": "Outcome_Mental",
"text": [
"effect on discrimination learning"
],
"offsets": [
[
445,
478
]
],
"normalized": []
},
{
"id": "73082",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
722,
734
]
],
"normalized": []
},
{
"id": "73083",
"type": "Outcome_Mental",
"text": [
"variety of symptoms"
],
"offsets": [
[
862,
881
]
],
"normalized": []
},
{
"id": "73084",
"type": "Participant_Condition",
"text": [
"autistic"
],
"offsets": [
[
81,
89
]
],
"normalized": []
},
{
"id": "73085",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
90,
98
]
],
"normalized": []
},
{
"id": "73086",
"type": "Participant_Condition",
"text": [
"."
],
"offsets": [
[
99,
100
]
],
"normalized": []
},
{
"id": "73087",
"type": "Participant_Sample-size",
"text": [
"Forty-five"
],
"offsets": [
[
481,
491
]
],
"normalized": []
},
{
"id": "73088",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
90,
98
]
],
"normalized": []
},
{
"id": "73089",
"type": "Participant_Sample-size",
"text": [
"2.02 to 7.58"
],
"offsets": [
[
503,
515
]
],
"normalized": []
},
{
"id": "73090",
"type": "Participant_Sample-size",
"text": [
"M = 4.49"
],
"offsets": [
[
528,
536
]
],
"normalized": []
}
] | [] | [] | [] |
73091 | 26650831 | [
{
"id": "73092",
"type": "document",
"text": [
"Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer . BACKGROUND The aim of this study was to evaluate the accuracy of clinical imaging of the primary breast tumour post-neoadjuvant chemotherapy ( NAC ) related to the post-neoadjuvant histological tumour size ( gold standard ) and whether this varies with breast cancer subtype . In this study , results of both magnetic resonance imaging ( MRI ) and ultrasound ( US ) were reported . METHODS Patients with invasive breast cancer were enrolled in the INTENS study between 2006 and 2009 . We included 182 patients , of whom data were available for post-NAC MRI ( n=155 ) , US ( n=123 ) , and histopathological tumour size . RESULTS MRI estimated residual tumour size with < 10-mm discordance in 54 % of patients , overestimated size in 28 % and underestimated size in 18 % of patients . With US , this was 63 % , 20 % and 17 % , respectively . The negative predictive value in hormone receptor-positive tumours for both MRI and US was low , 26 % and 33 % , respectively . The median deviation in clinical tumour size as percentage of pathological tumour was 63 % ( P25=26 , P75=100 ) and 49 % ( P25=22 , P75=100 ) for MRI and US , respectively ( P=0.06 ) . CONCLUSIONS In this study , US was at least as good as breast MRI in providing information on residual tumour size post-neoadjuvant chemotherapy . However , both modalities suffered from a substantial percentage of over- and underestimation of tumour size and in addition both showed a low negative predictive value of pathologic complete remission ( Gov nr : NCT00314977 ) ."
],
"offsets": [
[
0,
1664
]
]
}
] | [
{
"id": "73093",
"type": "Intervention_Physical",
"text": [
"Ultrasound"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "73094",
"type": "Intervention_Physical",
"text": [
"magnetic resonance imaging"
],
"offsets": [
[
34,
60
]
],
"normalized": []
},
{
"id": "73095",
"type": "Intervention_Physical",
"text": [
"primary breast tumour post-neoadjuvant chemotherapy ( NAC )"
],
"offsets": [
[
225,
284
]
],
"normalized": []
},
{
"id": "73096",
"type": "Intervention_Physical",
"text": [
"magnetic resonance imaging ( MRI )"
],
"offsets": [
[
445,
479
]
],
"normalized": []
},
{
"id": "73097",
"type": "Intervention_Physical",
"text": [
"ultrasound ( US )"
],
"offsets": [
[
484,
501
]
],
"normalized": []
},
{
"id": "73098",
"type": "Intervention_Physical",
"text": [
"MRI"
],
"offsets": [
[
474,
477
]
],
"normalized": []
},
{
"id": "73099",
"type": "Intervention_Physical",
"text": [
"US"
],
"offsets": [
[
497,
499
]
],
"normalized": []
},
{
"id": "73100",
"type": "Outcome_Physical",
"text": [
"predicting tumour size"
],
"offsets": [
[
64,
86
]
],
"normalized": []
},
{
"id": "73101",
"type": "Outcome_Other",
"text": [
"accuracy"
],
"offsets": [
[
189,
197
]
],
"normalized": []
},
{
"id": "73102",
"type": "Outcome_Physical",
"text": [
"residual tumour size"
],
"offsets": [
[
778,
798
]
],
"normalized": []
},
{
"id": "73103",
"type": "Outcome_Physical",
"text": [
"median deviation in clinical tumour size as percentage of pathological tumour"
],
"offsets": [
[
1108,
1185
]
],
"normalized": []
},
{
"id": "73104",
"type": "Outcome_Physical",
"text": [
"negative predictive value of pathologic complete remission"
],
"offsets": [
[
1579,
1637
]
],
"normalized": []
},
{
"id": "73105",
"type": "Participant_Condition",
"text": [
"chemotherapy in breast cancer ."
],
"offsets": [
[
104,
135
]
],
"normalized": []
},
{
"id": "73106",
"type": "Participant_Condition",
"text": [
"breast cancer subtype ."
],
"offsets": [
[
389,
412
]
],
"normalized": []
},
{
"id": "73107",
"type": "Participant_Condition",
"text": [
"invasive breast cancer"
],
"offsets": [
[
540,
562
]
],
"normalized": []
},
{
"id": "73108",
"type": "Participant_Sample-size",
"text": [
"182 patients"
],
"offsets": [
[
633,
645
]
],
"normalized": []
},
{
"id": "73109",
"type": "Participant_Condition",
"text": [
"histopathological tumour size"
],
"offsets": [
[
724,
753
]
],
"normalized": []
}
] | [] | [] | [] |
73110 | 26653722 | [
{
"id": "73111",
"type": "document",
"text": [
"NSAID Pretreatment Inhibits Prostaglandin Release in Femtosecond Laser-Assisted Cataract Surgery . PURPOSE To investigate whether short-term nonsteroidal anti-inflammatory drug ( NSAID ) pretreatment on the day of surgery inhibits prostaglandin release . Previous studies detected elevated prostaglandin levels after femtosecond laser treatment and identified them as a potential mediator for laser-induced miosis . METHODS Patients underwent either image-guided femtosecond laser cataract surgery or conventional cataract surgery ( n = 75 ) . Half of the eyes per group received topical NSAID treatment on the day of surgery . Aqueous humor was collected from all patients . ELISA measurements were performed to detect aqueous humor prostaglandin levels . RESULTS Femtosecond laser cataract surgery led to higher prostaglandin levels than conventional cataract surgery ( P = .007 ) . In both groups , NSAID pretreatment led to reduced prostaglandin release . In the femtosecond laser group , patients pretreated with NSAIDs had significantly lower prostaglandin values ( 65.3 ± 13.2 pg/mL ) than patients not pretreated with NSAIDs ( 294.4 ± 66.5 pg/mL ) ( P = .0009 ) . CONCLUSIONS The short-term NSAID treatment prevented prostaglandin release in patients treated with image-guided femtosecond laser . Therefore , it has potential to limit intraoperative laser-induced miosis ."
],
"offsets": [
[
0,
1380
]
]
}
] | [
{
"id": "73112",
"type": "Intervention_Pharmacological",
"text": [
"NSAID"
],
"offsets": [
[
0,
5
]
],
"normalized": []
},
{
"id": "73113",
"type": "Intervention_Surgical",
"text": [
"Femtosecond Laser-Assisted Cataract Surgery"
],
"offsets": [
[
53,
96
]
],
"normalized": []
},
{
"id": "73114",
"type": "Intervention_Pharmacological",
"text": [
"nonsteroidal anti-inflammatory drug ( NSAID"
],
"offsets": [
[
141,
184
]
],
"normalized": []
},
{
"id": "73115",
"type": "Intervention_Surgical",
"text": [
"femtosecond laser treatment"
],
"offsets": [
[
317,
344
]
],
"normalized": []
},
{
"id": "73116",
"type": "Intervention_Surgical",
"text": [
"image-guided femtosecond laser cataract surgery or conventional cataract surgery"
],
"offsets": [
[
450,
530
]
],
"normalized": []
},
{
"id": "73117",
"type": "Intervention_Pharmacological",
"text": [
"topical NSAID treatment"
],
"offsets": [
[
580,
603
]
],
"normalized": []
},
{
"id": "73118",
"type": "Intervention_Surgical",
"text": [
"Femtosecond laser cataract surgery"
],
"offsets": [
[
765,
799
]
],
"normalized": []
},
{
"id": "73119",
"type": "Intervention_Control",
"text": [
"conventional cataract surgery"
],
"offsets": [
[
501,
530
]
],
"normalized": []
},
{
"id": "73120",
"type": "Intervention_Pharmacological",
"text": [
"NSAID pretreatment"
],
"offsets": [
[
902,
920
]
],
"normalized": []
},
{
"id": "73121",
"type": "Intervention_Pharmacological",
"text": [
"pretreated with NSAIDs"
],
"offsets": [
[
1002,
1024
]
],
"normalized": []
},
{
"id": "73122",
"type": "Intervention_Pharmacological",
"text": [
"NSAIDs"
],
"offsets": [
[
1018,
1024
]
],
"normalized": []
},
{
"id": "73123",
"type": "Outcome_Physical",
"text": [
"Prostaglandin Release"
],
"offsets": [
[
28,
49
]
],
"normalized": []
},
{
"id": "73124",
"type": "Outcome_Physical",
"text": [
"prostaglandin release ."
],
"offsets": [
[
231,
254
]
],
"normalized": []
},
{
"id": "73125",
"type": "Outcome_Physical",
"text": [
"prostaglandin levels"
],
"offsets": [
[
290,
310
]
],
"normalized": []
},
{
"id": "73126",
"type": "Outcome_Physical",
"text": [
"aqueous humor prostaglandin levels ."
],
"offsets": [
[
720,
756
]
],
"normalized": []
},
{
"id": "73127",
"type": "Outcome_Physical",
"text": [
"prostaglandin levels"
],
"offsets": [
[
290,
310
]
],
"normalized": []
},
{
"id": "73128",
"type": "Outcome_Physical",
"text": [
"prostaglandin release"
],
"offsets": [
[
231,
252
]
],
"normalized": []
},
{
"id": "73129",
"type": "Outcome_Physical",
"text": [
"prostaglandin values"
],
"offsets": [
[
1049,
1069
]
],
"normalized": []
},
{
"id": "73130",
"type": "Outcome_Physical",
"text": [
"prevented prostaglandin release"
],
"offsets": [
[
1215,
1246
]
],
"normalized": []
},
{
"id": "73131",
"type": "Participant_Condition",
"text": [
"Cataract"
],
"offsets": [
[
80,
88
]
],
"normalized": []
},
{
"id": "73132",
"type": "Participant_Condition",
"text": [
"Patients underwent either image-guided femtosecond laser cataract surgery"
],
"offsets": [
[
424,
497
]
],
"normalized": []
},
{
"id": "73133",
"type": "Participant_Condition",
"text": [
"conventional cataract surgery"
],
"offsets": [
[
501,
530
]
],
"normalized": []
},
{
"id": "73134",
"type": "Participant_Sample-size",
"text": [
"( n = 75"
],
"offsets": [
[
531,
539
]
],
"normalized": []
},
{
"id": "73135",
"type": "Participant_Sample-size",
"text": [
"all patients"
],
"offsets": [
[
661,
673
]
],
"normalized": []
},
{
"id": "73136",
"type": "Participant_Sample-size",
"text": [
"femtosecond laser group"
],
"offsets": [
[
967,
990
]
],
"normalized": []
},
{
"id": "73137",
"type": "Participant_Condition",
"text": [
"patients treated with image-guided femtosecond laser"
],
"offsets": [
[
1250,
1302
]
],
"normalized": []
}
] | [] | [] | [] |
73138 | 26665290 | [
{
"id": "73139",
"type": "document",
"text": [
"Clinical Study to Assess the Stain Removal Effectiveness of a Tooth Whitening Regimen with Added Whitening Booster . OBJECTIVE This randomized , controlled clinical trial was conducted to assess the extrinsic stain reduction achieved by brushing with a whitening dentifrice and powered toothbrush , and to determine whether the addition of a whitening booster paste to this regimen would enhance its stain reducing effectiveness . METHODS Sixty qualifying subjects were randomly assigned either to Regimen One , a whitening dentifrice ( Arm & Hammer Truly Radiant [ TR ] toothpaste ] and powered toothbrush ( Arm & Hammer Truly Radiant [ TR ] Extra Whitening Spinbrush ) ; Regimen Two , the dentifrice and powered toothbrush with the addition of a whitening booster ; or Regimen Three , a negative control ( Colgate Cavity Protection toothpaste and an ADA standard manual brush ) . They were instructed in the use of their assigned products and then brushed unsupervised at home for two minutes , twice daily , for 14 days . Extrinsic tooth stain was assessed at baseline and after two , five , and 14 days using a Modified Lobene Stain Index ( MLSI ) with Lobene inclusion criteria of ≥ 1.5 . RESULTS All three treatment groups had statistically significant ( p < 0.0001 ) mean total MLSI reductions from baseline at each time point , in a time-dependent manner . Day 14 reductions were 22.2 % for Colgate Cavity Protection , 29.1 % for Regimen One , and 34.4 % for Regimen Two . Reductions for Regimen One and Regimen Two were significantly greater compared to Regimen Three , the negative control , at each time period ( p < 0.01 ) , and those for Regimen Two were significantly greater compared to Regimen One on days 2 and 14 ( p < 0.05 ) and directionally more effective on day 5 ( p = 0.0673 ) . CONCLUSION The combination of Truly Radiant toothpaste and Truly Radiant Spinbrush provides safe and effective stain removal that can be further enhanced by the addition of the whitening booster ."
],
"offsets": [
[
0,
1999
]
]
}
] | [
{
"id": "73140",
"type": "Intervention_Pharmacological",
"text": [
"Tooth Whitening Regimen with Added Whitening Booster ."
],
"offsets": [
[
62,
116
]
],
"normalized": []
},
{
"id": "73141",
"type": "Intervention_Pharmacological",
"text": [
"a whitening dentifrice"
],
"offsets": [
[
251,
273
]
],
"normalized": []
},
{
"id": "73142",
"type": "Intervention_Physical",
"text": [
"powered toothbrush"
],
"offsets": [
[
278,
296
]
],
"normalized": []
},
{
"id": "73143",
"type": "Intervention_Pharmacological",
"text": [
"the dentifrice"
],
"offsets": [
[
687,
701
]
],
"normalized": []
},
{
"id": "73144",
"type": "Intervention_Physical",
"text": [
"and powered toothbrush with the addition of a"
],
"offsets": [
[
702,
747
]
],
"normalized": []
},
{
"id": "73145",
"type": "Intervention_Pharmacological",
"text": [
"whitening booster ;"
],
"offsets": [
[
748,
767
]
],
"normalized": []
},
{
"id": "73146",
"type": "Intervention_Physical",
"text": [
"negative control ("
],
"offsets": [
[
789,
807
]
],
"normalized": []
},
{
"id": "73147",
"type": "Intervention_Pharmacological",
"text": [
"Colgate Cavity Protection toothpaste"
],
"offsets": [
[
808,
844
]
],
"normalized": []
},
{
"id": "73148",
"type": "Intervention_Physical",
"text": [
"and an ADA standard manual brush )"
],
"offsets": [
[
845,
879
]
],
"normalized": []
},
{
"id": "73149",
"type": "Outcome_Physical",
"text": [
"extrinsic stain reduction"
],
"offsets": [
[
199,
224
]
],
"normalized": []
},
{
"id": "73150",
"type": "Outcome_Other",
"text": [
"stain reducing effectiveness"
],
"offsets": [
[
400,
428
]
],
"normalized": []
},
{
"id": "73151",
"type": "Outcome_Physical",
"text": [
"Extrinsic tooth"
],
"offsets": [
[
1025,
1040
]
],
"normalized": []
},
{
"id": "73152",
"type": "Outcome_Physical",
"text": [
"Modified Lobene Stain Index ( MLSI )"
],
"offsets": [
[
1115,
1151
]
],
"normalized": []
},
{
"id": "73153",
"type": "Outcome_Other",
"text": [
"0.0001 ) mean total MLSI reductions"
],
"offsets": [
[
1265,
1300
]
],
"normalized": []
},
{
"id": "73154",
"type": "Outcome_Other",
"text": [
"Two"
],
"offsets": [
[
681,
684
]
],
"normalized": []
},
{
"id": "73155",
"type": "Outcome_Other",
"text": [
"Reductions"
],
"offsets": [
[
1481,
1491
]
],
"normalized": []
},
{
"id": "73156",
"type": "Outcome_Other",
"text": [
"provides safe and effective stain removal"
],
"offsets": [
[
1886,
1927
]
],
"normalized": []
},
{
"id": "73157",
"type": "Participant_Sample-size",
"text": [
"Sixty qualifying subjects"
],
"offsets": [
[
439,
464
]
],
"normalized": []
}
] | [] | [] | [] |
73158 | 26678641 | [
{
"id": "73159",
"type": "document",
"text": [
"Efficacy of colchicine versus placebo for the treatment of pericardial effusion after open-heart surgery : A randomized , placebo-controlled trial . BACKGROUND Pericardial effusion ( PE ) , a common complication after open-heart surgery , accounts for 50 % to 85 % of patients . Although reversible in most of the cases , it could be life threatening in the occurrence of tamponade in large effusions . We aimed to determine the therapeutic efficacy of colchicine on PE after open-heart surgery . METHODS The study is a prospective , randomized , triple-blind , placebo-controlled single-center trial at Tehran Heart Center . A total of 149 patients with mild or moderate PE in transthoracic echocardiography were randomly assigned to receive 1 mg/d colchicine ( n = 74 ) or 1 tablet of placebo ( n = 75 ) for 2 weeks and then underwent follow-up echocardiography . RESULTS Baseline and clinical characteristics were not significantly different between the 2 study groups except for age ( P = .02 ) and graft numbers ( P = .005 ) . There was no significant difference in pretreatment and posttreatment PE sizes between the 2 study groups ( P = .440 and .844 , respectively ) . Median ( 25th-75th percentiles ) of effusion changes was 5 mm ( 1-7.6 mm ) in the colchicine group and 5 mm ( 1-6.6 mm ) in the placebo group ( P = .932 ) . Intervention had no significant impact on pretreatment and posttreatment effusion values and changes in isolated coronary artery bypass graft surgery patients ( P = .607 , .539 , and .628 , respectively ) . After adjustment for possible confounders , there was still no significant difference in postoperative PE between the 2 study groups ( t = -0.285 , P = .776 ) . CONCLUSION We concluded that prescription of colchicine does not seem to be effective in treatment of asymptomatic postoperative PE . This could be justified in case that the etiology of most of the PEs might be contribution of noninflammatory factors which are better to be dealt with observational approaches ."
],
"offsets": [
[
0,
2014
]
]
}
] | [
{
"id": "73160",
"type": "Intervention_Pharmacological",
"text": [
"colchicine"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "73161",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
30,
37
]
],
"normalized": []
},
{
"id": "73162",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
122,
140
]
],
"normalized": []
},
{
"id": "73163",
"type": "Intervention_Pharmacological",
"text": [
"1 mg/d colchicine ( n = 74 )"
],
"offsets": [
[
743,
771
]
],
"normalized": []
},
{
"id": "73164",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
30,
37
]
],
"normalized": []
},
{
"id": "73165",
"type": "Intervention_Physical",
"text": [
"echocardiography"
],
"offsets": [
[
692,
708
]
],
"normalized": []
},
{
"id": "73166",
"type": "Intervention_Pharmacological",
"text": [
"colchicine"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "73167",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
30,
37
]
],
"normalized": []
},
{
"id": "73168",
"type": "Intervention_Pharmacological",
"text": [
"colchicine"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "73169",
"type": "Outcome_Physical",
"text": [
"Pericardial effusion ( PE )"
],
"offsets": [
[
160,
187
]
],
"normalized": []
},
{
"id": "73170",
"type": "Outcome_Physical",
"text": [
"PE"
],
"offsets": [
[
183,
185
]
],
"normalized": []
},
{
"id": "73171",
"type": "Outcome_Physical",
"text": [
"PE sizes"
],
"offsets": [
[
1102,
1110
]
],
"normalized": []
},
{
"id": "73172",
"type": "Outcome_Physical",
"text": [
"effusion changes"
],
"offsets": [
[
1213,
1229
]
],
"normalized": []
},
{
"id": "73173",
"type": "Outcome_Physical",
"text": [
"posttreatment effusion values and changes"
],
"offsets": [
[
1393,
1434
]
],
"normalized": []
},
{
"id": "73174",
"type": "Outcome_Physical",
"text": [
"isolated coronary artery bypass graft surgery patients"
],
"offsets": [
[
1438,
1492
]
],
"normalized": []
},
{
"id": "73175",
"type": "Outcome_Physical",
"text": [
"PE"
],
"offsets": [
[
183,
185
]
],
"normalized": []
},
{
"id": "73176",
"type": "Outcome_Physical",
"text": [
"asymptomatic postoperative PE ."
],
"offsets": [
[
1804,
1835
]
],
"normalized": []
},
{
"id": "73177",
"type": "Participant_Condition",
"text": [
"pericardial effusion"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "73178",
"type": "Participant_Condition",
"text": [
"open-heart surgery"
],
"offsets": [
[
86,
104
]
],
"normalized": []
},
{
"id": "73179",
"type": "Participant_Condition",
"text": [
"Pericardial effusion ( PE )"
],
"offsets": [
[
160,
187
]
],
"normalized": []
},
{
"id": "73180",
"type": "Participant_Condition",
"text": [
"PE"
],
"offsets": [
[
183,
185
]
],
"normalized": []
},
{
"id": "73181",
"type": "Participant_Condition",
"text": [
"open-heart surgery"
],
"offsets": [
[
86,
104
]
],
"normalized": []
},
{
"id": "73182",
"type": "Participant_Sample-size",
"text": [
"149"
],
"offsets": [
[
637,
640
]
],
"normalized": []
},
{
"id": "73183",
"type": "Participant_Condition",
"text": [
"mild or moderate PE"
],
"offsets": [
[
655,
674
]
],
"normalized": []
},
{
"id": "73184",
"type": "Participant_Condition",
"text": [
"PE"
],
"offsets": [
[
183,
185
]
],
"normalized": []
},
{
"id": "73185",
"type": "Participant_Condition",
"text": [
"PEs"
],
"offsets": [
[
1901,
1904
]
],
"normalized": []
}
] | [] | [] | [] |
73186 | 26691535 | [
{
"id": "73187",
"type": "document",
"text": [
"Cost-effectiveness analysis of a communication-focused therapy for pre-school children with autism : results from a randomised controlled trial . BACKGROUND Autism is associated with impairments that have life-time consequences for diagnosed individuals and a substantial impact on families . There is growing interest in early interventions for children with autism , yet despite the substantial economic burden , there is little evidence of the cost-effectiveness of such interventions with which to support resource allocation decisions . This study reports an economic evaluation of a parent-mediated , communication-focused therapy carried out within the Pre-School Autism Communication Trial ( PACT ) . METHODS 152 pre-school children with autism were randomly assigned to treatment as usual ( TAU ) or PACT + TAU . Primary outcome was severity of autism symptoms at 13-month follow-up . Economic data included health , education and social services , childcare , parental productivity losses and informal care . RESULTS Clinically meaningful symptom improvement was evident for 53 % of PACT + TAU versus 41 % of TAU ( odds ratio 1.91 , p = 0.074 ) . Service costs were significantly higher for PACT + TAU ( mean difference £4,489 , p < 0.001 ) , but the difference in societal costs was smaller and non-significant ( mean difference £1,385 , p = 0.788 ) due to lower informal care rates for PACT + TAU . CONCLUSIONS Improvements in outcome generated by PACT come at a cost . Although this cost is lower when burden on parents is included , the cost and effectiveness results presented do not support the cost-effectiveness of PACT + TAU compared to TAU alone . TRIAL REGISTRATION Current Controlled Trials ISRCTN58133827 ."
],
"offsets": [
[
0,
1729
]
]
}
] | [
{
"id": "73188",
"type": "Intervention_Educational",
"text": [
"communication-focused therapy"
],
"offsets": [
[
33,
62
]
],
"normalized": []
},
{
"id": "73189",
"type": "Intervention_Educational",
"text": [
"parent-mediated , communication-focused therapy"
],
"offsets": [
[
589,
636
]
],
"normalized": []
},
{
"id": "73190",
"type": "Intervention_Educational",
"text": [
"Pre-School Autism Communication Trial ( PACT ) ."
],
"offsets": [
[
660,
708
]
],
"normalized": []
},
{
"id": "73191",
"type": "Intervention_Educational",
"text": [
"treatment as usual ( TAU"
],
"offsets": [
[
779,
803
]
],
"normalized": []
},
{
"id": "73192",
"type": "Intervention_Educational",
"text": [
"PACT"
],
"offsets": [
[
700,
704
]
],
"normalized": []
},
{
"id": "73193",
"type": "Intervention_Educational",
"text": [
"TAU"
],
"offsets": [
[
800,
803
]
],
"normalized": []
},
{
"id": "73194",
"type": "Outcome_Other",
"text": [
"Cost-effectiveness analysis"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "73195",
"type": "Outcome_Other",
"text": [
"follow-up"
],
"offsets": [
[
882,
891
]
],
"normalized": []
},
{
"id": "73196",
"type": "Outcome_Other",
"text": [
"Economic data included health"
],
"offsets": [
[
894,
923
]
],
"normalized": []
},
{
"id": "73197",
"type": "Outcome_Other",
"text": [
"education and social services"
],
"offsets": [
[
926,
955
]
],
"normalized": []
},
{
"id": "73198",
"type": "Outcome_Mental",
"text": [
"childcare"
],
"offsets": [
[
958,
967
]
],
"normalized": []
},
{
"id": "73199",
"type": "Outcome_Mental",
"text": [
"parental productivity losses and informal care"
],
"offsets": [
[
970,
1016
]
],
"normalized": []
},
{
"id": "73200",
"type": "Outcome_Other",
"text": [
"RESULTS Clinically meaningful symptom improvement"
],
"offsets": [
[
1019,
1068
]
],
"normalized": []
},
{
"id": "73201",
"type": "Outcome_Other",
"text": [
"p = 0.074"
],
"offsets": [
[
1143,
1152
]
],
"normalized": []
},
{
"id": "73202",
"type": "Outcome_Other",
"text": [
"Service"
],
"offsets": [
[
1157,
1164
]
],
"normalized": []
},
{
"id": "73203",
"type": "Outcome_Other",
"text": [
"but the difference"
],
"offsets": [
[
1253,
1271
]
],
"normalized": []
},
{
"id": "73204",
"type": "Participant_Age",
"text": [
"pre-school children"
],
"offsets": [
[
67,
86
]
],
"normalized": []
},
{
"id": "73205",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
92,
98
]
],
"normalized": []
},
{
"id": "73206",
"type": "Participant_Sample-size",
"text": [
"152"
],
"offsets": [
[
717,
720
]
],
"normalized": []
},
{
"id": "73207",
"type": "Participant_Age",
"text": [
"pre-school children"
],
"offsets": [
[
67,
86
]
],
"normalized": []
},
{
"id": "73208",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
92,
98
]
],
"normalized": []
}
] | [] | [] | [] |
73209 | 26712084 | [
{
"id": "73210",
"type": "document",
"text": [
"Pembrolizumab versus docetaxel for previously treated , PD-L1-positive , advanced non-small-cell lung cancer ( KEYNOTE-010 ) : a randomised controlled trial . BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer , there remains a need for effective treatments for progressive disease . We assessed the efficacy of pembrolizumab for patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . METHODS We did this randomised , open-label , phase 2/3 study at 202 academic medical centres in 24 countries . Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells were randomly assigned ( 1:1:1 ) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg , pembrolizumab 10 mg/kg , or docetaxel 75 mg/m ( 2 ) every 3 weeks . The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50 % of tumour cells . We used a threshold for significance of p < 0.00825 ( one-sided ) for the analysis of overall survival and a threshold of p < 0.001 for progression-free survival . This trial is registered at ClinicalTrials.gov , number NCT01905657 . FINDINGS Between Aug 28 , 2013 , and Feb 27 , 2015 , we enrolled 1034 patients : 345 allocated to pembrolizumab 2 mg/kg , 346 allocated to pembrolizumab 10 mg/kg , and 343 allocated to docetaxel . By Sept 30 , 2015 , 521 patients had died . In the total population , median overall survival was 10.4 months with pembrolizumab 2 mg/kg , 12.7 months with pembrolizumab 10 mg/kg , and 8.5 months with docetaxel . Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel ( hazard ratio [ HR ] 0.71 , 95 % CI 0.58-0.88 ; p=0.0008 ) and for pembrolizumab 10 mg/kg versus docetaxel ( 0.61 , 0.49-0.75 ; p < 0.0001 ) . Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg , 4.0 months with pembrolizumab 10 mg/kg , and 4.0 months with docetaxel , with no significant difference for pembrolizumab 2 mg/kg versus docetaxel ( 0.88 , 0.74-1.05 ; p=0.07 ) or for pembrolizumab 10 mg/kg versus docetaxel ( HR 0.79 , 95 % CI 0.66-0.94 ; p=0.004 ) . Among patients with at least 50 % of tumour cells expressing PD-L1 , overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 14.9 months vs 8.2 months ; HR 0.54 , 95 % CI 0.38-0.77 ; p=0.0002 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 17.3 months vs 8.2 months ; 0.50 , 0.36-0.70 ; p < 0.0001 ) . Likewise , for this patient population , progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel ( median 5.0 months vs 4.1 months ; HR 0.59 , 95 % CI 0.44-0.78 ; p=0.0001 ) and with pembrolizumab 10 mg/kg than with docetaxel ( 5.2 months vs 4.1 months ; 0.59 , 0.45-0.78 ; p < 0.0001 ) . Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel ( 43 [ 13 % ] of 339 patients given 2 mg/kg , 55 [ 16 % ] of 343 given 10 mg/kg , and 109 [ 35 % ] of 309 given docetaxel ) . INTERPRETATION Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated , PD-L1-positive , advanced non-small-cell lung cancer . These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection . FUNDING Merck & Co ."
],
"offsets": [
[
0,
3531
]
]
}
] | [
{
"id": "73211",
"type": "Intervention_Pharmacological",
"text": [
"Pembrolizumab"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "73212",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73213",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73214",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73215",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73216",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73217",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73218",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73219",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73220",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73221",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73222",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73223",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73224",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73225",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73226",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73227",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73228",
"type": "Intervention_Pharmacological",
"text": [
"docetaxel"
],
"offsets": [
[
21,
30
]
],
"normalized": []
},
{
"id": "73229",
"type": "Intervention_Pharmacological",
"text": [
"Pembrolizumab"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "73230",
"type": "Intervention_Pharmacological",
"text": [
"pembrolizumab"
],
"offsets": [
[
352,
365
]
],
"normalized": []
},
{
"id": "73231",
"type": "Outcome_Mortality",
"text": [
"survival and progression-free survival"
],
"offsets": [
[
928,
966
]
],
"normalized": []
},
{
"id": "73232",
"type": "Outcome_Mortality",
"text": [
"median overall survival"
],
"offsets": [
[
1570,
1593
]
],
"normalized": []
},
{
"id": "73233",
"type": "Outcome_Mortality",
"text": [
"Overall survival"
],
"offsets": [
[
1713,
1729
]
],
"normalized": []
},
{
"id": "73234",
"type": "Outcome_Mortality",
"text": [
"Median progression-free survival"
],
"offsets": [
[
1942,
1974
]
],
"normalized": []
},
{
"id": "73235",
"type": "Outcome_Mortality",
"text": [
"overall survival"
],
"offsets": [
[
920,
936
]
],
"normalized": []
},
{
"id": "73236",
"type": "Outcome_Mortality",
"text": [
"progression-free survival"
],
"offsets": [
[
941,
966
]
],
"normalized": []
},
{
"id": "73237",
"type": "Outcome_Adverse-effects",
"text": [
"Grade 3-5 treatment-related adverse events"
],
"offsets": [
[
2970,
3012
]
],
"normalized": []
},
{
"id": "73238",
"type": "Outcome_Mortality",
"text": [
"overall survival"
],
"offsets": [
[
920,
936
]
],
"normalized": []
},
{
"id": "73239",
"type": "Participant_Condition",
"text": [
"previously treated , PD-L1-positive , advanced non-small-cell lung cancer"
],
"offsets": [
[
35,
108
]
],
"normalized": []
},
{
"id": "73240",
"type": "Participant_Condition",
"text": [
"advanced non-small-cell lung cancer"
],
"offsets": [
[
73,
108
]
],
"normalized": []
},
{
"id": "73241",
"type": "Participant_Condition",
"text": [
"previously treated , PD-L1-positive , advanced non-small-cell lung cancer"
],
"offsets": [
[
35,
108
]
],
"normalized": []
},
{
"id": "73242",
"type": "Participant_Condition",
"text": [
"Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1 % of tumour cells"
],
"offsets": [
[
572,
685
]
],
"normalized": []
},
{
"id": "73243",
"type": "Participant_Sample-size",
"text": [
"1034 patients"
],
"offsets": [
[
1368,
1381
]
],
"normalized": []
}
] | [] | [] | [] |
73244 | 2672925 | [
{
"id": "73245",
"type": "document",
"text": [
"Amiprilose hydrochloride for rheumatoid arthritis . STUDY OBJECTIVE To assess the safety and efficacy of amiprilose hydrochloride ( HCl ) , a novel synthetic carbohydrate with anti-inflammatory and immunomodulatory properties , in patients with rheumatoid arthritis . DESIGN Prospective , multicenter , randomized , parallel group , double-blind placebo-controlled 12-week trial . PATIENTS Two hundred and one functional class I and II patients with definite or classic rheumatoid arthritis , previously untreated with disease modifying antirheumatic drugs . INTERVENTIONS Patients were withdrawn from nonsteroidal anti-inflammatory drug therapy . Those who flared were randomly assigned to amiprilose HCl , 6 g/d , or placebo for 12 weeks . No concomitant anti-inflammatory or antirheumatic drug therapy was permitted during the study . Combination acetaminophen and propoxyphene napsylate was the only supplemental analgesic medication allowed . MEASUREMENTS AND MAIN RESULTS The number of painful joints and swollen joints , joint pain and joint swelling indices , left and right grip strength , investigator global assessment , and patient global assessment returned to baseline for the amiprilose group and showed statistically significant ( P less than 0.05 ) differences from the placebo group within 4 to 6 weeks . The protocol criteria for overall therapeutic response were satisfied by 41 % of the amiprilose patients , compared with 21 % of the placebo group ( P = 0.003 ) . Approximately 0.5 tablet per day less analgesic medication was taken by the amiprilose group ( P less than 0.05 at weeks 6 and 12 ) . There were no statistically significant differences in morning stiffness , walking time , erythrocyte sedimentation rate , C-reactive protein , or rheumatoid factor between the groups . A similar number of adverse experiences were reported by the patients on amiprilose ( 67 % ) and on placebo ( 63 % ) . One patient on amiprilose developed thrombocytopenia of unknown cause ; no other reported adverse effects were serious . CONCLUSIONS Amiprilose HCl has significant anti-inflammatory activity and a favorable safety profile when used as the sole antirheumatic therapy in patients with active rheumatoid arthritis . Synthetic carbohydrates may represent an important new class of drugs for the treatment of inflammatory , autoimmune diseases ."
],
"offsets": [
[
0,
2365
]
]
}
] | [
{
"id": "73246",
"type": "Intervention_Pharmacological",
"text": [
"Amiprilose hydrochloride"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "73247",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose hydrochloride ( HCl )"
],
"offsets": [
[
105,
137
]
],
"normalized": []
},
{
"id": "73248",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
346,
364
]
],
"normalized": []
},
{
"id": "73249",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose HCl , 6 g/d"
],
"offsets": [
[
691,
713
]
],
"normalized": []
},
{
"id": "73250",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose"
],
"offsets": [
[
105,
115
]
],
"normalized": []
},
{
"id": "73251",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
346,
353
]
],
"normalized": []
},
{
"id": "73252",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose"
],
"offsets": [
[
105,
115
]
],
"normalized": []
},
{
"id": "73253",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
346,
353
]
],
"normalized": []
},
{
"id": "73254",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose"
],
"offsets": [
[
105,
115
]
],
"normalized": []
},
{
"id": "73255",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
346,
353
]
],
"normalized": []
},
{
"id": "73256",
"type": "Intervention_Pharmacological",
"text": [
"amiprilose"
],
"offsets": [
[
105,
115
]
],
"normalized": []
},
{
"id": "73257",
"type": "Intervention_Pharmacological",
"text": [
"Amiprilose HCl"
],
"offsets": [
[
2058,
2072
]
],
"normalized": []
},
{
"id": "73258",
"type": "Outcome_Other",
"text": [
"safety"
],
"offsets": [
[
82,
88
]
],
"normalized": []
},
{
"id": "73259",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
93,
101
]
],
"normalized": []
},
{
"id": "73260",
"type": "Outcome_Physical",
"text": [
"number of painful joints"
],
"offsets": [
[
982,
1006
]
],
"normalized": []
},
{
"id": "73261",
"type": "Outcome_Physical",
"text": [
"swollen joints"
],
"offsets": [
[
1011,
1025
]
],
"normalized": []
},
{
"id": "73262",
"type": "Outcome_Pain",
"text": [
"joint pain"
],
"offsets": [
[
1028,
1038
]
],
"normalized": []
},
{
"id": "73263",
"type": "Outcome_Physical",
"text": [
"joint swelling indices"
],
"offsets": [
[
1043,
1065
]
],
"normalized": []
},
{
"id": "73264",
"type": "Outcome_Physical",
"text": [
"left and right grip strength"
],
"offsets": [
[
1068,
1096
]
],
"normalized": []
},
{
"id": "73265",
"type": "Outcome_Physical",
"text": [
"investigator global assessment"
],
"offsets": [
[
1099,
1129
]
],
"normalized": []
},
{
"id": "73266",
"type": "Outcome_Physical",
"text": [
"patient global assessment"
],
"offsets": [
[
1136,
1161
]
],
"normalized": []
},
{
"id": "73267",
"type": "Outcome_Other",
"text": [
"overall therapeutic response"
],
"offsets": [
[
1349,
1377
]
],
"normalized": []
},
{
"id": "73268",
"type": "Outcome_Other",
"text": [
"analgesic medication"
],
"offsets": [
[
917,
937
]
],
"normalized": []
},
{
"id": "73269",
"type": "Outcome_Physical",
"text": [
"morning stiffness , walking time , erythrocyte sedimentation rate"
],
"offsets": [
[
1675,
1740
]
],
"normalized": []
},
{
"id": "73270",
"type": "Outcome_Physical",
"text": [
"C-reactive protein"
],
"offsets": [
[
1743,
1761
]
],
"normalized": []
},
{
"id": "73271",
"type": "Outcome_Physical",
"text": [
"rheumatoid factor"
],
"offsets": [
[
1767,
1784
]
],
"normalized": []
},
{
"id": "73272",
"type": "Outcome_Adverse-effects",
"text": [
"adverse experiences"
],
"offsets": [
[
1826,
1845
]
],
"normalized": []
},
{
"id": "73273",
"type": "Outcome_Adverse-effects",
"text": [
"thrombocytopenia"
],
"offsets": [
[
1961,
1977
]
],
"normalized": []
},
{
"id": "73274",
"type": "Outcome_Other",
"text": [
"anti-inflammatory activity"
],
"offsets": [
[
2089,
2115
]
],
"normalized": []
},
{
"id": "73275",
"type": "Outcome_Other",
"text": [
"favorable safety profile"
],
"offsets": [
[
2122,
2146
]
],
"normalized": []
},
{
"id": "73276",
"type": "Participant_Condition",
"text": [
"rheumatoid arthritis ."
],
"offsets": [
[
29,
51
]
],
"normalized": []
},
{
"id": "73277",
"type": "Participant_Condition",
"text": [
"rheumatoid arthritis"
],
"offsets": [
[
29,
49
]
],
"normalized": []
},
{
"id": "73278",
"type": "Participant_Sample-size",
"text": [
"Two hundred and one"
],
"offsets": [
[
390,
409
]
],
"normalized": []
},
{
"id": "73279",
"type": "Participant_Condition",
"text": [
"rheumatoid arthritis"
],
"offsets": [
[
29,
49
]
],
"normalized": []
},
{
"id": "73280",
"type": "Participant_Condition",
"text": [
"active rheumatoid arthritis"
],
"offsets": [
[
2208,
2235
]
],
"normalized": []
}
] | [] | [] | [] |
73281 | 26742304 | [
{
"id": "73282",
"type": "document",
"text": [
"Effect of direct current pulse stimulating acupoints of JiaJi ( T10-13 ) and Ciliao ( BL 32 ) with Han 's Acupoint Nerve Stimulator on labour pain in women : a randomized controlled clinical study . OBJECTIVE To assess the clinical effect and safety of direct current ( DC ) pulse produced by Han 's Acupoint Nerve Stimulator in reduction ( HANS ) of labor pain . METHODS Totally 120 participants were enrolled in this clinical trial , and were randomly divided into 4 groups including : HANS group , patient controlled intravenous analgesia ( PCIA ) group , patient-controlled epidural analgesia ( PCEA ) group and control group . The HANS group was treated by stimulating the acupoints of JiaJi ( T10-L3 ) and Ciliao ( BL 32 ) with DC pulse of 100 Hz and 15-30 mA produced by a portable battery-powered Han 's Acupoint Nerve Stimulator for 30 min . The PCIA group was intravenously infused Ondansetron ( 8 mg ) for 5 min , then tramadol injection ( 1.5 mg/kg ) was slowly dripped by using BaxterAP II electronic pump with 50 mL tramadol ( 0.70 % ) + ondansetron ( 8 mg ) , background infusion 2 mL/h , PCA dose of 2 mL , lockout interval of 10 min . In PCEA group , women received intrathecal injection ropivacaine ( 3 mg ) in L2-3 , and epidural catheter was connected to BaxterAP II electronic pump , with 100 mL Ropivacaine ( 0.1 % ) and Sufentanil ( 50 ug ) , background infusion 5 mL , Patient controlled analgesia ( PCA ) dose of 5 mL , lockout interval of 10 min . The control group was not received analgesia . The visual analogue scale ( VAS ) , stage and manner of labor , Apgar score of newborn , neonatal weights , oxytocin dosage , postpartum hemorrhage and side effects were monitored in all groups . RESULTS The vital signs were all stable in the four analgesic groups . After analgesia , there was statistical difference in VAS score between HANS group and control group , between PCEA group and the control group , between PCIA group and control group . The analgesic effect in the PCEA group was significantly better than that of other two groups . The second stage of labor in the PCEA group was longer than the other three groups , showing significant difference between them . The Apgar score of newborn 1 min after birth in the PCIA group was slightly lower than that of the other two groups , showing significant difference between them . The neonatal weights between four groups were not significantly different . The rate of cesarean section in the control group was significantly higher than that of the labor analgesia group , there was statistically difference in four groups . The number of PCIA group that used oxytocin was lower than that of other three groups . There was no significant difference in postpartum hemorrhage between four groups . The side effects of the PCEA group were itching , uroschesis and neonatal asphyxia and PCIA group were nausea and vomiting and neonatal asphyxia . However , fewer side-effects were observed in the HANS group . CONCLUSION The DC pulse produced by HANS may be a non-pharmacological alternative to labor pain with fewer side effects ."
],
"offsets": [
[
0,
3110
]
]
}
] | [
{
"id": "73283",
"type": "Intervention_Physical",
"text": [
"direct current pulse stimulating acupoints of JiaJi"
],
"offsets": [
[
10,
61
]
],
"normalized": []
},
{
"id": "73284",
"type": "Intervention_Physical",
"text": [
"Han 's Acupoint Nerve Stimulator"
],
"offsets": [
[
99,
131
]
],
"normalized": []
},
{
"id": "73285",
"type": "Intervention_Physical",
"text": [
"direct current ( DC ) pulse produced by Han 's Acupoint Nerve Stimulator"
],
"offsets": [
[
253,
325
]
],
"normalized": []
},
{
"id": "73286",
"type": "Intervention_Pharmacological",
"text": [
"HANS group"
],
"offsets": [
[
488,
498
]
],
"normalized": []
},
{
"id": "73287",
"type": "Intervention_Pharmacological",
"text": [
"patient controlled intravenous analgesia ( PCIA ) group"
],
"offsets": [
[
501,
556
]
],
"normalized": []
},
{
"id": "73288",
"type": "Intervention_Pharmacological",
"text": [
"patient-controlled epidural analgesia ( PCEA )"
],
"offsets": [
[
559,
605
]
],
"normalized": []
},
{
"id": "73289",
"type": "Intervention_Physical",
"text": [
"HANS"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73290",
"type": "Intervention_Physical",
"text": [
"acupoints of JiaJi"
],
"offsets": [
[
43,
61
]
],
"normalized": []
},
{
"id": "73291",
"type": "Intervention_Physical",
"text": [
"Ciliao"
],
"offsets": [
[
77,
83
]
],
"normalized": []
},
{
"id": "73292",
"type": "Intervention_Physical",
"text": [
"DC pulse"
],
"offsets": [
[
734,
742
]
],
"normalized": []
},
{
"id": "73293",
"type": "Intervention_Physical",
"text": [
"portable battery-powered Han 's Acupoint Nerve Stimulator"
],
"offsets": [
[
780,
837
]
],
"normalized": []
},
{
"id": "73294",
"type": "Intervention_Physical",
"text": [
"PCIA"
],
"offsets": [
[
544,
548
]
],
"normalized": []
},
{
"id": "73295",
"type": "Intervention_Pharmacological",
"text": [
"Ondansetron"
],
"offsets": [
[
892,
903
]
],
"normalized": []
},
{
"id": "73296",
"type": "Intervention_Pharmacological",
"text": [
"tramadol injection"
],
"offsets": [
[
930,
948
]
],
"normalized": []
},
{
"id": "73297",
"type": "Intervention_Pharmacological",
"text": [
"tramadol"
],
"offsets": [
[
930,
938
]
],
"normalized": []
},
{
"id": "73298",
"type": "Intervention_Pharmacological",
"text": [
"ondansetron"
],
"offsets": [
[
1052,
1063
]
],
"normalized": []
},
{
"id": "73299",
"type": "Intervention_Pharmacological",
"text": [
"PCEA"
],
"offsets": [
[
599,
603
]
],
"normalized": []
},
{
"id": "73300",
"type": "Intervention_Pharmacological",
"text": [
"injection ropivacaine"
],
"offsets": [
[
1195,
1216
]
],
"normalized": []
},
{
"id": "73301",
"type": "Intervention_Pharmacological",
"text": [
"Ropivacaine"
],
"offsets": [
[
1317,
1328
]
],
"normalized": []
},
{
"id": "73302",
"type": "Intervention_Pharmacological",
"text": [
"Sufentanil"
],
"offsets": [
[
1343,
1353
]
],
"normalized": []
},
{
"id": "73303",
"type": "Intervention_Pharmacological",
"text": [
"Patient controlled analgesia ( PCA )"
],
"offsets": [
[
1393,
1429
]
],
"normalized": []
},
{
"id": "73304",
"type": "Intervention_Physical",
"text": [
"HANS"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73305",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
171,
178
]
],
"normalized": []
},
{
"id": "73306",
"type": "Intervention_Physical",
"text": [
"PCEA"
],
"offsets": [
[
599,
603
]
],
"normalized": []
},
{
"id": "73307",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
171,
178
]
],
"normalized": []
},
{
"id": "73308",
"type": "Intervention_Physical",
"text": [
"PCIA"
],
"offsets": [
[
544,
548
]
],
"normalized": []
},
{
"id": "73309",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
171,
178
]
],
"normalized": []
},
{
"id": "73310",
"type": "Intervention_Physical",
"text": [
"PCEA"
],
"offsets": [
[
599,
603
]
],
"normalized": []
},
{
"id": "73311",
"type": "Intervention_Physical",
"text": [
"PCEA"
],
"offsets": [
[
599,
603
]
],
"normalized": []
},
{
"id": "73312",
"type": "Intervention_Physical",
"text": [
"PCIA"
],
"offsets": [
[
544,
548
]
],
"normalized": []
},
{
"id": "73313",
"type": "Intervention_Physical",
"text": [
"PCIA"
],
"offsets": [
[
544,
548
]
],
"normalized": []
},
{
"id": "73314",
"type": "Intervention_Physical",
"text": [
"PCEA"
],
"offsets": [
[
599,
603
]
],
"normalized": []
},
{
"id": "73315",
"type": "Intervention_Physical",
"text": [
"PCIA"
],
"offsets": [
[
544,
548
]
],
"normalized": []
},
{
"id": "73316",
"type": "Intervention_Physical",
"text": [
"HANS"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73317",
"type": "Intervention_Physical",
"text": [
"HANS"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73318",
"type": "Outcome_Pain",
"text": [
"labour pain"
],
"offsets": [
[
135,
146
]
],
"normalized": []
},
{
"id": "73319",
"type": "Outcome_Pain",
"text": [
"labor pain ."
],
"offsets": [
[
351,
363
]
],
"normalized": []
},
{
"id": "73320",
"type": "Outcome_Physical",
"text": [
"The"
],
"offsets": [
[
632,
635
]
],
"normalized": []
},
{
"id": "73321",
"type": "Outcome_Pain",
"text": [
"visual analogue scale ( VAS )"
],
"offsets": [
[
1525,
1554
]
],
"normalized": []
},
{
"id": "73322",
"type": "Outcome_Physical",
"text": [
", stage and manner of labor , Apgar score of newborn , neonatal weights , oxytocin dosage ,"
],
"offsets": [
[
1555,
1646
]
],
"normalized": []
},
{
"id": "73323",
"type": "Outcome_Adverse-effects",
"text": [
"postpartum hemorrhage and side effects"
],
"offsets": [
[
1647,
1685
]
],
"normalized": []
},
{
"id": "73324",
"type": "Outcome_Pain",
"text": [
"VAS score"
],
"offsets": [
[
1842,
1851
]
],
"normalized": []
},
{
"id": "73325",
"type": "Outcome_Pain",
"text": [
"analgesic effect"
],
"offsets": [
[
1977,
1993
]
],
"normalized": []
},
{
"id": "73326",
"type": "Outcome_Physical",
"text": [
"neonatal weights"
],
"offsets": [
[
1610,
1626
]
],
"normalized": []
},
{
"id": "73327",
"type": "Outcome_Physical",
"text": [
"rate of cesarean section"
],
"offsets": [
[
2444,
2468
]
],
"normalized": []
},
{
"id": "73328",
"type": "Outcome_Other",
"text": [
"used oxytocin"
],
"offsets": [
[
2638,
2651
]
],
"normalized": []
},
{
"id": "73329",
"type": "Outcome_Adverse-effects",
"text": [
"postpartum hemorrhage"
],
"offsets": [
[
1647,
1668
]
],
"normalized": []
},
{
"id": "73330",
"type": "Outcome_Adverse-effects",
"text": [
"itching , uroschesis and neonatal asphyxia"
],
"offsets": [
[
2819,
2861
]
],
"normalized": []
},
{
"id": "73331",
"type": "Outcome_Adverse-effects",
"text": [
"nausea and vomiting and neonatal asphyxia ."
],
"offsets": [
[
2882,
2925
]
],
"normalized": []
},
{
"id": "73332",
"type": "Outcome_Adverse-effects",
"text": [
"side-effects"
],
"offsets": [
[
2942,
2954
]
],
"normalized": []
},
{
"id": "73333",
"type": "Participant_Condition",
"text": [
"labour pain"
],
"offsets": [
[
135,
146
]
],
"normalized": []
},
{
"id": "73334",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
150,
155
]
],
"normalized": []
},
{
"id": "73335",
"type": "Participant_Sample-size",
"text": [
"120"
],
"offsets": [
[
380,
383
]
],
"normalized": []
}
] | [] | [] | [] |
73336 | 26746121 | [
{
"id": "73337",
"type": "document",
"text": [
"Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder : A Randomized Trial . OBJECTIVES To determine safety and efficacy of the 5HT1A serotonin partial agonist buspirone on core autism and associated features in children with autism spectrum disorder ( ASD ) . STUDY DESIGN Children 2-6 years of age with ASD ( N = 166 ) were randomized to receive placebo or 2.5 or 5.0 mg of buspirone twice daily . The primary objective was to evaluate the effects of 24 weeks of buspirone on the Autism Diagnostic Observation Schedule ( ADOS ) Composite Total Score . Secondary objectives included evaluating the effects of buspirone on social competence , repetitive behaviors , language , sensory dysfunction , and anxiety and to assess side effects . Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy . RESULTS There was no difference in the ADOS Composite Total Score between baseline and 24 weeks among the 3 treatment groups ( P = .400 ) ; however , the ADOS Restricted and Repetitive Behavior score showed a time-by-treatment effect ( P = .006 ) ; the 2.5-mg buspirone group showed significant improvement ( P = .003 ) , whereas placebo and 5.0-mg buspirone groups showed no change . Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography ( P = .018 ) or if they showed normal levels of blood serotonin ( P = .044 ) . Adverse events did not differ significantly among treatment groups . CONCLUSIONS Treatment with 2.5 mg of buspirone in young children with ASD might be a useful adjunct therapy to target restrictive and repetitive behaviors in conjunction with behavioral interventions . TRIAL REGISTRATION ClinicalTrials.gov : NCT00873509 ."
],
"offsets": [
[
0,
1905
]
]
}
] | [
{
"id": "73338",
"type": "Intervention_Pharmacological",
"text": [
"Low-Dose Buspirone"
],
"offsets": [
[
12,
30
]
],
"normalized": []
},
{
"id": "73339",
"type": "Intervention_Pharmacological",
"text": [
"5HT1A serotonin partial agonist buspirone"
],
"offsets": [
[
192,
233
]
],
"normalized": []
},
{
"id": "73340",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
412,
419
]
],
"normalized": []
},
{
"id": "73341",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73342",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73343",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73344",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73345",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73346",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
412,
419
]
],
"normalized": []
},
{
"id": "73347",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73348",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73349",
"type": "Intervention_Pharmacological",
"text": [
"buspirone"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "73350",
"type": "Outcome_Physical",
"text": [
"Autism Diagnostic Observation Schedule ( ADOS ) Composite Total Score"
],
"offsets": [
[
546,
615
]
],
"normalized": []
},
{
"id": "73351",
"type": "Outcome_Physical",
"text": [
"social competence"
],
"offsets": [
[
687,
704
]
],
"normalized": []
},
{
"id": "73352",
"type": "Outcome_Physical",
"text": [
"repetitive behaviors"
],
"offsets": [
[
707,
727
]
],
"normalized": []
},
{
"id": "73353",
"type": "Outcome_Physical",
"text": [
"language"
],
"offsets": [
[
730,
738
]
],
"normalized": []
},
{
"id": "73354",
"type": "Outcome_Physical",
"text": [
"sensory dysfunction"
],
"offsets": [
[
741,
760
]
],
"normalized": []
},
{
"id": "73355",
"type": "Outcome_Physical",
"text": [
"anxiety"
],
"offsets": [
[
767,
774
]
],
"normalized": []
},
{
"id": "73356",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
789,
801
]
],
"normalized": []
},
{
"id": "73357",
"type": "Outcome_Physical",
"text": [
"Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations"
],
"offsets": [
[
804,
901
]
],
"normalized": []
},
{
"id": "73358",
"type": "Outcome_Physical",
"text": [
"ADOS Composite Total Score"
],
"offsets": [
[
993,
1019
]
],
"normalized": []
},
{
"id": "73359",
"type": "Outcome_Physical",
"text": [
"ADOS Restricted and Repetitive Behavior score"
],
"offsets": [
[
1108,
1153
]
],
"normalized": []
},
{
"id": "73360",
"type": "Participant_Age",
"text": [
"Young Children"
],
"offsets": [
[
73,
87
]
],
"normalized": []
},
{
"id": "73361",
"type": "Participant_Condition",
"text": [
"Autism Spectrum Disorder"
],
"offsets": [
[
93,
117
]
],
"normalized": []
},
{
"id": "73362",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
276,
284
]
],
"normalized": []
},
{
"id": "73363",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder ( ASD )"
],
"offsets": [
[
290,
322
]
],
"normalized": []
},
{
"id": "73364",
"type": "Participant_Age",
"text": [
"Children 2-6 years of age"
],
"offsets": [
[
338,
363
]
],
"normalized": []
},
{
"id": "73365",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
317,
320
]
],
"normalized": []
},
{
"id": "73366",
"type": "Participant_Sample-size",
"text": [
"166"
],
"offsets": [
[
379,
382
]
],
"normalized": []
},
{
"id": "73367",
"type": "Participant_Age",
"text": [
"young children"
],
"offsets": [
[
1700,
1714
]
],
"normalized": []
},
{
"id": "73368",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
317,
320
]
],
"normalized": []
}
] | [] | [] | [] |
73369 | 2678349 | [
{
"id": "73370",
"type": "document",
"text": [
"Covariance analysis in generalized linear measurement error models . We summarize some of the recent work on the errors-in-variables problem in generalized linear models . The focus is on covariance analysis , and in particular testing for and estimation of treatment effects . There is a considerable difference between the randomized and non-randomized models when testing for an effect . In randomized studies , simple techniques exist for testing for a treatment effect . In some instances , such as linear and multiplicative regression , simple methods exist for estimating the treatment effect . In other examples such as logistic regression , estimating a treatment effect requires careful attention to measurement error . In non-randomized studies , there is no recourse to understanding and modelling measurement error . In particular ignoring measurement error can lead to the wrong conclusions , for example the true but unobserved data may indicate a positive effect for treatment , while the observed data indicate the opposite . Some of the possible methods are outlined and compared ."
],
"offsets": [
[
0,
1099
]
]
}
] | [
{
"id": "73371",
"type": "Intervention_Physical",
"text": [
"Covariance analysis"
],
"offsets": [
[
0,
19
]
],
"normalized": []
}
] | [] | [] | [] |
73372 | 2679258 | [
{
"id": "73373",
"type": "document",
"text": [
"Prospective trial of timing of bacillus Calmette-Guérin vaccination in Canadian Cree infants . We studied 184 Cree Indian infants in randomized , prospective fashion to assess the effect of age on lymphocyte sensitization to purified protein derivative ( PPD ) before and after and without bacillus Calmette-Guérin ( BCG ) vaccination . Lymphocyte responses to PPD , Candida , and streptokinase were measured at birth and at intervals later . The mean response of paired values from 26 infants without BCG vaccination rose for the PPD stimulation index ( SI ) from 2.7 at birth to 3.9 before 2 yr of age . The SI for both Candida and streptokinase for this group of infants rose significantly in the first 2 yr ( p less than 0.05 ) . In 66 infants who received BCG in the first 7 days of life , the PPD-SI rose from 3.1 to 35.3 ( p less than 0.001 ) . In 17 infants who received the vaccine later but before 9 months , it rose from 3.1 at birth to 24.9 , and in 14 who received it between 9 months and 2 yr , it rose from 2.2 to 52.9 . The lymphocyte responses to PPD after BCG in these two groups were significantly different ( p less than 0.05 ) . There was no evidence in the older infants that a raised PPD-SI before BCG vaccination affected lymphocyte sensitization by the vaccine . We conclude that increasing the age at vaccination with BCG from birth to more than 9 months enhances immunologic sensitization to PPD significantly in this population ."
],
"offsets": [
[
0,
1457
]
]
}
] | [
{
"id": "73374",
"type": "Intervention_Pharmacological",
"text": [
"bacillus Calmette-Guérin vaccination"
],
"offsets": [
[
31,
67
]
],
"normalized": []
},
{
"id": "73375",
"type": "Intervention_Pharmacological",
"text": [
"bacillus Calmette-Guérin ( BCG ) vaccination"
],
"offsets": [
[
290,
334
]
],
"normalized": []
},
{
"id": "73376",
"type": "Outcome_Physical",
"text": [
"lymphocyte responses"
],
"offsets": [
[
1040,
1060
]
],
"normalized": []
},
{
"id": "73377",
"type": "Outcome_Physical",
"text": [
"lymphocyte sensitization"
],
"offsets": [
[
197,
221
]
],
"normalized": []
}
] | [] | [] | [] |
73378 | 2682347 | [
{
"id": "73379",
"type": "document",
"text": [
"Auditory evoked potential modifications according to clinical and biochemical responsiveness to fenfluramine treatment in children with autistic behavior . Evoked potentials to auditory stimulations varying in intensity were studied in 13 children with autistic behavior treated with fenfluramine . Modifications of both amplitude and single-trial potential variability were considered according to the clinical and biochemical responsiveness to this drug . Six children ( responders ) were clinically improved by the treatment . Electrophysiological data were affected according to the clinical and biochemical responsiveness to fenfluramine : the auditory evoked potential amplitude increased , and the single-trial potential variability decreased at each intensity level only in responders whose dopaminergic metabolism was significantly modified by fenfluramine treatment . No modification was found in nonresponders . Both biochemical and electrophysiological results argued for an amphetamine-like action of fenfluramine in those autistic children whose attention deficits are associated with motor disturbances including hyperactivity ."
],
"offsets": [
[
0,
1143
]
]
}
] | [
{
"id": "73380",
"type": "Intervention_Pharmacological",
"text": [
"fenfluramine treatment"
],
"offsets": [
[
96,
118
]
],
"normalized": []
},
{
"id": "73381",
"type": "Intervention_Pharmacological",
"text": [
"fenfluramine"
],
"offsets": [
[
96,
108
]
],
"normalized": []
},
{
"id": "73382",
"type": "Intervention_Pharmacological",
"text": [
"fenfluramine"
],
"offsets": [
[
96,
108
]
],
"normalized": []
},
{
"id": "73383",
"type": "Intervention_Pharmacological",
"text": [
"fenfluramine"
],
"offsets": [
[
96,
108
]
],
"normalized": []
},
{
"id": "73384",
"type": "Outcome_Other",
"text": [
"Modifications of both amplitude"
],
"offsets": [
[
299,
330
]
],
"normalized": []
},
{
"id": "73385",
"type": "Outcome_Other",
"text": [
"single-trial potential variability"
],
"offsets": [
[
335,
369
]
],
"normalized": []
},
{
"id": "73386",
"type": "Outcome_Other",
"text": [
"auditory evoked potential amplitude"
],
"offsets": [
[
649,
684
]
],
"normalized": []
},
{
"id": "73387",
"type": "Outcome_Other",
"text": [
"single-trial potential variability"
],
"offsets": [
[
335,
369
]
],
"normalized": []
},
{
"id": "73388",
"type": "Outcome_Physical",
"text": [
"dopaminergic metabolism"
],
"offsets": [
[
799,
822
]
],
"normalized": []
},
{
"id": "73389",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
122,
130
]
],
"normalized": []
},
{
"id": "73390",
"type": "Participant_Condition",
"text": [
"autistic"
],
"offsets": [
[
136,
144
]
],
"normalized": []
},
{
"id": "73391",
"type": "Participant_Sample-size",
"text": [
"13"
],
"offsets": [
[
236,
238
]
],
"normalized": []
},
{
"id": "73392",
"type": "Participant_Condition",
"text": [
"autistic behavior"
],
"offsets": [
[
136,
153
]
],
"normalized": []
},
{
"id": "73393",
"type": "Participant_Condition",
"text": [
"fenfluramine ."
],
"offsets": [
[
284,
298
]
],
"normalized": []
}
] | [] | [] | [] |
73394 | 2688237 | [
{
"id": "73395",
"type": "document",
"text": [
"[ EMLA cream ( lidocaine/prilocaine ) versus infiltration analgesia with carbocaine ( mepivacaine ) in vasectomy ] . The analgesic efficacy of EMLA cream was compared with infiltration with 1 % carbocaine in 13 bilateral vasectomies . Twelve patients preferred infiltration analgesia . EMLA analgesia was only effective in the skin , and had to be supplemented as the incision reached subcutaneous tissue ."
],
"offsets": [
[
0,
406
]
]
}
] | [
{
"id": "73396",
"type": "Intervention_Pharmacological",
"text": [
"EMLA cream ( lidocaine/prilocaine )"
],
"offsets": [
[
2,
37
]
],
"normalized": []
},
{
"id": "73397",
"type": "Intervention_Pharmacological",
"text": [
"infiltration analgesia with carbocaine ( mepivacaine )"
],
"offsets": [
[
45,
99
]
],
"normalized": []
},
{
"id": "73398",
"type": "Intervention_Pharmacological",
"text": [
"EMLA cream"
],
"offsets": [
[
2,
12
]
],
"normalized": []
},
{
"id": "73399",
"type": "Intervention_Pharmacological",
"text": [
"infiltration with 1 % carbocaine"
],
"offsets": [
[
172,
204
]
],
"normalized": []
},
{
"id": "73400",
"type": "Intervention_Pharmacological",
"text": [
"EMLA analgesia"
],
"offsets": [
[
286,
300
]
],
"normalized": []
},
{
"id": "73401",
"type": "Outcome_Pain",
"text": [
"analgesic efficacy"
],
"offsets": [
[
121,
139
]
],
"normalized": []
},
{
"id": "73402",
"type": "Outcome_Other",
"text": [
"only effective in the skin"
],
"offsets": [
[
305,
331
]
],
"normalized": []
},
{
"id": "73403",
"type": "Outcome_Other",
"text": [
"had to be supplemented"
],
"offsets": [
[
338,
360
]
],
"normalized": []
}
] | [] | [] | [] |
73404 | 26882812 | [
{
"id": "73405",
"type": "document",
"text": [
"The Effects of Valsartan and Amlodipine on the Levels of Irisin , Adropin , and Perilipin . BACKGROUND Hypertension and obesity are two major threats for public health . Up to the present , antihypertensive medications have been used to lower blood pressure , which seem to provide a better life with lower morbidity and mortality rates . Their effect on etiopathogenesis of hypertension is now an area of developing research . The association between hypertension and obesity also suggests the link between antihypertensive agents and energy hemostasis . We aimed to investigate the effects of antihypertensive treatment on the irisin , adropin , and perilipin levels in patients with essential hypertension and to compare them with healthy volunteers in terms of their effect on energy hemostasis . METHODS In total , 85 newly diagnosed patients with untreated essential hypertension were admitted to the outpatient clinic . Patients were randomized to one of the following treatment protocols : amlodipine or valsartan for a 12 week period . 42 patients were randomized into the valsartan group and 43 patients into the amlodipine group . Serum perilipin , irisin , and adropin levels were measured before and after drug treatment by ELISA kits . RESULTS We discovered that the hypertensive patients have lower levels of perilipin and higher levels of adropin compared with the control group . Both amlodipine and valsartan increased the levels of perilipin , irisin , and adropin after 12 weeks of treatment . CONCLUSIONS In conclusion , in regulating energy balance , perilipin , irisin , and adropin , could be of pathogenic importance in obesity-induced hypertension . Hence , ongoing trials need to elucidate this mechanism ."
],
"offsets": [
[
0,
1733
]
]
}
] | [
{
"id": "73406",
"type": "Intervention_Pharmacological",
"text": [
"Valsartan"
],
"offsets": [
[
15,
24
]
],
"normalized": []
},
{
"id": "73407",
"type": "Intervention_Pharmacological",
"text": [
"Amlodipine"
],
"offsets": [
[
29,
39
]
],
"normalized": []
},
{
"id": "73408",
"type": "Intervention_Pharmacological",
"text": [
"Irisin"
],
"offsets": [
[
57,
63
]
],
"normalized": []
},
{
"id": "73409",
"type": "Intervention_Pharmacological",
"text": [
"Adropin"
],
"offsets": [
[
66,
73
]
],
"normalized": []
},
{
"id": "73410",
"type": "Intervention_Pharmacological",
"text": [
"Perilipin"
],
"offsets": [
[
80,
89
]
],
"normalized": []
},
{
"id": "73411",
"type": "Intervention_Pharmacological",
"text": [
"amlodipine"
],
"offsets": [
[
998,
1008
]
],
"normalized": []
},
{
"id": "73412",
"type": "Intervention_Pharmacological",
"text": [
"valsartan"
],
"offsets": [
[
1012,
1021
]
],
"normalized": []
},
{
"id": "73413",
"type": "Intervention_Pharmacological",
"text": [
"valsartan"
],
"offsets": [
[
1012,
1021
]
],
"normalized": []
},
{
"id": "73414",
"type": "Intervention_Pharmacological",
"text": [
"amlodipine"
],
"offsets": [
[
998,
1008
]
],
"normalized": []
},
{
"id": "73415",
"type": "Intervention_Pharmacological",
"text": [
"ELISA kits"
],
"offsets": [
[
1237,
1247
]
],
"normalized": []
},
{
"id": "73416",
"type": "Intervention_Pharmacological",
"text": [
"amlodipine"
],
"offsets": [
[
998,
1008
]
],
"normalized": []
},
{
"id": "73417",
"type": "Intervention_Pharmacological",
"text": [
"valsartan"
],
"offsets": [
[
1012,
1021
]
],
"normalized": []
},
{
"id": "73418",
"type": "Outcome_Physical",
"text": [
"Serum perilipin , irisin , and adropin levels"
],
"offsets": [
[
1142,
1187
]
],
"normalized": []
},
{
"id": "73419",
"type": "Outcome_Physical",
"text": [
"levels of perilipin"
],
"offsets": [
[
1314,
1333
]
],
"normalized": []
},
{
"id": "73420",
"type": "Outcome_Physical",
"text": [
"levels of adropin"
],
"offsets": [
[
1345,
1362
]
],
"normalized": []
},
{
"id": "73421",
"type": "Outcome_Physical",
"text": [
"levels of perilipin , irisin , and adropin"
],
"offsets": [
[
1441,
1483
]
],
"normalized": []
}
] | [] | [] | [] |
73422 | 26902035 | [
{
"id": "73423",
"type": "document",
"text": [
"Oxidized Regenerated Cellulose Reduces the Amount of Fluid Drainage after Liver Resection : A Randomized Prospective Clinical Trial . BACKGROUND/AIMS Oxidized regenerated cellulose ( ORC ) has been registered as adjuncts to stimulate hemostasis in liver surgery . However , most previous studies were primarily designed to study the intra-operative hemostatic efficacy , and the effect on prophylactic application was never studied as a primary endpoint . This randomized prospective clinical trial was undertaken to evaluate whether ORC is safe and effective when used as a prophylactic agent covering the raw cut surface during the hepatectomy to reduce the volume and duration of drainage . METHODOLOGY Between June 2011 and August 2012 , a total of 40 patients undergoing major hepatectomy were randomly assigned to ORC or control groups ( 20 in each group ) . Patient characteristics , resection-related factors , debit of drainage and postoperative complications were compared between the two groups . RESULTS The two groups were comparable in terms of demographics , indications for surgery , extent of hepatectomy , and intraoperative blood loss . The amount of drainage after operation was significantly less in the ORC group compared with the control group ( 406.9 ± 308.1 vs. 627.0 ± 301.6 ml , P = 0.028 ) . CONCLUSIONS Application of ORC covering the raw cut surface during the hepatectomy can significantly decrease the amount of drainage ."
],
"offsets": [
[
0,
1454
]
]
}
] | [
{
"id": "73424",
"type": "Intervention_Pharmacological",
"text": [
"Oxidized Regenerated Cellulose"
],
"offsets": [
[
0,
30
]
],
"normalized": []
},
{
"id": "73425",
"type": "Intervention_Pharmacological",
"text": [
"Oxidized regenerated cellulose ( ORC )"
],
"offsets": [
[
150,
188
]
],
"normalized": []
},
{
"id": "73426",
"type": "Intervention_Pharmacological",
"text": [
"ORC"
],
"offsets": [
[
183,
186
]
],
"normalized": []
},
{
"id": "73427",
"type": "Intervention_Pharmacological",
"text": [
"ORC"
],
"offsets": [
[
183,
186
]
],
"normalized": []
},
{
"id": "73428",
"type": "Intervention_Control",
"text": [
"control groups"
],
"offsets": [
[
827,
841
]
],
"normalized": []
},
{
"id": "73429",
"type": "Outcome_Other",
"text": [
"debit of drainage"
],
"offsets": [
[
919,
936
]
],
"normalized": []
},
{
"id": "73430",
"type": "Outcome_Adverse-effects",
"text": [
"postoperative complications"
],
"offsets": [
[
941,
968
]
],
"normalized": []
},
{
"id": "73431",
"type": "Outcome_Physical",
"text": [
"indications for surgery"
],
"offsets": [
[
1074,
1097
]
],
"normalized": []
},
{
"id": "73432",
"type": "Outcome_Physical",
"text": [
"hepatectomy"
],
"offsets": [
[
634,
645
]
],
"normalized": []
},
{
"id": "73433",
"type": "Outcome_Adverse-effects",
"text": [
"intraoperative blood loss"
],
"offsets": [
[
1128,
1153
]
],
"normalized": []
},
{
"id": "73434",
"type": "Outcome_Other",
"text": [
"amount of drainage after operation"
],
"offsets": [
[
1160,
1194
]
],
"normalized": []
},
{
"id": "73435",
"type": "Participant_Condition",
"text": [
"hepatectomy"
],
"offsets": [
[
634,
645
]
],
"normalized": []
},
{
"id": "73436",
"type": "Participant_Sample-size",
"text": [
"40 patients"
],
"offsets": [
[
753,
764
]
],
"normalized": []
},
{
"id": "73437",
"type": "Participant_Condition",
"text": [
"hepatectomy"
],
"offsets": [
[
634,
645
]
],
"normalized": []
},
{
"id": "73438",
"type": "Participant_Condition",
"text": [
"hepatectomy"
],
"offsets": [
[
634,
645
]
],
"normalized": []
}
] | [] | [] | [] |
73439 | 2690913 | [
{
"id": "73440",
"type": "document",
"text": [
"West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer : results after a median follow-up of 7 years . I . Patients with involved axillary lymph nodes . The aim of this study was to test the effectiveness of a regimen of combination chemotherapy known to be active in advanced breast cancer when given as an adjuvant treatment after mastectomy . A total of 569 patients with cancer of the breast and involvement of axillary lymph nodes were randomised , after simple mastectomy with axillary sampling , to receive either no adjuvant treatment or intravenous adriamycin 50 mg , vincristine 1 mg , cyclophosphamide 250 mg , methotrexate 150 mg and fluorouracil 250 mg ( AVCMF ) every 21 days for eight cycles . Randomisation was stratified according to menopausal status and tumour size . Treatment was started within 14 days of surgery in 94 % of patients . Eighty-eight per cent of patients received at least seven cycles of chemotherapy with no dose reduction . The median relapse-free survival was prolonged by 14 months in patients treated with AVCMF ( chi2 1 = 11.7 ; P = 0.0006 ) . In the premenopausal group this period was 17 months ( chi2 1 = 8.8 ; P = 0.003 ) compared with 8 months in the post-menopausal group ( chi2 1 = 3.3 ; P = 0.07 ) . Neither overall survival nor survival in these subgroups was significantly influenced by treatment ."
],
"offsets": [
[
0,
1389
]
]
}
] | [
{
"id": "73441",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant chemotherapy"
],
"offsets": [
[
45,
66
]
],
"normalized": []
},
{
"id": "73442",
"type": "Intervention_Pharmacological",
"text": [
"regimen of combination chemotherapy"
],
"offsets": [
[
248,
283
]
],
"normalized": []
},
{
"id": "73443",
"type": "Intervention_Surgical",
"text": [
"simple mastectomy with axillary sampling"
],
"offsets": [
[
498,
538
]
],
"normalized": []
},
{
"id": "73444",
"type": "Intervention_Pharmacological",
"text": [
"no adjuvant treatment"
],
"offsets": [
[
559,
580
]
],
"normalized": []
},
{
"id": "73445",
"type": "Intervention_Pharmacological",
"text": [
"intravenous adriamycin"
],
"offsets": [
[
584,
606
]
],
"normalized": []
},
{
"id": "73446",
"type": "Intervention_Pharmacological",
"text": [
"vincristine"
],
"offsets": [
[
615,
626
]
],
"normalized": []
},
{
"id": "73447",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
634,
650
]
],
"normalized": []
},
{
"id": "73448",
"type": "Intervention_Pharmacological",
"text": [
"methotrexate"
],
"offsets": [
[
660,
672
]
],
"normalized": []
},
{
"id": "73449",
"type": "Intervention_Pharmacological",
"text": [
"fluorouracil"
],
"offsets": [
[
684,
696
]
],
"normalized": []
},
{
"id": "73450",
"type": "Intervention_Pharmacological",
"text": [
"( AVCMF )"
],
"offsets": [
[
704,
713
]
],
"normalized": []
},
{
"id": "73451",
"type": "Intervention_Pharmacological",
"text": [
"AVCMF"
],
"offsets": [
[
706,
711
]
],
"normalized": []
},
{
"id": "73452",
"type": "Outcome_Mortality",
"text": [
"median relapse-free survival"
],
"offsets": [
[
1005,
1033
]
],
"normalized": []
},
{
"id": "73453",
"type": "Outcome_Mortality",
"text": [
"overall survival nor survival"
],
"offsets": [
[
1297,
1326
]
],
"normalized": []
},
{
"id": "73454",
"type": "Participant_Condition",
"text": [
"breast cancer :"
],
"offsets": [
[
79,
94
]
],
"normalized": []
},
{
"id": "73455",
"type": "Participant_Condition",
"text": [
"involved axillary lymph nodes"
],
"offsets": [
[
159,
188
]
],
"normalized": []
},
{
"id": "73456",
"type": "Participant_Sample-size",
"text": [
"569"
],
"offsets": [
[
395,
398
]
],
"normalized": []
},
{
"id": "73457",
"type": "Participant_Condition",
"text": [
"cancer of the breast and involvement of axillary lymph nodes"
],
"offsets": [
[
413,
473
]
],
"normalized": []
},
{
"id": "73458",
"type": "Participant_Condition",
"text": [
"premenopausal"
],
"offsets": [
[
1132,
1145
]
],
"normalized": []
},
{
"id": "73459",
"type": "Participant_Condition",
"text": [
"post-menopausal"
],
"offsets": [
[
1237,
1252
]
],
"normalized": []
}
] | [] | [] | [] |
73460 | 2691638 | [
{
"id": "73461",
"type": "document",
"text": [
"The Relaxation Inventory : self-report scales of relaxation training effects . The development of a self-report measure to assess the effects of relaxation training was examined . A rigorous statistical method of scale construction consisting of a modification of the scale discrimination technique was employed , resulting in a 45-item questionnaire representing three orthogonally derived scales . The three scales , Physiological Tension , Physical Assessment , and Cognitive Tension , demonstrated adequate internal consistency with KR20 reliability coefficients of .89 , .95 , and .81 , respectively . In a second study of predictive validity , 40 individuals were randomly assigned to one of four conditions : relaxation training , tension inducement , pre-postcontrol , or postcontrol . Univariate analysis of variance indicated significant findings for each of the three dimensions of the inventory . The Physiological Tension Scale detected significant increases in tension following tension inducement , whereas the Physical Assessment Scale and Cognitive Tension Scale detected increases in relaxation following relaxation training . Recommendations were made for future research on the inventory ."
],
"offsets": [
[
0,
1209
]
]
}
] | [
{
"id": "73462",
"type": "Intervention_Physical",
"text": [
"relaxation training effects"
],
"offsets": [
[
49,
76
]
],
"normalized": []
},
{
"id": "73463",
"type": "Intervention_Educational",
"text": [
"45-item questionnaire"
],
"offsets": [
[
329,
350
]
],
"normalized": []
},
{
"id": "73464",
"type": "Intervention_Physical",
"text": [
"relaxation training"
],
"offsets": [
[
49,
68
]
],
"normalized": []
},
{
"id": "73465",
"type": "Intervention_Psychological",
"text": [
","
],
"offsets": [
[
312,
313
]
],
"normalized": []
},
{
"id": "73466",
"type": "Intervention_Physical",
"text": [
"tension inducement"
],
"offsets": [
[
738,
756
]
],
"normalized": []
},
{
"id": "73467",
"type": "Intervention_Psychological",
"text": [
", pre-postcontrol , or postcontrol ."
],
"offsets": [
[
757,
793
]
],
"normalized": []
},
{
"id": "73468",
"type": "Intervention_Physical",
"text": [
"relaxation training"
],
"offsets": [
[
49,
68
]
],
"normalized": []
},
{
"id": "73469",
"type": "Intervention_Psychological",
"text": [
"."
],
"offsets": [
[
77,
78
]
],
"normalized": []
},
{
"id": "73470",
"type": "Outcome_Physical",
"text": [
"tension"
],
"offsets": [
[
738,
745
]
],
"normalized": []
},
{
"id": "73471",
"type": "Outcome_Physical",
"text": [
"relaxation"
],
"offsets": [
[
49,
59
]
],
"normalized": []
},
{
"id": "73472",
"type": "Participant_Sample-size",
"text": [
"40"
],
"offsets": [
[
650,
652
]
],
"normalized": []
}
] | [] | [] | [] |
73473 | 2691974 | [
{
"id": "73474",
"type": "document",
"text": [
"[ Are there indications for adjuvant chemotherapy after excision of colorectal cancer ? ] ."
],
"offsets": [
[
0,
91
]
]
}
] | [
{
"id": "73475",
"type": "Intervention_Physical",
"text": [
"adjuvant chemotherapy after"
],
"offsets": [
[
28,
55
]
],
"normalized": []
},
{
"id": "73476",
"type": "Participant_Condition",
"text": [
"excision of colorectal cancer"
],
"offsets": [
[
56,
85
]
],
"normalized": []
}
] | [] | [] | [] |
73477 | 2693850 | [
{
"id": "73478",
"type": "document",
"text": [
"Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma : a randomized phase II study . In a phase II study 119 patients with disseminated malignant melanoma were randomized to receive treatment with dacarbazine alone or in combination with vindesine . The study was designed to reveal an additive response rate when the drugs were combined . Dacarbazine was given i.v . at 250 mg m-2 per day X V every 4 weeks . In the combination regimen vindesine given at 3 mg m-2 per week was included . One hundred and ten patients were available for evaluation of response . With dacarbazine 4/51 patients obtained a complete remission ( 8 % ) and 5/51 patients a partial remission ( 10 % ) . Overall response rate was 18 % . With dacarbazine-vindesine 8/59 patients obtained a complete remission ( 13 % ) and 7/59 patients a partial remission ( 12 % ) . Overall response rate was 25 % . The difference in response rates observed between the treatment arms is not statistically significant . Median response duration was 123 days for dacarbazine patients and 171 days for patients receiving dacarbazine-vindesine ( difference not statistically significant ) ."
],
"offsets": [
[
0,
1169
]
]
}
] | [
{
"id": "73479",
"type": "Intervention_Pharmacological",
"text": [
"Dacarbazine"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "73480",
"type": "Intervention_Pharmacological",
"text": [
"dacarbazine-vindesine"
],
"offsets": [
[
19,
40
]
],
"normalized": []
},
{
"id": "73481",
"type": "Intervention_Pharmacological",
"text": [
"dacarbazine"
],
"offsets": [
[
19,
30
]
],
"normalized": []
},
{
"id": "73482",
"type": "Intervention_Pharmacological",
"text": [
"Dacarbazine was given i.v"
],
"offsets": [
[
363,
388
]
],
"normalized": []
},
{
"id": "73483",
"type": "Intervention_Pharmacological",
"text": [
"vindesine"
],
"offsets": [
[
31,
40
]
],
"normalized": []
},
{
"id": "73484",
"type": "Intervention_Pharmacological",
"text": [
"dacarbazine"
],
"offsets": [
[
19,
30
]
],
"normalized": []
},
{
"id": "73485",
"type": "Intervention_Pharmacological",
"text": [
"dacarbazine-vindesine"
],
"offsets": [
[
19,
40
]
],
"normalized": []
},
{
"id": "73486",
"type": "Outcome_Other",
"text": [
"complete remission"
],
"offsets": [
[
627,
645
]
],
"normalized": []
},
{
"id": "73487",
"type": "Outcome_Other",
"text": [
"partial remission"
],
"offsets": [
[
674,
691
]
],
"normalized": []
},
{
"id": "73488",
"type": "Outcome_Other",
"text": [
"Overall response rate"
],
"offsets": [
[
703,
724
]
],
"normalized": []
},
{
"id": "73489",
"type": "Outcome_Other",
"text": [
"complete remission"
],
"offsets": [
[
627,
645
]
],
"normalized": []
},
{
"id": "73490",
"type": "Outcome_Other",
"text": [
"partial remission"
],
"offsets": [
[
674,
691
]
],
"normalized": []
},
{
"id": "73491",
"type": "Outcome_Other",
"text": [
"Overall response rate"
],
"offsets": [
[
703,
724
]
],
"normalized": []
},
{
"id": "73492",
"type": "Outcome_Physical",
"text": [
"response rates"
],
"offsets": [
[
916,
930
]
],
"normalized": []
},
{
"id": "73493",
"type": "Participant_Sample-size",
"text": [
"119 patients"
],
"offsets": [
[
128,
140
]
],
"normalized": []
},
{
"id": "73494",
"type": "Participant_Condition",
"text": [
"disseminated malignant melanoma"
],
"offsets": [
[
44,
75
]
],
"normalized": []
},
{
"id": "73495",
"type": "Participant_Sample-size",
"text": [
"One hundred and ten"
],
"offsets": [
[
512,
531
]
],
"normalized": []
}
] | [] | [] | [] |
73496 | 2694356 | [
{
"id": "73497",
"type": "document",
"text": [
"Low power laser therapy of shoulder tendonitis . 30 patients with supraspinatus or bicipital tendonitis were randomly allocated to active infrared laser therapy at 904 nm three times weekly for 2 weeks , dummy laser or drug treatment for 2 weeks . Objectively maximum active extension , flexion and abduction of the shoulder , and subjectively pain stiffness movement and function were measured at 0 and 2 weeks . Significant improvement of active over dummy laser was noted for all seven assessments . Active laser therapy produced significant improvement over drug therapy for all three objective measures and pain . Naproxen sodium significantly improved only movement and function compared to dummy laser . These results demonstrate the effectiveness of laser therapy in tendonitis of the shoulder ."
],
"offsets": [
[
0,
803
]
]
}
] | [
{
"id": "73498",
"type": "Intervention_Physical",
"text": [
"Low power laser therapy"
],
"offsets": [
[
0,
23
]
],
"normalized": []
},
{
"id": "73499",
"type": "Intervention_Physical",
"text": [
"active infrared laser therapy"
],
"offsets": [
[
131,
160
]
],
"normalized": []
},
{
"id": "73500",
"type": "Intervention_Control",
"text": [
"dummy laser"
],
"offsets": [
[
204,
215
]
],
"normalized": []
},
{
"id": "73501",
"type": "Intervention_Physical",
"text": [
"or drug treatment"
],
"offsets": [
[
216,
233
]
],
"normalized": []
},
{
"id": "73502",
"type": "Intervention_Pharmacological",
"text": [
"Naproxen sodium"
],
"offsets": [
[
619,
634
]
],
"normalized": []
},
{
"id": "73503",
"type": "Outcome_Other",
"text": [
"Significant improvement of active over dummy laser was noted"
],
"offsets": [
[
414,
474
]
],
"normalized": []
},
{
"id": "73504",
"type": "Outcome_Pain",
"text": [
"Active laser therapy produced significant improvement over drug therapy for all three objective measures and pain"
],
"offsets": [
[
503,
616
]
],
"normalized": []
},
{
"id": "73505",
"type": "Outcome_Other",
"text": [
"Naproxen sodium significantly improved only movement and function compared to dummy laser"
],
"offsets": [
[
619,
708
]
],
"normalized": []
},
{
"id": "73506",
"type": "Participant_Condition",
"text": [
"shoulder tendonitis ."
],
"offsets": [
[
27,
48
]
],
"normalized": []
},
{
"id": "73507",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
49,
51
]
],
"normalized": []
},
{
"id": "73508",
"type": "Participant_Condition",
"text": [
"with supraspinatus or bicipital tendonitis"
],
"offsets": [
[
61,
103
]
],
"normalized": []
}
] | [] | [] | [] |
73509 | 2696035 | [
{
"id": "73510",
"type": "document",
"text": [
"Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer ."
],
"offsets": [
[
0,
91
]
]
}
] | [
{
"id": "73511",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant therapy"
],
"offsets": [
[
55,
71
]
],
"normalized": []
},
{
"id": "73512",
"type": "Outcome_Other",
"text": [
"treatment efficacy"
],
"offsets": [
[
22,
40
]
],
"normalized": []
},
{
"id": "73513",
"type": "Participant_Condition",
"text": [
"breast cancer"
],
"offsets": [
[
76,
89
]
],
"normalized": []
}
] | [] | [] | [] |
73514 | 2698934 | [
{
"id": "73515",
"type": "document",
"text": [
"Chlorthalidone does not increase the hypotensive effect of nifedipine in essential hypertensives : a crossover multicentre study . To determine whether the combination of nifedipine + chlorthalidone exerts an additive antihypertensive effect when compared with single-drug treatment , we studied 66 uncomplicated essential hypertensives , with diastolic blood pressure of greater than 100 and less than 115 mmHg . At the end of a 1-month washout placebo period , using a double-blind crossover design , the patients were randomly allocated to nifedipine ( 20 mg twice a day ) , chlorthalidone ( 25 mg once a day ) , the two drugs combined at the same doses and the corresponding placebo . Compared with the randomly allocated placebo , the three active treatments significantly reduced blood pressure without changing the heart rate or body weight . Both the absolute and percentage decreases in mean blood pressure induced by nifedipine and the combination compared with placebo were similar and significantly greater than those induced by chlorthalidone . Taken together , these data show that the combination of nifedipine + chlorthalidone does not exert any additive antihypertensive effect compared with nifedipine alone . This finding indicates that the combination of a dihydropyridine calcium antagonist + a thiazide diuretic is probably devoid of any particular clinical significance in the treatment of uncomplicated essential hypertensives ."
],
"offsets": [
[
0,
1452
]
]
}
] | [
{
"id": "73516",
"type": "Intervention_Pharmacological",
"text": [
"Chlorthalidone"
],
"offsets": [
[
0,
14
]
],
"normalized": []
},
{
"id": "73517",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
59,
69
]
],
"normalized": []
},
{
"id": "73518",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine + chlorthalidone"
],
"offsets": [
[
171,
198
]
],
"normalized": []
},
{
"id": "73519",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
446,
453
]
],
"normalized": []
},
{
"id": "73520",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
59,
69
]
],
"normalized": []
},
{
"id": "73521",
"type": "Intervention_Pharmacological",
"text": [
"chlorthalidone"
],
"offsets": [
[
184,
198
]
],
"normalized": []
},
{
"id": "73522",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
446,
453
]
],
"normalized": []
},
{
"id": "73523",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
59,
69
]
],
"normalized": []
},
{
"id": "73524",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
446,
453
]
],
"normalized": []
},
{
"id": "73525",
"type": "Intervention_Pharmacological",
"text": [
"chlorthalidone"
],
"offsets": [
[
184,
198
]
],
"normalized": []
},
{
"id": "73526",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine + chlorthalidone"
],
"offsets": [
[
171,
198
]
],
"normalized": []
},
{
"id": "73527",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
59,
69
]
],
"normalized": []
},
{
"id": "73528",
"type": "Intervention_Pharmacological",
"text": [
"dihydropyridine calcium antagonist + a thiazide diuretic"
],
"offsets": [
[
1277,
1333
]
],
"normalized": []
},
{
"id": "73529",
"type": "Outcome_Physical",
"text": [
"hypotensive effect"
],
"offsets": [
[
37,
55
]
],
"normalized": []
},
{
"id": "73530",
"type": "Outcome_Physical",
"text": [
"additive antihypertensive effect"
],
"offsets": [
[
209,
241
]
],
"normalized": []
},
{
"id": "73531",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
354,
368
]
],
"normalized": []
},
{
"id": "73532",
"type": "Outcome_Physical",
"text": [
"heart rate or body weight ."
],
"offsets": [
[
822,
849
]
],
"normalized": []
},
{
"id": "73533",
"type": "Outcome_Physical",
"text": [
"mean blood pressure"
],
"offsets": [
[
896,
915
]
],
"normalized": []
},
{
"id": "73534",
"type": "Outcome_Physical",
"text": [
"additive antihypertensive effect"
],
"offsets": [
[
209,
241
]
],
"normalized": []
},
{
"id": "73535",
"type": "Outcome_Physical",
"text": [
"clinical significance"
],
"offsets": [
[
1371,
1392
]
],
"normalized": []
},
{
"id": "73536",
"type": "Participant_Condition",
"text": [
"crossover multicentre study ."
],
"offsets": [
[
101,
130
]
],
"normalized": []
},
{
"id": "73537",
"type": "Participant_Condition",
"text": [
"66 uncomplicated essential hypertensives , with diastolic blood pressure of greater than 100 and less than 115 mmHg ."
],
"offsets": [
[
296,
413
]
],
"normalized": []
}
] | [] | [] | [] |
73538 | 2699786 | [
{
"id": "73539",
"type": "document",
"text": [
"[ Cannulation of the internal jugular vein using 2 ultrasonic technics . A comparative controlled study ] . The internal jugular vein ( IJV ) is a common access route to the central venous system . Anatomical landmarks ( group I ) are normally used for localization of the IJV . We have compared this method with two other methods based on ultrasonic waves to identify the IJV and the carotid artery ( CA ) ( even in atypical positions ) . We employed an ultrasound Doppler device in group II and a real-time ultrasonograph in group III . Central venous catheters were placed into the right IJV by the Seldinger technique . The IJV could be located in all patients with both ultrasound methods , but the course of the IJV could only be identified by ultrasonography . For this reason , the direction of the IJV was classified as \" typical \" in 80 % of group I , in 85 % of group II , but in only 45 % of group III . No intergroup differences were found with respect to the number of punctures ( mean value 1.6 +/- 0.83 ) and the incidence of complications . The time required to locate the site and direction of puncture increased with technical sophistication . There was , however , no difference in the total time for catheter placement , because puncture was performed faster when aided by sonography . In four patients in groups I and II , in whom attempts to puncture the IJV had not been successful , this could subsequently be achieved with ultrasonographic aid . One patient ( group I ) displayed a hematoma following inadvertent puncture of the CA . In one patient in group II the IJV and CA could not be distinguished as one was overlying the other . The echocamera provided improved localization of the IJV and the CA in comparison with the Doppler ultrasound . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1809
]
]
}
] | [
{
"id": "73540",
"type": "Intervention_Surgical",
"text": [
"Cannulation of the internal jugular vein using 2 ultrasonic technics"
],
"offsets": [
[
2,
70
]
],
"normalized": []
},
{
"id": "73541",
"type": "Intervention_Physical",
"text": [
"ultrasound Doppler device in group II and a real-time ultrasonograph in group III"
],
"offsets": [
[
455,
536
]
],
"normalized": []
},
{
"id": "73542",
"type": "Intervention_Surgical",
"text": [
"Central venous catheters were placed into the right IJV by the Seldinger technique"
],
"offsets": [
[
539,
621
]
],
"normalized": []
},
{
"id": "73543",
"type": "Outcome_Physical",
"text": [
"IJV"
],
"offsets": [
[
136,
139
]
],
"normalized": []
},
{
"id": "73544",
"type": "Outcome_Physical",
"text": [
"IJV"
],
"offsets": [
[
136,
139
]
],
"normalized": []
},
{
"id": "73545",
"type": "Outcome_Other",
"text": [
"number of punctures"
],
"offsets": [
[
973,
992
]
],
"normalized": []
},
{
"id": "73546",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of complications"
],
"offsets": [
[
1029,
1055
]
],
"normalized": []
},
{
"id": "73547",
"type": "Outcome_Other",
"text": [
"time required to locate the site"
],
"offsets": [
[
1062,
1094
]
],
"normalized": []
},
{
"id": "73548",
"type": "Outcome_Other",
"text": [
"direction of puncture"
],
"offsets": [
[
1099,
1120
]
],
"normalized": []
},
{
"id": "73549",
"type": "Outcome_Other",
"text": [
"total time for catheter placement"
],
"offsets": [
[
1206,
1239
]
],
"normalized": []
},
{
"id": "73550",
"type": "Outcome_Adverse-effects",
"text": [
"hematoma"
],
"offsets": [
[
1508,
1516
]
],
"normalized": []
},
{
"id": "73551",
"type": "Participant_Condition",
"text": [
"Cannulation of the internal jugular vein"
],
"offsets": [
[
2,
42
]
],
"normalized": []
}
] | [] | [] | [] |
73552 | 27025129 | [
{
"id": "73553",
"type": "document",
"text": [
"[ PLACE REMAXOL AS A HEPATOPROTECTOR IN INTENSIVE THERAPY OF PERVASIVE PERITONITIS ] . UNLABELLED PERPOSE OF RESEARCH : to evaluate the effectiveness of Remaxol in patients with pervasive peritonitis . MATERIALS AND METHODS assessed the effectiveness of a balanced infusion of the drug ( Remaxol ) in the treatment of 44 patients agedfrom 18 to 50 years . Patients were devided into 2 groups by the method of envelopes . All patients received a comprehensive differential therapy : 21 patient 1 group consisting of infusion therapy in the postoperative period received Remaxol at a dose of 800 mg/day for 7 days . RESULTS the comporative assessment of indicators of systemic hemodinamics , oxygen transport , asid base status , glucose , lactose and free radical oxydation . Patients on the first background was used Remaxol have experiensed a more rapid relief of metabolic disorders , endotoxemia and hepatic dysfunction compared with the indices of the 2 group patients . Noted earlier stabilization of rudicators of systemic hemodynamics and oxygen transport . This has reduced the duration of respiratory and vasopressor suppot , early start ofparenteral intreduction in case the power ( p < 0.05 ) . CONCLUSIONS this study shows that use of the drug for the purpose of relief Remaxol hepatic dysfunction and prevention of drug liver toxicity in conditions ofperitonitis , after 48 hours of operation , provides a positive dynamics and stabilization ofparameters of central hemodynamics , contributing to the abolition of vasopressor support , and contributes to the effective utilization of oxygen , while providing antioxidant effect ."
],
"offsets": [
[
0,
1642
]
]
}
] | [
{
"id": "73554",
"type": "Intervention_Pharmacological",
"text": [
"REMAXOL"
],
"offsets": [
[
8,
15
]
],
"normalized": []
},
{
"id": "73555",
"type": "Intervention_Pharmacological",
"text": [
"Remaxol"
],
"offsets": [
[
153,
160
]
],
"normalized": []
},
{
"id": "73556",
"type": "Intervention_Pharmacological",
"text": [
"drug ( Remaxol )"
],
"offsets": [
[
281,
297
]
],
"normalized": []
},
{
"id": "73557",
"type": "Intervention_Physical",
"text": [
"infusion therapy"
],
"offsets": [
[
515,
531
]
],
"normalized": []
},
{
"id": "73558",
"type": "Intervention_Pharmacological",
"text": [
"Remaxol"
],
"offsets": [
[
153,
160
]
],
"normalized": []
},
{
"id": "73559",
"type": "Intervention_Pharmacological",
"text": [
"Remaxol"
],
"offsets": [
[
153,
160
]
],
"normalized": []
},
{
"id": "73560",
"type": "Intervention_Pharmacological",
"text": [
"Remaxol"
],
"offsets": [
[
153,
160
]
],
"normalized": []
},
{
"id": "73561",
"type": "Outcome_Physical",
"text": [
"indicators of systemic hemodinamics , oxygen transport , asid base status , glucose , lactose and free radical oxydation ."
],
"offsets": [
[
652,
774
]
],
"normalized": []
},
{
"id": "73562",
"type": "Outcome_Physical",
"text": [
"rapid relief of metabolic disorders , endotoxemia and hepatic dysfunction compared"
],
"offsets": [
[
849,
931
]
],
"normalized": []
},
{
"id": "73563",
"type": "Outcome_Physical",
"text": [
"systemic hemodynamics and oxygen transport ."
],
"offsets": [
[
1020,
1064
]
],
"normalized": []
},
{
"id": "73564",
"type": "Outcome_Physical",
"text": [
"duration of respiratory and vasopressor suppot"
],
"offsets": [
[
1086,
1132
]
],
"normalized": []
}
] | [] | [] | [] |
73565 | 27036056 | [
{
"id": "73566",
"type": "document",
"text": [
"Internet-based Mindfulness Meditation for Cognition and Mood in Older Adults : A Pilot Study . CONTEXT Older adults are at risk for greater chronic stress and cognitive decline . Training in mindfulness meditation ( MM ) may help reduce stress and , thus , cognitive decline in older adults , but little research has explored that hypothesis . OBJECTIVE The current study 's primary aim was to evaluate the feasibility and acceptability for use by older adults of the Internet Mindfulness Meditation Intervention ( IMMI ) , a program that had been developed by the research team , as well as of an Internet-based health-and-wellness education program , the control . The secondary aim was to collect preliminary pre- and postintervention data on mood and cognitive function . DESIGN The study was a randomized , controlled trial ( RCT ) , a pilot study , with participants randomized either to the meditation group or the education group . SETTING Participants obtained access to the programs from their homes , and the baseline and endpoint assessments occurred in their homes as well . PARTICIPANTS Older adults aged 65-90 y were recruited from the Portland , OR , metropolitan area . Twenty-one people enrolled in the study . INTERVENTION Participants in both groups took part in a 1-h online session each week for 6 wk , with 30 min of daily home practice . OUTCOME MEASURES Feasibility and acceptability were assessed through measures of adherence to the protocol and a client satisfaction questionnaire . Mood and cognitive outcomes were also evaluated before and after the interventions . RESULTS Sixteen participants completed the study , 8 in each group , and 5 dropped out , for a 76 % completion rate . Participants ' mean age was 76.2 y ; 88 % were Caucasian , and 50 % were female . Acceptability was high for the interventions , based on above-average scores on the client satisfaction questionnaire . The IMMI participants completed ( 1 ) 4.25 ± 2.4 sessions , with a range of 0-6 ; ( 2 ) 604 ± 506 home-practice minutes , with a range 0-1432 ; and ( 3 ) 21.3 ± 15.5 d of practice , with a range of 0-46 . The education group completed ( 1 ) 4.75 ± 1.8 sessions , with a range of 2-6 ; ( 2 ) 873 ± 395 home-practice minutes , with a range of 327-1524 ; and ( 3 ) 25.6 d of practice , with a range of 11-35 . The intervention and control formats were both feasible , and the control group was appropriate . As expected due to the pilot nature of the study , no differences existed between groups for the mood or cognitive outcomes . CONCLUSIONS Administering interventions via the Internet to older adults is feasible . The 2 interventions were acceptable to participants and equal with regard to perceived credibility and acceptability . Future RCTs are planned to evaluate the clinical efficacy of the 2 interventions ."
],
"offsets": [
[
0,
2835
]
]
}
] | [
{
"id": "73567",
"type": "Intervention_Physical",
"text": [
"Internet-based Mindfulness Meditation"
],
"offsets": [
[
0,
37
]
],
"normalized": []
},
{
"id": "73568",
"type": "Intervention_Physical",
"text": [
"mindfulness meditation ( MM )"
],
"offsets": [
[
191,
220
]
],
"normalized": []
},
{
"id": "73569",
"type": "Intervention_Physical",
"text": [
"Internet Mindfulness Meditation Intervention ( IMMI )"
],
"offsets": [
[
468,
521
]
],
"normalized": []
},
{
"id": "73570",
"type": "Intervention_Physical",
"text": [
"meditation"
],
"offsets": [
[
203,
213
]
],
"normalized": []
},
{
"id": "73571",
"type": "Intervention_Educational",
"text": [
"education"
],
"offsets": [
[
633,
642
]
],
"normalized": []
},
{
"id": "73572",
"type": "Intervention_Physical",
"text": [
"IMMI"
],
"offsets": [
[
515,
519
]
],
"normalized": []
},
{
"id": "73573",
"type": "Intervention_Educational",
"text": [
"education"
],
"offsets": [
[
633,
642
]
],
"normalized": []
},
{
"id": "73574",
"type": "Outcome_Mental",
"text": [
"Mood"
],
"offsets": [
[
56,
60
]
],
"normalized": []
},
{
"id": "73575",
"type": "Outcome_Mental",
"text": [
"chronic stress"
],
"offsets": [
[
140,
154
]
],
"normalized": []
},
{
"id": "73576",
"type": "Outcome_Mental",
"text": [
"cognitive decline ."
],
"offsets": [
[
159,
178
]
],
"normalized": []
},
{
"id": "73577",
"type": "Outcome_Mental",
"text": [
"stress"
],
"offsets": [
[
148,
154
]
],
"normalized": []
},
{
"id": "73578",
"type": "Outcome_Mental",
"text": [
"cognitive decline"
],
"offsets": [
[
159,
176
]
],
"normalized": []
},
{
"id": "73579",
"type": "Outcome_Other",
"text": [
"feasibility and acceptability"
],
"offsets": [
[
407,
436
]
],
"normalized": []
},
{
"id": "73580",
"type": "Outcome_Mental",
"text": [
"mood"
],
"offsets": [
[
746,
750
]
],
"normalized": []
},
{
"id": "73581",
"type": "Outcome_Mental",
"text": [
"cognitive function ."
],
"offsets": [
[
755,
775
]
],
"normalized": []
},
{
"id": "73582",
"type": "Outcome_Other",
"text": [
"Feasibility and acceptability"
],
"offsets": [
[
1379,
1408
]
],
"normalized": []
},
{
"id": "73583",
"type": "Outcome_Other",
"text": [
"client satisfaction"
],
"offsets": [
[
1475,
1494
]
],
"normalized": []
},
{
"id": "73584",
"type": "Outcome_Mental",
"text": [
"Mood"
],
"offsets": [
[
56,
60
]
],
"normalized": []
},
{
"id": "73585",
"type": "Outcome_Mental",
"text": [
"cognitive outcomes"
],
"offsets": [
[
1520,
1538
]
],
"normalized": []
},
{
"id": "73586",
"type": "Outcome_Other",
"text": [
"Acceptability"
],
"offsets": [
[
1796,
1809
]
],
"normalized": []
}
] | [] | [] | [] |
73587 | 2709180 | [
{
"id": "73588",
"type": "document",
"text": [
"Effects of heat and cold on the perineum after episiotomy/laceration . The Redness Edema Ecchymosis Discharge Approximation ( REEDA ) tool , devised to evaluate postpartum healing of the perineum following an episiotomy/laceration , was used to evaluate the effects of heat and cold on the perineum during the first 24 hours after delivery . Ninety patients were randomly assigned to one of three treatment groups . Treatment consisted of 30 subjects applying a warm perineal pack , 30 applying a cold perineal pack , and 30 taking a warm sitz bath . Analysis of variance indicated no difference in the REEDA score before or two hours after treatment . A Pearson r correlation indicated the REEDA score was associated with a laceration and not with infant weight . Although these findings do not support assumptions from the literature , this study provides baseline data and trends for future study ."
],
"offsets": [
[
0,
901
]
]
}
] | [
{
"id": "73589",
"type": "Intervention_Physical",
"text": [
"heat and cold"
],
"offsets": [
[
11,
24
]
],
"normalized": []
},
{
"id": "73590",
"type": "Intervention_Physical",
"text": [
"episiotomy/laceration"
],
"offsets": [
[
47,
68
]
],
"normalized": []
},
{
"id": "73591",
"type": "Intervention_Physical",
"text": [
"heat and cold"
],
"offsets": [
[
11,
24
]
],
"normalized": []
},
{
"id": "73592",
"type": "Intervention_Physical",
"text": [
"warm perineal pack"
],
"offsets": [
[
462,
480
]
],
"normalized": []
},
{
"id": "73593",
"type": "Intervention_Other",
"text": [
"cold perineal pack"
],
"offsets": [
[
497,
515
]
],
"normalized": []
},
{
"id": "73594",
"type": "Intervention_Other",
"text": [
"warm sitz bath"
],
"offsets": [
[
534,
548
]
],
"normalized": []
},
{
"id": "73595",
"type": "Outcome_Physical",
"text": [
"Redness Edema Ecchymosis Discharge Approximation ( REEDA ) tool"
],
"offsets": [
[
75,
138
]
],
"normalized": []
},
{
"id": "73596",
"type": "Outcome_Physical",
"text": [
"REEDA"
],
"offsets": [
[
126,
131
]
],
"normalized": []
},
{
"id": "73597",
"type": "Outcome_Physical",
"text": [
"laceration and not with infant weight"
],
"offsets": [
[
725,
762
]
],
"normalized": []
},
{
"id": "73598",
"type": "Participant_Condition",
"text": [
"episiotomy/laceration"
],
"offsets": [
[
47,
68
]
],
"normalized": []
},
{
"id": "73599",
"type": "Participant_Sample-size",
"text": [
"Ninety"
],
"offsets": [
[
342,
348
]
],
"normalized": []
},
{
"id": "73600",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
439,
441
]
],
"normalized": []
},
{
"id": "73601",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
439,
441
]
],
"normalized": []
},
{
"id": "73602",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
439,
441
]
],
"normalized": []
}
] | [] | [] | [] |
73603 | 2711711 | [
{
"id": "73604",
"type": "document",
"text": [
"[ Dose-reduced antihypertensive agents -- use in complex nonmedicamentous therapy of hypertension ] . In order to estimate the influence of a non-medicamentous therapy ( CNT ) on the consumption of medicaments and coronary risk in high blood pressure 73 hypertensives of a medicamentously stabilized CNT-group were examined in comparison to a group of the same size of patients with hypertension who were managed exclusively medicamentously for behaviour of blood pressure , need of antihypertensive drugs and changes of hypertension-associated risk factors . After an exactly controlled 6-month treatment hypertensives with additionally recommended far-reaching CNT showed an economization of medicaments by scarcely the half in comparison to the reference group . By means of suitable control methods a causal non-medicamentously conditioned decrease of blood pressure could be excluded . A different need of antihypertensive drugs was simulated by the exacter intake of medicaments in the index-patients . Notwithstanding the metabolic effects of the additional therapy have induced a positive change of atherogenic lipids . The examinations indicate in general the difficulty of the judgement of efficacy of non-medicamentous therapeutic measures in connection with a rational dose-reduced long-term therapy with antihypertensive drugs ."
],
"offsets": [
[
0,
1341
]
]
}
] | [
{
"id": "73605",
"type": "Intervention_Pharmacological",
"text": [
"antihypertensive agents -- use"
],
"offsets": [
[
15,
45
]
],
"normalized": []
},
{
"id": "73606",
"type": "Intervention_Educational",
"text": [
"nonmedicamentous"
],
"offsets": [
[
57,
73
]
],
"normalized": []
},
{
"id": "73607",
"type": "Intervention_Pharmacological",
"text": [
"non-medicamentous therapy ( CNT )"
],
"offsets": [
[
142,
175
]
],
"normalized": []
},
{
"id": "73608",
"type": "Intervention_Pharmacological",
"text": [
"antihypertensive drugs"
],
"offsets": [
[
483,
505
]
],
"normalized": []
},
{
"id": "73609",
"type": "Intervention_Pharmacological",
"text": [
"non-medicamentously"
],
"offsets": [
[
812,
831
]
],
"normalized": []
},
{
"id": "73610",
"type": "Intervention_Pharmacological",
"text": [
"antihypertensive drugs"
],
"offsets": [
[
483,
505
]
],
"normalized": []
},
{
"id": "73611",
"type": "Intervention_Pharmacological",
"text": [
"non-medicamentous therapeutic"
],
"offsets": [
[
1212,
1241
]
],
"normalized": []
},
{
"id": "73612",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
236,
250
]
],
"normalized": []
},
{
"id": "73613",
"type": "Outcome_Physical",
"text": [
"atherogenic lipids ."
],
"offsets": [
[
1107,
1127
]
],
"normalized": []
},
{
"id": "73614",
"type": "Participant_Sample-size",
"text": [
"73"
],
"offsets": [
[
251,
253
]
],
"normalized": []
},
{
"id": "73615",
"type": "Participant_Condition",
"text": [
"hypertensives"
],
"offsets": [
[
254,
267
]
],
"normalized": []
},
{
"id": "73616",
"type": "Participant_Condition",
"text": [
"hypertension"
],
"offsets": [
[
85,
97
]
],
"normalized": []
},
{
"id": "73617",
"type": "Participant_Condition",
"text": [
"hypertensives"
],
"offsets": [
[
254,
267
]
],
"normalized": []
}
] | [] | [] | [] |
73618 | 27348905 | [
{
"id": "73619",
"type": "document",
"text": [
"[ Diabetic constipation treated with acupoint embedding therapy and forlax : a randomized controlled trial ] . OBJECTIVE To compare the difference among the combined method of oral administration of forlaxand acupoint embedding therapy , the simple acupoint embedding therapy and the simple oral administration of for-lax in the clinical efficacy on diabetic constipation . METHODS One hundred and fifty patients were randomized intoa comprehensive group , an acupoint embedding group and a forlax group , 50 cases in each one . In the acupointembedding group , the embedding therapy was applied to bilateral Tianshu ( ST 25 ) , Daheng ( SP 15 ) , Shangjuxu ( ST 37 ) and Dachangshu ( BL 25 ) , once a week . In the forlax group , forlax ( polyethylene glycol ) was prescribedfor oral administration , once a day , 10 g each time . In the comprehensive group , the acupoint embedding therapyand forlax were combined and the methods were the same as the first two groups . The treatment for 4 weeks wasas one session , and 2 sessions were required in the three groups . Separately , in 4 weeks , 8 weeks of treatment and2 months after treatment , the constipation symptom scores were compared among the three groups . At the end of2 sessions of treatment , the clinical efficacy and adverse reactions were compared among the three groups . In2 months after treatment , the recurrence rate was compared among the three groups . RESULTS The total effectiverate was 98 . 0 % ( 49/50 ) in the comprehensive group , better than 86 . 0 % ( 43/50 ) in the acupoint embeddinggroup and 78 . 0 % ( 11/50 ) in the forlax group ( both P < 0 . 01 ) . In the 4 weeks and 8 weeks of treatment , the con-stipation symptom scores were reduced significantly as compared with those before treatment in the three groups ( all P < 0 . 05 ) . The results in the comprehensive group were lower than those in the other two groups ( all P < 0 . 05 ) . In the 4 weeks of treatment , the scores were not different significantly between the acupoint embedding group and the forlax group ( P > 0.05 ) . In 8 weeks of treatment and 2 months after treatment , the scores in the acupoint embedding group were better tan those in the forlax group ( all p < 0.05 ) . There were 2 cases of drug adverse reaction in the comprehensive group , 6 cases in the forlax group and 0 case in the acupoint embedding group . The recurrence rate was 8.1 % ( 4/49 ) in the comprehensive group , lower than 32.6 % ( 14/43 ) in the acupoint embedding group and 59.0 % ( 23/39 ) in the forlax group ( both P < 0.01 ) . CONCLUSION the combined therapy of acupoint embedding and forlax achieves the better clinical efficacy on diabetic constipation and constipation symptom scores as compared with the simple acupoint embedding therapy and the oral administration of forlax the short-term efficacy of the simple acupoint embedding therapy is not different significantly from the simple forlax medication , but the long-term efficacy and safety are better than those of simple forlax medicaiton ."
],
"offsets": [
[
0,
3041
]
]
}
] | [
{
"id": "73620",
"type": "Intervention_Pharmacological",
"text": [
"oral administration of forlaxand acupoint embedding therapy"
],
"offsets": [
[
176,
235
]
],
"normalized": []
},
{
"id": "73621",
"type": "Intervention_Pharmacological",
"text": [
"simple acupoint embedding therapy"
],
"offsets": [
[
242,
275
]
],
"normalized": []
},
{
"id": "73622",
"type": "Intervention_Pharmacological",
"text": [
"simple oral administration of for-lax"
],
"offsets": [
[
284,
321
]
],
"normalized": []
},
{
"id": "73623",
"type": "Intervention_Physical",
"text": [
"acupoint embedding group and a forlax group"
],
"offsets": [
[
460,
503
]
],
"normalized": []
},
{
"id": "73624",
"type": "Intervention_Physical",
"text": [
"acupointembedding group"
],
"offsets": [
[
536,
559
]
],
"normalized": []
},
{
"id": "73625",
"type": "Intervention_Physical",
"text": [
"embedding therapy"
],
"offsets": [
[
46,
63
]
],
"normalized": []
},
{
"id": "73626",
"type": "Intervention_Pharmacological",
"text": [
"bilateral Tianshu ( ST 25 )"
],
"offsets": [
[
599,
626
]
],
"normalized": []
},
{
"id": "73627",
"type": "Intervention_Pharmacological",
"text": [
"Daheng ( SP 15 )"
],
"offsets": [
[
629,
645
]
],
"normalized": []
},
{
"id": "73628",
"type": "Intervention_Pharmacological",
"text": [
"Shangjuxu ( ST 37 )"
],
"offsets": [
[
648,
667
]
],
"normalized": []
},
{
"id": "73629",
"type": "Intervention_Pharmacological",
"text": [
"Dachangshu"
],
"offsets": [
[
672,
682
]
],
"normalized": []
},
{
"id": "73630",
"type": "Intervention_Pharmacological",
"text": [
"forlax group , forlax ( polyethylene glycol )"
],
"offsets": [
[
716,
761
]
],
"normalized": []
},
{
"id": "73631",
"type": "Intervention_Pharmacological",
"text": [
"acupoint embedding"
],
"offsets": [
[
37,
55
]
],
"normalized": []
},
{
"id": "73632",
"type": "Intervention_Physical",
"text": [
"therapyand forlax"
],
"offsets": [
[
884,
901
]
],
"normalized": []
},
{
"id": "73633",
"type": "Intervention_Physical",
"text": [
"combined therapy of acupoint embedding and forlax"
],
"offsets": [
[
2582,
2631
]
],
"normalized": []
},
{
"id": "73634",
"type": "Intervention_Physical",
"text": [
"simple acupoint embedding therapy"
],
"offsets": [
[
242,
275
]
],
"normalized": []
},
{
"id": "73635",
"type": "Intervention_Pharmacological",
"text": [
"oral administration of forlax"
],
"offsets": [
[
176,
205
]
],
"normalized": []
},
{
"id": "73636",
"type": "Outcome_Other",
"text": [
"clinical efficacy"
],
"offsets": [
[
329,
346
]
],
"normalized": []
},
{
"id": "73637",
"type": "Outcome_Adverse-effects",
"text": [
"adverse reactions"
],
"offsets": [
[
1282,
1299
]
],
"normalized": []
},
{
"id": "73638",
"type": "Outcome_Other",
"text": [
"total effectiverate"
],
"offsets": [
[
1438,
1457
]
],
"normalized": []
},
{
"id": "73639",
"type": "Outcome_Physical",
"text": [
"con-stipation symptom scores"
],
"offsets": [
[
1683,
1711
]
],
"normalized": []
},
{
"id": "73640",
"type": "Outcome_Other",
"text": [
"recurrence rate"
],
"offsets": [
[
1372,
1387
]
],
"normalized": []
},
{
"id": "73641",
"type": "Outcome_Physical",
"text": [
"constipation symptom scores"
],
"offsets": [
[
1150,
1177
]
],
"normalized": []
},
{
"id": "73642",
"type": "Participant_Condition",
"text": [
"[ Diabetic constipation"
],
"offsets": [
[
0,
23
]
],
"normalized": []
},
{
"id": "73643",
"type": "Participant_Condition",
"text": [
"diabetic constipation ."
],
"offsets": [
[
350,
373
]
],
"normalized": []
},
{
"id": "73644",
"type": "Participant_Sample-size",
"text": [
"One hundred and fifty"
],
"offsets": [
[
382,
403
]
],
"normalized": []
},
{
"id": "73645",
"type": "Participant_Condition",
"text": [
"diabetic constipation"
],
"offsets": [
[
350,
371
]
],
"normalized": []
}
] | [] | [] | [] |
73646 | 2741888 | [
{
"id": "73647",
"type": "document",
"text": [
"A comparison of high and low fat meals on postprandial esophageal acid exposure . Fatty foods have been identified as precipitating factors in symptomatic gastroesophageal reflux ( GER ) . A fat meal has also been found to decrease lower esophageal sphincter pressure ( LESP ) in normal subjects . We used the ambulatory 24-h pH monitor to assess esophageal acid exposure in 10 normal subjects and 10 GER patients following low and high fat meals eaten in two body positions . The meals had nearly identical protein content , volumes , and calories . On successive days , patients ingested one of the meals twice , followed by random assignment to 3 h upright and 3 h recumbent position . Acid exposure for each hour over a 3-h postprandial ( PP ) period was assessed as the percent time pH less than 4.0 . Increased upright acid exposure occurred in normals after the high fat ( 6.2 +/- 2.1 % ; mean +/- SE ) compared with the low fat meal ( 1.5 +/- 0.5 % ; p less than 0.05 ) . GER patients had greater ( p less than 0.05 ) acid exposure than normals in all study periods , but no differences were found between low and high fat meals in either study position . High fat meals induce upright GER in normals , but do not significantly affect the abnormal amount of GER in patients . In addition , progressive increases in acid exposure were found over the 3 postprandial hours in GER patients in a recumbent position . The findings are consistent with prior data showing decreased LESP with a fat meal in normals ."
],
"offsets": [
[
0,
1515
]
]
}
] | [
{
"id": "73648",
"type": "Intervention_Other",
"text": [
"high and low fat meals"
],
"offsets": [
[
16,
38
]
],
"normalized": []
},
{
"id": "73649",
"type": "Intervention_Pharmacological",
"text": [
"low and high fat meals"
],
"offsets": [
[
424,
446
]
],
"normalized": []
},
{
"id": "73650",
"type": "Intervention_Pharmacological",
"text": [
"two body positions"
],
"offsets": [
[
456,
474
]
],
"normalized": []
},
{
"id": "73651",
"type": "Intervention_Pharmacological",
"text": [
"meals"
],
"offsets": [
[
33,
38
]
],
"normalized": []
},
{
"id": "73652",
"type": "Intervention_Other",
"text": [
"upright and"
],
"offsets": [
[
652,
663
]
],
"normalized": []
},
{
"id": "73653",
"type": "Intervention_Physical",
"text": [
"recumbent position"
],
"offsets": [
[
668,
686
]
],
"normalized": []
},
{
"id": "73654",
"type": "Outcome_Physical",
"text": [
"esophageal sphincter pressure ( LESP )"
],
"offsets": [
[
238,
276
]
],
"normalized": []
},
{
"id": "73655",
"type": "Outcome_Physical",
"text": [
"Acid exposure for each hour"
],
"offsets": [
[
689,
716
]
],
"normalized": []
},
{
"id": "73656",
"type": "Outcome_Physical",
"text": [
"upright acid exposure"
],
"offsets": [
[
817,
838
]
],
"normalized": []
},
{
"id": "73657",
"type": "Outcome_Physical",
"text": [
"acid exposure"
],
"offsets": [
[
66,
79
]
],
"normalized": []
},
{
"id": "73658",
"type": "Outcome_Physical",
"text": [
"upright GER"
],
"offsets": [
[
1186,
1197
]
],
"normalized": []
},
{
"id": "73659",
"type": "Outcome_Physical",
"text": [
"acid exposure"
],
"offsets": [
[
66,
79
]
],
"normalized": []
},
{
"id": "73660",
"type": "Outcome_Physical",
"text": [
"LESP"
],
"offsets": [
[
270,
274
]
],
"normalized": []
},
{
"id": "73661",
"type": "Participant_Condition",
"text": [
"postprandial esophageal"
],
"offsets": [
[
42,
65
]
],
"normalized": []
},
{
"id": "73662",
"type": "Participant_Condition",
"text": [
"gastroesophageal reflux"
],
"offsets": [
[
155,
178
]
],
"normalized": []
},
{
"id": "73663",
"type": "Participant_Condition",
"text": [
"GER"
],
"offsets": [
[
181,
184
]
],
"normalized": []
},
{
"id": "73664",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
375,
377
]
],
"normalized": []
},
{
"id": "73665",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
375,
377
]
],
"normalized": []
}
] | [] | [] | [] |
73666 | 27532829 | [
{
"id": "73667",
"type": "document",
"text": [
"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis . BACKGROUND Primary biliary cholangitis ( formerly called primary biliary cirrhosis ) can progress to cirrhosis and death despite ursodiol therapy . Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death . Obeticholic acid , a farnesoid X receptor agonist , has shown potential benefit in patients with this disease . METHODS In this 12-month , double-blind , placebo-controlled , phase 3 trial , we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg ( the 10-mg group ) , obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable ( the 5-10-mg group ) , or placebo . The primary end point was an alkaline phosphatase level of less than 1.67 times the upper limit of the normal range , with a reduction of at least 15 % from baseline , and a normal total bilirubin level . RESULTS Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo , 93 % received ursodiol as background therapy . The primary end point occurred in more patients in the 5-10-mg group ( 46 % ) and the 10-mg group ( 47 % ) than in the placebo group ( 10 % ; P < 0.001 for both comparisons ) . Patients in the 5-10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alkaline phosphatase level ( least-squares mean , -113 and -130 U per liter , respectively , vs. -14 U per liter ; P < 0.001 for both comparisons ) and total bilirubin level ( -0.02 and -0.05 mg per deciliter [ -0.3 and -0.9 μmol per liter ] , respectively , vs. 0.12 mg per deciliter [ 2.0 μmol per liter ] ; P < 0.001 for both comparisons ) . Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 months . Pruritus was more common with obeticholic acid than with placebo ( 56 % of patients in the 5-10-mg group and 68 % of those in the 10-mg group vs. 38 % in the placebo group ) . The rate of serious adverse events was 16 % in the 5-10-mg group , 11 % in the 10-mg group , and 4 % in the placebo group . CONCLUSIONS Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo . There were more serious adverse events with obeticholic acid . ( Funded by Intercept Pharmaceuticals ; POISE ClinicalTrials.gov number , NCT01473524 ; Current Controlled Trials number , ISRCTN89514817 . ) ."
],
"offsets": [
[
0,
2785
]
]
}
] | [
{
"id": "73668",
"type": "Intervention_Pharmacological",
"text": [
"Obeticholic Acid"
],
"offsets": [
[
30,
46
]
],
"normalized": []
},
{
"id": "73669",
"type": "Intervention_Pharmacological",
"text": [
"ursodiol"
],
"offsets": [
[
209,
217
]
],
"normalized": []
},
{
"id": "73670",
"type": "Intervention_Pharmacological",
"text": [
"receive obeticholic acid at a dose of 10 mg ( the 10-mg group ) , obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable ( the 5-10-mg group )"
],
"offsets": [
[
656,
817
]
],
"normalized": []
},
{
"id": "73671",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
484,
491
]
],
"normalized": []
},
{
"id": "73672",
"type": "Intervention_Pharmacological",
"text": [
"obeticholic acid"
],
"offsets": [
[
664,
680
]
],
"normalized": []
},
{
"id": "73673",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
484,
491
]
],
"normalized": []
},
{
"id": "73674",
"type": "Intervention_Pharmacological",
"text": [
"ursodiol"
],
"offsets": [
[
209,
217
]
],
"normalized": []
},
{
"id": "73675",
"type": "Outcome_Physical",
"text": [
"alkaline phosphatase level"
],
"offsets": [
[
862,
888
]
],
"normalized": []
},
{
"id": "73676",
"type": "Outcome_Physical",
"text": [
"bilirubin level ."
],
"offsets": [
[
1020,
1037
]
],
"normalized": []
},
{
"id": "73677",
"type": "Outcome_Physical",
"text": [
"alkaline phosphatase level"
],
"offsets": [
[
862,
888
]
],
"normalized": []
},
{
"id": "73678",
"type": "Outcome_Physical",
"text": [
"total bilirubin level"
],
"offsets": [
[
1014,
1035
]
],
"normalized": []
}
] | [] | [] | [] |
73679 | 2755692 | [
{
"id": "73680",
"type": "document",
"text": [
"An evaluation of sealing ability of calcium hydroxide sealers . Solid core filling material such as gutta-percha has been used to fill the root canal in conjunction with a sealer to prevent apical leakage . The purpose of this study was to compare apical seal of five different root canal sealers . Sixty roots of maxillary central incisors were cleansed and shaped and randomly assigned to one of six groups of ten roots each . The root canals were obturated with gutta-percha and one of the sealers by the lateral-vertical condensation technique . Groups I , II , III , IV , and V consisted of roots in which the canal was filled with gutta-percha along with either Roth 's sealer , AH26 , Sealapex , CRCS , or Nogenol sealer , respectively . Group VI was filled with gutta-percha and without sealer to serve as a control . The access opening was filled with amalgam . Each tooth was then placed in a capped vial containing 2 X 2 inch gauze pads saturated with distilled water , and the sealer was allowed to set at 37 degrees C in the humidor for 48 hours . The roots , except for the apical 2 mm , were coated with two layers of nail polish . The roots were stained with india ink , decalcified , dehydrated , and then placed in methylsalicylate to make them transparent . The leakage was measured with a filar micrometer eyepiece under a dissecting microscope . The mean apical leakage of six groups was as follows : I = 0.45 mm , II = 0.277 mm , III = 0.343 mm , IV = 0.263 mm , V = 0.336 mm , and VI = 2.310 mm . Results showed no significant difference in the apical seal produced by gutta-percha and the tested root canal sealers . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1676
]
]
}
] | [
{
"id": "73681",
"type": "Intervention_Pharmacological",
"text": [
"calcium hydroxide sealers"
],
"offsets": [
[
36,
61
]
],
"normalized": []
},
{
"id": "73682",
"type": "Intervention_Surgical",
"text": [
"apical seal"
],
"offsets": [
[
248,
259
]
],
"normalized": []
},
{
"id": "73683",
"type": "Intervention_Pharmacological",
"text": [
"root canal sealers"
],
"offsets": [
[
278,
296
]
],
"normalized": []
},
{
"id": "73684",
"type": "Intervention_Pharmacological",
"text": [
"gutta-percha"
],
"offsets": [
[
100,
112
]
],
"normalized": []
},
{
"id": "73685",
"type": "Intervention_Physical",
"text": [
"sealers"
],
"offsets": [
[
54,
61
]
],
"normalized": []
},
{
"id": "73686",
"type": "Intervention_Physical",
"text": [
"canal was filled with gutta-percha along with either Roth 's sealer , AH26 , Sealapex , CRCS , or Nogenol sealer , respectively"
],
"offsets": [
[
615,
742
]
],
"normalized": []
},
{
"id": "73687",
"type": "Intervention_Control",
"text": [
"filled with gutta-percha and without sealer"
],
"offsets": [
[
758,
801
]
],
"normalized": []
},
{
"id": "73688",
"type": "Intervention_Pharmacological",
"text": [
"amalgam"
],
"offsets": [
[
861,
868
]
],
"normalized": []
},
{
"id": "73689",
"type": "Outcome_Other",
"text": [
"sealing ability"
],
"offsets": [
[
17,
32
]
],
"normalized": []
},
{
"id": "73690",
"type": "Outcome_Physical",
"text": [
"mean apical leakage"
],
"offsets": [
[
1371,
1390
]
],
"normalized": []
}
] | [] | [] | [] |
73691 | 2761917 | [
{
"id": "73692",
"type": "document",
"text": [
"Randomized clinical trial comparing systemic interferon with diathermocoagulation in primary multiple and widespread anogenital condyloma . Two hundred three patients ( median age 26 years ; range 18-45 ) with untreated multiple and widespread anogenital condyloma were randomly assigned to one of four study arms in order to compare the efficacy , toxicity , and tolerability of recombinant interferon alpha-2b with those of diathermocoagulation . Of 200 evaluable patients , 51 were treated intramuscularly ( IM ) with 3 x 10 ( 6 ) U ( 3 MU ) /m2 daily for 3 weeks ( total dose 63 MU/m2 ) , 50 received subcutaneous thrice-weekly injections of 3 MU/m2 for 4 weeks ( total dose 36 MU/m2 ) , 51 underwent diathermocoagulation , and 48 were not treated and were used as a control group . Six months after the end of treatment , the overall response rate ( complete and partial responses ) was 70 % : 57 and 82 % for patients receiving interferon alpha-2b ( IM and subcutaneously ) and diathermocoagulation , respectively , and 8 % for the control group . After 6 months from therapy , no significant differences in complete response were found among the different types of treatment : 20 , 20 , and 35 % for the two interferon groups and the diathermocoagulation group , respectively . Fifteen and two complete responders in the cauterization and interferon groups , respectively , experienced disease recurrence ( P less than .01 ) . All patients given interferon therapy complained of flu-like symptoms , which declined progressively after the first week of treatment . Fatigue , lasting as long as patients received interferon , was the most prevalent chronic side effect . We conclude that systemic recombinant interferon alpha-2b is active in treating patients with primary condyloma lesions and does so as well as cauterization . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1870
]
]
}
] | [
{
"id": "73693",
"type": "Intervention_Pharmacological",
"text": [
"interferon"
],
"offsets": [
[
45,
55
]
],
"normalized": []
},
{
"id": "73694",
"type": "Intervention_Pharmacological",
"text": [
"diathermocoagulation"
],
"offsets": [
[
61,
81
]
],
"normalized": []
},
{
"id": "73695",
"type": "Intervention_Pharmacological",
"text": [
"recombinant interferon alpha-2b"
],
"offsets": [
[
380,
411
]
],
"normalized": []
},
{
"id": "73696",
"type": "Intervention_Pharmacological",
"text": [
"diathermocoagulation"
],
"offsets": [
[
61,
81
]
],
"normalized": []
},
{
"id": "73697",
"type": "Intervention_Physical",
"text": [
"intramuscularly"
],
"offsets": [
[
493,
508
]
],
"normalized": []
},
{
"id": "73698",
"type": "Intervention_Pharmacological",
"text": [
"diathermocoagulation"
],
"offsets": [
[
61,
81
]
],
"normalized": []
},
{
"id": "73699",
"type": "Intervention_Pharmacological",
"text": [
"interferon alpha-2b"
],
"offsets": [
[
392,
411
]
],
"normalized": []
},
{
"id": "73700",
"type": "Intervention_Pharmacological",
"text": [
"diathermocoagulation"
],
"offsets": [
[
61,
81
]
],
"normalized": []
},
{
"id": "73701",
"type": "Intervention_Pharmacological",
"text": [
"diathermocoagulation"
],
"offsets": [
[
61,
81
]
],
"normalized": []
},
{
"id": "73702",
"type": "Intervention_Pharmacological",
"text": [
"interferon therapy"
],
"offsets": [
[
1453,
1471
]
],
"normalized": []
},
{
"id": "73703",
"type": "Intervention_Pharmacological",
"text": [
"interferon"
],
"offsets": [
[
45,
55
]
],
"normalized": []
},
{
"id": "73704",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
338,
346
]
],
"normalized": []
},
{
"id": "73705",
"type": "Outcome_Physical",
"text": [
"toxicity"
],
"offsets": [
[
349,
357
]
],
"normalized": []
},
{
"id": "73706",
"type": "Outcome_Other",
"text": [
"tolerability"
],
"offsets": [
[
364,
376
]
],
"normalized": []
},
{
"id": "73707",
"type": "Outcome_Other",
"text": [
"overall response rate ( complete and partial responses )"
],
"offsets": [
[
831,
887
]
],
"normalized": []
},
{
"id": "73708",
"type": "Outcome_Other",
"text": [
"complete response"
],
"offsets": [
[
1114,
1131
]
],
"normalized": []
},
{
"id": "73709",
"type": "Outcome_Physical",
"text": [
"disease recurrence"
],
"offsets": [
[
1393,
1411
]
],
"normalized": []
},
{
"id": "73710",
"type": "Outcome_Adverse-effects",
"text": [
"flu-like symptoms"
],
"offsets": [
[
1486,
1503
]
],
"normalized": []
},
{
"id": "73711",
"type": "Outcome_Adverse-effects",
"text": [
"Fatigue"
],
"offsets": [
[
1571,
1578
]
],
"normalized": []
},
{
"id": "73712",
"type": "Outcome_Adverse-effects",
"text": [
"side effect"
],
"offsets": [
[
1662,
1673
]
],
"normalized": []
}
] | [] | [] | [] |
73713 | 2764265 | [
{
"id": "73714",
"type": "document",
"text": [
"[ Preventive use of Pentaglobin in intensive care treatment of trauma patients ] . Basing on 50 posttraumatic intensive-care patients with medium grade lesions ( ISS criteria ) , the prophylactic effect of an intravenously applicable IgM preparation ( Pentaglobin ) against nosocomial infections was investigated . The prophylaxis group received on the 3rd , 4th and 5th day a daily dose of 10 g each . At the same times the controls were given 12.5 g human albumin each . Whereas no difference was seen between both groups regarding the definitive outcome of the treatment , the prophylaxis group clearly showed fewer infection pointers during the clinical course . In particular , the incidence and magnitude of febrile temperatures were significantly lower between the 4th and 8th days of treatment . Our results indicate , however , that the prophylactic use those patients who are at particularly high infection exposure risk , e.g . through reintervention surgery , haemorrhage complications or extensive diagnostic interventions ."
],
"offsets": [
[
0,
1037
]
]
}
] | [
{
"id": "73715",
"type": "Intervention_Pharmacological",
"text": [
"Pentaglobin"
],
"offsets": [
[
20,
31
]
],
"normalized": []
},
{
"id": "73716",
"type": "Intervention_Pharmacological",
"text": [
"Pentaglobin"
],
"offsets": [
[
20,
31
]
],
"normalized": []
},
{
"id": "73717",
"type": "Intervention_Pharmacological",
"text": [
"12.5 g human albumin"
],
"offsets": [
[
445,
465
]
],
"normalized": []
},
{
"id": "73718",
"type": "Outcome_Physical",
"text": [
"infections"
],
"offsets": [
[
285,
295
]
],
"normalized": []
},
{
"id": "73719",
"type": "Outcome_Physical",
"text": [
"infection pointers"
],
"offsets": [
[
619,
637
]
],
"normalized": []
},
{
"id": "73720",
"type": "Outcome_Physical",
"text": [
"incidence and magnitude of febrile temperatures"
],
"offsets": [
[
687,
734
]
],
"normalized": []
},
{
"id": "73721",
"type": "Outcome_Physical",
"text": [
"reintervention surgery , haemorrhage complications"
],
"offsets": [
[
947,
997
]
],
"normalized": []
},
{
"id": "73722",
"type": "Outcome_Physical",
"text": [
"extensive diagnostic interventions"
],
"offsets": [
[
1001,
1035
]
],
"normalized": []
},
{
"id": "73723",
"type": "Participant_Condition",
"text": [
"trauma"
],
"offsets": [
[
63,
69
]
],
"normalized": []
},
{
"id": "73724",
"type": "Participant_Sample-size",
"text": [
"50"
],
"offsets": [
[
93,
95
]
],
"normalized": []
},
{
"id": "73725",
"type": "Participant_Condition",
"text": [
"posttraumatic intensive-care"
],
"offsets": [
[
96,
124
]
],
"normalized": []
},
{
"id": "73726",
"type": "Participant_Condition",
"text": [
"lesions"
],
"offsets": [
[
152,
159
]
],
"normalized": []
},
{
"id": "73727",
"type": "Participant_Condition",
"text": [
"ISS criteria"
],
"offsets": [
[
162,
174
]
],
"normalized": []
},
{
"id": "73728",
"type": "Participant_Condition",
"text": [
"infection"
],
"offsets": [
[
285,
294
]
],
"normalized": []
},
{
"id": "73729",
"type": "Participant_Condition",
"text": [
"reintervention surgery"
],
"offsets": [
[
947,
969
]
],
"normalized": []
},
{
"id": "73730",
"type": "Participant_Condition",
"text": [
"haemorrhage complications"
],
"offsets": [
[
972,
997
]
],
"normalized": []
},
{
"id": "73731",
"type": "Participant_Condition",
"text": [
"diagnostic interventions"
],
"offsets": [
[
1011,
1035
]
],
"normalized": []
}
] | [] | [] | [] |
73732 | 2768768 | [
{
"id": "73733",
"type": "document",
"text": [
"Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions ."
],
"offsets": [
[
0,
1614
]
]
}
] | [
{
"id": "73734",
"type": "Intervention_Physical",
"text": [
"aerobic exercise"
],
"offsets": [
[
41,
57
]
],
"normalized": []
},
{
"id": "73735",
"type": "Intervention_Physical",
"text": [
"aerobic exercise training"
],
"offsets": [
[
41,
66
]
],
"normalized": []
},
{
"id": "73736",
"type": "Intervention_Physical",
"text": [
"Aerobic Exercise"
],
"offsets": [
[
314,
330
]
],
"normalized": []
},
{
"id": "73737",
"type": "Intervention_Surgical",
"text": [
"group"
],
"offsets": [
[
331,
336
]
],
"normalized": []
},
{
"id": "73738",
"type": "Intervention_Physical",
"text": [
"Yoga"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73739",
"type": "Intervention_Surgical",
"text": [
"and"
],
"offsets": [
[
15,
18
]
],
"normalized": []
},
{
"id": "73740",
"type": "Intervention_Physical",
"text": [
"Flexibility control"
],
"offsets": [
[
350,
369
]
],
"normalized": []
},
{
"id": "73741",
"type": "Intervention_Surgical",
"text": [
"group"
],
"offsets": [
[
331,
336
]
],
"normalized": []
},
{
"id": "73742",
"type": "Intervention_Other",
"text": [
"Waiting List control group"
],
"offsets": [
[
383,
409
]
],
"normalized": []
},
{
"id": "73743",
"type": "Intervention_Physical",
"text": [
"aerobic exercise"
],
"offsets": [
[
41,
57
]
],
"normalized": []
},
{
"id": "73744",
"type": "Intervention_Physical",
"text": [
"Yoga"
],
"offsets": [
[
341,
345
]
],
"normalized": []
},
{
"id": "73745",
"type": "Intervention_Other",
"text": [
"Waiting List"
],
"offsets": [
[
383,
395
]
],
"normalized": []
},
{
"id": "73746",
"type": "Intervention_Physical",
"text": [
"aerobic exercise"
],
"offsets": [
[
41,
57
]
],
"normalized": []
},
{
"id": "73747",
"type": "Outcome_Physical",
"text": [
"Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold ."
],
"offsets": [
[
536,
744
]
],
"normalized": []
},
{
"id": "73748",
"type": "Outcome_Mental",
"text": [
"Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning ."
],
"offsets": [
[
745,
855
]
],
"normalized": []
},
{
"id": "73749",
"type": "Participant_Age",
"text": [
"older"
],
"offsets": [
[
78,
83
]
],
"normalized": []
},
{
"id": "73750",
"type": "Participant_Sex",
"text": [
"men and women"
],
"offsets": [
[
84,
97
]
],
"normalized": []
},
{
"id": "73751",
"type": "Participant_Sample-size",
"text": [
"101"
],
"offsets": [
[
226,
229
]
],
"normalized": []
},
{
"id": "73752",
"type": "Participant_Age",
"text": [
"older"
],
"offsets": [
[
78,
83
]
],
"normalized": []
}
] | [] | [] | [] |
73753 | 2780120 | [
{
"id": "73754",
"type": "document",
"text": [
"Milk intolerance in children with persistent sleeplessness : a prospective double-blind crossover evaluation . From July 1986 to July 1988 , 146 children less than 5 years of age were referred by their physicians to our university sleep clinic for continual waking and crying during sleep hours . For 85 children ( 58.2 % ) , the sleeplessness was attributed to inappropriate sleep habits . For 17 children ( 11.6 % ) , no explanation was found for the sleep difficulties in spite of an extensive workup . Their median age at referral was 13.5 months ( range 2.5 to 29 months ) . Their persistent sleeplessness was tentatively attributed to an undiagnosed intolerance to cow 's milk . Cow 's milk was excluded from their diet . In 15 children sleep normalized after 5 weeks ( range 4 to 6 weeks ) . As seen from the parents ' logs , the median time needed by the children to fall asleep decreased from 15 minutes ( range 15 to 60 minutes ) to 10 minutes ( range 10 to 15 minutes , P = .001 ) . The number of complete arousals decreased from 5 ( range 1 to 12 ) to less than 1 per night ( range 0 to 2 ) ( P = .001 ) . Total sleep time per 24 hours increased from 5.5 hours ( range 3 to 8.5 hours ) to 13.0 hours ( range 10 to 14.5 hours , P = .001 ) . Sleep normalized in one child who continued to receive no cow 's milk only after the hydrolyzed hypoallergenic diet was discontinued . In every child , a double-blind crossover challenge was conducted involving a control diet containing no cow 's milk and a diet containing cow 's milk . The challenge induced the reappearance of insomnia and agitated behavior in all except one child . The child 's initial sleep difficulties were retrospectively attributed to inappropriate sleep habits . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1778
]
]
}
] | [
{
"id": "73755",
"type": "Intervention_Pharmacological",
"text": [
"Cow 's milk was excluded from their diet"
],
"offsets": [
[
685,
725
]
],
"normalized": []
},
{
"id": "73756",
"type": "Intervention_Control",
"text": [
"control diet containing no cow 's milk"
],
"offsets": [
[
1465,
1503
]
],
"normalized": []
},
{
"id": "73757",
"type": "Intervention_Pharmacological",
"text": [
"diet containing cow 's milk"
],
"offsets": [
[
1510,
1537
]
],
"normalized": []
},
{
"id": "73758",
"type": "Outcome_Physical",
"text": [
"Milk intolerance"
],
"offsets": [
[
0,
16
]
],
"normalized": []
},
{
"id": "73759",
"type": "Outcome_Mental",
"text": [
"median time needed by the children to fall asleep"
],
"offsets": [
[
837,
886
]
],
"normalized": []
},
{
"id": "73760",
"type": "Outcome_Mental",
"text": [
"number of complete arousals"
],
"offsets": [
[
998,
1025
]
],
"normalized": []
},
{
"id": "73761",
"type": "Outcome_Mental",
"text": [
"Total sleep time per 24 hours"
],
"offsets": [
[
1118,
1147
]
],
"normalized": []
},
{
"id": "73762",
"type": "Outcome_Mental",
"text": [
"Sleep"
],
"offsets": [
[
1252,
1257
]
],
"normalized": []
},
{
"id": "73763",
"type": "Outcome_Mental",
"text": [
"reappearance of insomnia and agitated behavior"
],
"offsets": [
[
1566,
1612
]
],
"normalized": []
}
] | [] | [] | [] |
73764 | 2788816 | [
{
"id": "73765",
"type": "document",
"text": [
"A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices . We compared two procedures for the emergency treatment of bleeding esophageal varices in patients who did not respond to blood transfusion and vasoactive drugs . We randomly assigned 101 patients with cirrhosis of the liver and bleeding esophageal varices to undergo either emergency sclerotherapy ( n = 50 ) or staple transection of the esophagus ( n = 51 ) . Four patients assigned to sclerotherapy and 12 assigned to staple transection did not actually undergo those procedures , but all analyses were made on an intention-to-treat basis . Total mortality did not differ significantly between the two groups ; the relative risk of death for staple transection as compared with sclerotherapy was 0.88 ( 95 percent confidence interval , 0.51 to 1.54 ) . Mortality at six weeks was 44 percent among those assigned to sclerotherapy and 35 percent among those assigned to staple transection . Complication rates were similar for the two groups . An interval of five days without bleeding was achieved in 88 percent of those assigned to staple transection and in 62 percent of those assigned to sclerotherapy after a single injection ( P less than 0.01 ) and 82 percent after three injections . In only 2 of the 11 patients who received a third sclerotherapy injection was bleeding controlled for more than five days , and 9 died . We conclude that staple transection of the esophagus is as safe as sclerotherapy for the emergency treatment of bleeding esophageal varices and that it is more effective than a single sclerotherapy procedure . We currently recommend surgery after two injection treatments have failed ."
],
"offsets": [
[
0,
1749
]
]
}
] | [
{
"id": "73766",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73767",
"type": "Intervention_Surgical",
"text": [
"staple transection of the esophagus"
],
"offsets": [
[
35,
70
]
],
"normalized": []
},
{
"id": "73768",
"type": "Intervention_Surgical",
"text": [
"undergo either emergency sclerotherapy"
],
"offsets": [
[
394,
432
]
],
"normalized": []
},
{
"id": "73769",
"type": "Intervention_Surgical",
"text": [
"staple transection of the esophagus"
],
"offsets": [
[
35,
70
]
],
"normalized": []
},
{
"id": "73770",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73771",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73772",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73773",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73774",
"type": "Intervention_Surgical",
"text": [
"sclerotherapy"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "73775",
"type": "Outcome_Physical",
"text": [
"control of bleeding"
],
"offsets": [
[
89,
108
]
],
"normalized": []
},
{
"id": "73776",
"type": "Outcome_Physical",
"text": [
"bleeding"
],
"offsets": [
[
100,
108
]
],
"normalized": []
},
{
"id": "73777",
"type": "Outcome_Mortality",
"text": [
"Total mortality"
],
"offsets": [
[
678,
693
]
],
"normalized": []
},
{
"id": "73778",
"type": "Outcome_Mortality",
"text": [
"relative risk of death"
],
"offsets": [
[
752,
774
]
],
"normalized": []
},
{
"id": "73779",
"type": "Outcome_Mortality",
"text": [
"Mortality"
],
"offsets": [
[
890,
899
]
],
"normalized": []
},
{
"id": "73780",
"type": "Outcome_Physical",
"text": [
"Complication rates"
],
"offsets": [
[
1026,
1044
]
],
"normalized": []
},
{
"id": "73781",
"type": "Outcome_Physical",
"text": [
"interval of five days without bleeding"
],
"offsets": [
[
1082,
1120
]
],
"normalized": []
},
{
"id": "73782",
"type": "Outcome_Physical",
"text": [
"bleeding controlled"
],
"offsets": [
[
1405,
1424
]
],
"normalized": []
},
{
"id": "73783",
"type": "Outcome_Other",
"text": [
"safe as sclerotherapy"
],
"offsets": [
[
1523,
1544
]
],
"normalized": []
},
{
"id": "73784",
"type": "Outcome_Physical",
"text": [
"emergency treatment of bleeding"
],
"offsets": [
[
170,
201
]
],
"normalized": []
},
{
"id": "73785",
"type": "Participant_Condition",
"text": [
"bleeding from esophageal varices"
],
"offsets": [
[
100,
132
]
],
"normalized": []
},
{
"id": "73786",
"type": "Participant_Condition",
"text": [
"bleeding esophageal varices in patients who did not respond to blood transfusion and vasoactive drugs"
],
"offsets": [
[
193,
294
]
],
"normalized": []
},
{
"id": "73787",
"type": "Participant_Sample-size",
"text": [
"101 patients"
],
"offsets": [
[
318,
330
]
],
"normalized": []
},
{
"id": "73788",
"type": "Participant_Condition",
"text": [
"with cirrhosis of the liver and bleeding esophageal varices"
],
"offsets": [
[
331,
390
]
],
"normalized": []
}
] | [] | [] | [] |
73789 | 2808984 | [
{
"id": "73790",
"type": "document",
"text": [
"Rate-modulated cardiac pacing based on transthoracic impedance measurements of minute ventilation : correlation with exercise gas exchange . The relation of pacing rate to physiologic variables of metabolic demand was examined in 10 consecutive patients with a minute ventilation-sensing , rate-modulating ventricular pacemaker implanted for complete heart block . All patients had paroxysmal ( seven patients ) or chronic ( three patients ) atrial fibrillation and were referred for catheter ablation of the atrioventricular junction . Treadmill exercise testing with measurement of expired gas exchange and respiratory flow was performed before ablation and 4 weeks after pacemaker implantation , with the pacemaker programmed to both the fixed-rate VVI and rate-modulating minute ventilation VVIR pacing modes in random sequence . The relation of pacing rate to oxygen consumption ( VO2 ) , expired carbon dioxide concentration ( VCO2 ) , respiratory quotient , tidal volume , respiratory rate and minute ventilation was determined during exercise in the rate-modulating minute ventilation pacing mode . Pacing rate was highly correlated with minute ventilation ( r = 0.89 ) , respiratory quotient ( r = 0.89 ) , VCO2 ( r = 0.87 ) , tidal volume ( r = 0.87 ) , VO2 ( r = 0.84 ) and respiratory rate ( r = 0.84 ) . The mean exercise duration increased from 8.3 +/- 2.8 min in the fixed rate pacing mode to 10.2 +/- 3.4 min in the rate-modulating , minute ventilation mode ( p = 0.0001 ) . The maximal VO2 increased from 13.4 +/- 3.4 to 16.3 +/- 4.1 cc/kg per min ( p = 0.0004 ) . The maximal heart rate achieved in the minute ventilation pacing mode was 136 +/- 9.7 beats/min , similar to that observed in the patient 's intrinsic cardiac rhythm before ablation ( 134.9 +/- 30.1 beats/min , p = NS ) . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1839
]
]
}
] | [
{
"id": "73791",
"type": "Intervention_Surgical",
"text": [
"catheter ablation of the atrioventricular junction"
],
"offsets": [
[
484,
534
]
],
"normalized": []
},
{
"id": "73792",
"type": "Intervention_Physical",
"text": [
"Treadmill exercise testing"
],
"offsets": [
[
537,
563
]
],
"normalized": []
},
{
"id": "73793",
"type": "Outcome_Physical",
"text": [
"expired gas exchange and respiratory flow"
],
"offsets": [
[
584,
625
]
],
"normalized": []
},
{
"id": "73794",
"type": "Outcome_Physical",
"text": [
"relation of pacing rate to oxygen consumption ( VO2 )"
],
"offsets": [
[
838,
891
]
],
"normalized": []
},
{
"id": "73795",
"type": "Outcome_Physical",
"text": [
"expired carbon dioxide concentration ( VCO2 )"
],
"offsets": [
[
894,
939
]
],
"normalized": []
},
{
"id": "73796",
"type": "Outcome_Physical",
"text": [
"respiratory quotient"
],
"offsets": [
[
942,
962
]
],
"normalized": []
},
{
"id": "73797",
"type": "Outcome_Physical",
"text": [
"tidal volume"
],
"offsets": [
[
965,
977
]
],
"normalized": []
},
{
"id": "73798",
"type": "Outcome_Physical",
"text": [
"respiratory rate and minute ventilation"
],
"offsets": [
[
980,
1019
]
],
"normalized": []
},
{
"id": "73799",
"type": "Outcome_Physical",
"text": [
"Pacing rate"
],
"offsets": [
[
1107,
1118
]
],
"normalized": []
},
{
"id": "73800",
"type": "Outcome_Other",
"text": [
"minute ventilation"
],
"offsets": [
[
79,
97
]
],
"normalized": []
},
{
"id": "73801",
"type": "Outcome_Physical",
"text": [
"respiratory quotient"
],
"offsets": [
[
942,
962
]
],
"normalized": []
},
{
"id": "73802",
"type": "Outcome_Physical",
"text": [
"VCO2"
],
"offsets": [
[
933,
937
]
],
"normalized": []
},
{
"id": "73803",
"type": "Outcome_Physical",
"text": [
"tidal volume"
],
"offsets": [
[
965,
977
]
],
"normalized": []
},
{
"id": "73804",
"type": "Outcome_Physical",
"text": [
"VO2"
],
"offsets": [
[
886,
889
]
],
"normalized": []
},
{
"id": "73805",
"type": "Outcome_Physical",
"text": [
"respiratory rate"
],
"offsets": [
[
980,
996
]
],
"normalized": []
},
{
"id": "73806",
"type": "Outcome_Physical",
"text": [
"mean exercise duration"
],
"offsets": [
[
1321,
1343
]
],
"normalized": []
},
{
"id": "73807",
"type": "Outcome_Physical",
"text": [
"maximal VO2"
],
"offsets": [
[
1495,
1506
]
],
"normalized": []
},
{
"id": "73808",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
230,
232
]
],
"normalized": []
},
{
"id": "73809",
"type": "Participant_Condition",
"text": [
"paroxysmal"
],
"offsets": [
[
382,
392
]
],
"normalized": []
},
{
"id": "73810",
"type": "Participant_Sample-size",
"text": [
"seven"
],
"offsets": [
[
395,
400
]
],
"normalized": []
},
{
"id": "73811",
"type": "Participant_Sample-size",
"text": [
"three"
],
"offsets": [
[
425,
430
]
],
"normalized": []
},
{
"id": "73812",
"type": "Participant_Condition",
"text": [
"atrial fibrillation"
],
"offsets": [
[
442,
461
]
],
"normalized": []
}
] | [] | [] | [] |
73813 | 2831788 | [
{
"id": "73814",
"type": "document",
"text": [
"Combined action of enalapril or timolol with hydrochlorothiazide plus amiloride in hypertension . 59 mild to moderate hypertensives were treated for four weeks with 50 mg hydrochlorothiazide plus 5 mg of amiloride , then concomitantly with these diuretics with either enalapril ( 10-20 mg ) or timolol ( 10-20 mg ) in two parallel treatment groups for an additional 12 weeks in an open study . Addition of these drugs lowered the blood pressure by 25 +/- 3/16 +/- 2 mm Hg and 15 +/- 3/14 +/- 1 mm Hg , respectively . The difference of the reduction of the systolic blood pressure between enalapril and timolol group at the end of the combined treatment was statistically significant ( p less than 0.01 ) . The mean serum potassium was elevated by 0.3 mmol/l after addition of enalapril to the diuretic treatment , but none of the patients developed hyperkalaemia . No adverse effects on other routine laboratory values were observed . Both drug combinations can be considered efficient , well tolerated and safe in the treatment of mild to moderate hypertension ."
],
"offsets": [
[
0,
1063
]
]
}
] | [
{
"id": "73815",
"type": "Intervention_Pharmacological",
"text": [
"enalapril"
],
"offsets": [
[
19,
28
]
],
"normalized": []
},
{
"id": "73816",
"type": "Intervention_Pharmacological",
"text": [
"timolol"
],
"offsets": [
[
32,
39
]
],
"normalized": []
},
{
"id": "73817",
"type": "Intervention_Pharmacological",
"text": [
"hydrochlorothiazide plus amiloride"
],
"offsets": [
[
45,
79
]
],
"normalized": []
},
{
"id": "73818",
"type": "Intervention_Pharmacological",
"text": [
"hydrochlorothiazide"
],
"offsets": [
[
45,
64
]
],
"normalized": []
},
{
"id": "73819",
"type": "Intervention_Pharmacological",
"text": [
"amiloride"
],
"offsets": [
[
70,
79
]
],
"normalized": []
},
{
"id": "73820",
"type": "Intervention_Pharmacological",
"text": [
"enalapril"
],
"offsets": [
[
19,
28
]
],
"normalized": []
},
{
"id": "73821",
"type": "Intervention_Pharmacological",
"text": [
"timolol"
],
"offsets": [
[
32,
39
]
],
"normalized": []
},
{
"id": "73822",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
430,
444
]
],
"normalized": []
},
{
"id": "73823",
"type": "Outcome_Physical",
"text": [
"systolic blood pressure"
],
"offsets": [
[
556,
579
]
],
"normalized": []
},
{
"id": "73824",
"type": "Outcome_Physical",
"text": [
"mean serum potassium"
],
"offsets": [
[
710,
730
]
],
"normalized": []
},
{
"id": "73825",
"type": "Outcome_Physical",
"text": [
"hyperkalaemia"
],
"offsets": [
[
849,
862
]
],
"normalized": []
},
{
"id": "73826",
"type": "Outcome_Adverse-effects",
"text": [
"adverse effects"
],
"offsets": [
[
868,
883
]
],
"normalized": []
},
{
"id": "73827",
"type": "Outcome_Other",
"text": [
"tolerated and safe"
],
"offsets": [
[
993,
1011
]
],
"normalized": []
},
{
"id": "73828",
"type": "Participant_Condition",
"text": [
"hypertension"
],
"offsets": [
[
83,
95
]
],
"normalized": []
},
{
"id": "73829",
"type": "Participant_Sample-size",
"text": [
"59"
],
"offsets": [
[
98,
100
]
],
"normalized": []
},
{
"id": "73830",
"type": "Participant_Condition",
"text": [
"mild to moderate hypertensives"
],
"offsets": [
[
101,
131
]
],
"normalized": []
}
] | [] | [] | [] |
73831 | 2834996 | [
{
"id": "73832",
"type": "document",
"text": [
"Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds . In a double-blind , placebo-controlled study , patients with naturally occurring common colds of less than or equal to 48 h duration were randomly assigned to receive nasal sprays of recombinant alfa-2b interferon at 10 or 20 MU/day or placebo four times per day for 5 days . The 10-MU ( n = 74 ) , 20-MU ( n = 74 ) , and placebo ( n = 72 ) groups had comparable frequencies of documented rhinovirus colds ( 50 to 65 % ) and mean durations of pretreatment symptoms ( 26 to 27 h ) . The median duration of colds tended to be longer in the 20-MU group ( 10 days ) than the 10-MU group ( 8 days ) or placebo group ( 8 days ) ( P = 0.06 ) . In those with proven rhinovirus colds treated within 24 h , the median duration was significantly longer in the 20-MU group ( 9 days ) than in the placebo group ( 6 days ) . No differences favoring interferon treatment were found in respiratory symptom scores or resolution of specific symptoms . On days 5 and 7 , nasal washings from compliant subjects with proven rhinovirus colds yielded rhinoviruses more often in placebo ( 47 and 48 % , respectively ) than in interferon ( 15 and 16 % , respectively ) recipients ( P less than 0.02 ) , but no differences in new respiratory illness occurrence were observed in household contacts . Interferon recipients had significantly higher frequencies of blood in nasal mucus ( 16 to 18 % ) than did placebo recipients ( 4 % ) during treatment . Antibiotics for presumed secondary infections were given more often in the 20-MU group ( 11 % ) than in the placebo group ( 0 % ) ( P less than 0.01 ) . Nasal sprays of recombinant alfa-2b interferon were not an effective treatment for natural colds and were associated with toxicity ."
],
"offsets": [
[
0,
1801
]
]
}
] | [
{
"id": "73833",
"type": "Intervention_Pharmacological",
"text": [
"alfa-2b interferon"
],
"offsets": [
[
23,
41
]
],
"normalized": []
},
{
"id": "73834",
"type": "Intervention_Pharmacological",
"text": [
"recombinant alfa-2b interferon"
],
"offsets": [
[
11,
41
]
],
"normalized": []
},
{
"id": "73835",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73836",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73837",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73838",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73839",
"type": "Intervention_Physical",
"text": [
"nasal washings"
],
"offsets": [
[
1042,
1056
]
],
"normalized": []
},
{
"id": "73840",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73841",
"type": "Intervention_Pharmacological",
"text": [
"interferon"
],
"offsets": [
[
31,
41
]
],
"normalized": []
},
{
"id": "73842",
"type": "Intervention_Pharmacological",
"text": [
"Interferon"
],
"offsets": [
[
1363,
1373
]
],
"normalized": []
},
{
"id": "73843",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73844",
"type": "Intervention_Pharmacological",
"text": [
"Antibiotics"
],
"offsets": [
[
1516,
1527
]
],
"normalized": []
},
{
"id": "73845",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
110,
117
]
],
"normalized": []
},
{
"id": "73846",
"type": "Intervention_Pharmacological",
"text": [
"alfa-2b interferon"
],
"offsets": [
[
23,
41
]
],
"normalized": []
},
{
"id": "73847",
"type": "Outcome_Physical",
"text": [
"naturally occurring common colds"
],
"offsets": [
[
55,
87
]
],
"normalized": []
},
{
"id": "73848",
"type": "Outcome_Physical",
"text": [
"median duration of colds"
],
"offsets": [
[
576,
600
]
],
"normalized": []
},
{
"id": "73849",
"type": "Outcome_Physical",
"text": [
"median duration"
],
"offsets": [
[
576,
591
]
],
"normalized": []
},
{
"id": "73850",
"type": "Outcome_Physical",
"text": [
"respiratory symptom scores or resolution of specific symptoms"
],
"offsets": [
[
960,
1021
]
],
"normalized": []
},
{
"id": "73851",
"type": "Outcome_Physical",
"text": [
"respiratory illness occurrence"
],
"offsets": [
[
1294,
1324
]
],
"normalized": []
},
{
"id": "73852",
"type": "Outcome_Adverse-effects",
"text": [
"in nasal mucus"
],
"offsets": [
[
1431,
1445
]
],
"normalized": []
},
{
"id": "73853",
"type": "Outcome_Physical",
"text": [
"Antibiotics"
],
"offsets": [
[
1516,
1527
]
],
"normalized": []
},
{
"id": "73854",
"type": "Outcome_Physical",
"text": [
"effective treatment for natural colds"
],
"offsets": [
[
1728,
1765
]
],
"normalized": []
},
{
"id": "73855",
"type": "Outcome_Adverse-effects",
"text": [
"toxicity"
],
"offsets": [
[
1791,
1799
]
],
"normalized": []
},
{
"id": "73856",
"type": "Participant_Condition",
"text": [
"common colds"
],
"offsets": [
[
75,
87
]
],
"normalized": []
},
{
"id": "73857",
"type": "Participant_Condition",
"text": [
"naturally occurring common colds"
],
"offsets": [
[
55,
87
]
],
"normalized": []
},
{
"id": "73858",
"type": "Participant_Sample-size",
"text": [
"74"
],
"offsets": [
[
382,
384
]
],
"normalized": []
},
{
"id": "73859",
"type": "Participant_Sample-size",
"text": [
"74"
],
"offsets": [
[
382,
384
]
],
"normalized": []
},
{
"id": "73860",
"type": "Participant_Sample-size",
"text": [
"72"
],
"offsets": [
[
426,
428
]
],
"normalized": []
}
] | [] | [] | [] |
73861 | 2855516 | [
{
"id": "73862",
"type": "document",
"text": [
"Strategies for dietary and anti-smoking advice . Practical experiences from the Oslo Study . One of the 2 controlled preventive trials within the Oslo Study was a non-drug trial on the effect of diet and smoking intervention on coronary heart disease in 1232 middleaged , normotensive , healthy men . All had elevated serum cholesterol and 4 out of 5 smoked every day . The participants in the intervention group met every 6 months during the 5-year study for clinical examination and for dietary and smoking counselling . The effect on serum cholesterol was a 13 % lowering ( i.e . 10 % net reduction compared with control group ) , and about a 50 % reduction in cigarette consumption . The effect on coronary heart disease ( fatal and non-fatal myocardial infarction or sudden death ) was a 47 % lowering of the 5-year incidence in the intervention group compared with the control group ( p = 0.02 , 2-sided ) . The main intervention strategies were : information about the risk factor concept to participant and spouse ( in groups ) individual diet and anti-smoking counselling after finishing an extensive clinical and electrocardiographic examination , including exercise-ECG basis and background for the counselling strategy : the total situation of the participant . Some of the most important items : personality , motivation , diet history , bodyweight , blood lipids and blood sugar anti-smoking advice given individually to all smokers in the intervention group advice that smoking cessation was expected to be of special importance for those with elevated blood lipids ."
],
"offsets": [
[
0,
1582
]
]
}
] | [
{
"id": "73863",
"type": "Intervention_Other",
"text": [
"diet"
],
"offsets": [
[
15,
19
]
],
"normalized": []
},
{
"id": "73864",
"type": "Intervention_Psychological",
"text": [
"smoking intervention"
],
"offsets": [
[
204,
224
]
],
"normalized": []
},
{
"id": "73865",
"type": "Intervention_Physical",
"text": [
"dietary"
],
"offsets": [
[
15,
22
]
],
"normalized": []
},
{
"id": "73866",
"type": "Intervention_Educational",
"text": [
"smoking counselling"
],
"offsets": [
[
501,
520
]
],
"normalized": []
},
{
"id": "73867",
"type": "Intervention_Psychological",
"text": [
"individual diet and anti-smoking counselling"
],
"offsets": [
[
1036,
1080
]
],
"normalized": []
},
{
"id": "73868",
"type": "Outcome_Other",
"text": [
"effect of diet"
],
"offsets": [
[
185,
199
]
],
"normalized": []
},
{
"id": "73869",
"type": "Outcome_Other",
"text": [
"smoking intervention"
],
"offsets": [
[
204,
224
]
],
"normalized": []
},
{
"id": "73870",
"type": "Outcome_Other",
"text": [
"dietary and smoking counselling"
],
"offsets": [
[
489,
520
]
],
"normalized": []
},
{
"id": "73871",
"type": "Outcome_Physical",
"text": [
"effect on serum cholesterol"
],
"offsets": [
[
527,
554
]
],
"normalized": []
},
{
"id": "73872",
"type": "Outcome_Mental",
"text": [
"cigarette consumption ."
],
"offsets": [
[
664,
687
]
],
"normalized": []
},
{
"id": "73873",
"type": "Outcome_Other",
"text": [
"effect on"
],
"offsets": [
[
527,
536
]
],
"normalized": []
},
{
"id": "73874",
"type": "Outcome_Physical",
"text": [
"coronary heart disease"
],
"offsets": [
[
228,
250
]
],
"normalized": []
}
] | [] | [] | [] |
73875 | 2859779 | [
{
"id": "73876",
"type": "document",
"text": [
"Effect of acebutolol on left ventricular performance . The effect of acebutolol on left ventricular performance was examined by various noninvasive means in three studies . M-mode echocardiographic measurements were made in 21 patients with coronary artery disease who were receiving placebo , acebutolol , and propranolol in a double-blind , randomized , crossover study . In these patients with normal or near-normal resting left ventricular function , neither drug induced depression of left ventricular function . In 26 patients with chronic angina pectoris receiving acebutolol under double-blind , placebo-controlled conditions , gated ( equilibrium ) myocardial blood pool imaging using red blood cells labeled with technetium 99m showed acebutolol to have no clinically significant negative effect on left ventricular performance at rest or during supine bicycle exercise . Acebutolol at effective antianginal doses modestly improved resting global and regional myocardial function . In 13 patients with stable angina pectoris , single-pass studies of left ventricular function with indium 113 under double-blind , placebo-controlled conditions similarly showed acebutolol to have no clinically significant negative inotropic effects . In conclusion , acebutolol is safe for use in patients with coronary disease and a wide range of ejection fractions but , as with all beta blockers , should be used cautiously in patients with markedly reduced resting left ventricular function ."
],
"offsets": [
[
0,
1489
]
]
}
] | [
{
"id": "73877",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73878",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73879",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
284,
291
]
],
"normalized": []
},
{
"id": "73880",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73881",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
311,
322
]
],
"normalized": []
},
{
"id": "73882",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73883",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
604,
622
]
],
"normalized": []
},
{
"id": "73884",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73885",
"type": "Intervention_Pharmacological",
"text": [
"Acebutolol"
],
"offsets": [
[
882,
892
]
],
"normalized": []
},
{
"id": "73886",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73887",
"type": "Intervention_Pharmacological",
"text": [
"acebutolol"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "73888",
"type": "Outcome_Physical",
"text": [
"resting global and regional myocardial function ."
],
"offsets": [
[
942,
991
]
],
"normalized": []
},
{
"id": "73889",
"type": "Participant_Condition",
"text": [
"21 patients with coronary artery disease who were receiving placebo , acebutolol , and propranolol in a double-blind"
],
"offsets": [
[
224,
340
]
],
"normalized": []
}
] | [] | [] | [] |
73890 | 2860373 | [
{
"id": "73891",
"type": "document",
"text": [
"Primary hypothyroidism associated with interferon therapy of breast cancer ."
],
"offsets": [
[
0,
76
]
]
}
] | [
{
"id": "73892",
"type": "Intervention_Pharmacological",
"text": [
"interferon"
],
"offsets": [
[
39,
49
]
],
"normalized": []
},
{
"id": "73893",
"type": "Outcome_Physical",
"text": [
"Primary hypothyroidism"
],
"offsets": [
[
0,
22
]
],
"normalized": []
},
{
"id": "73894",
"type": "Participant_Condition",
"text": [
"Primary hypothyroidism"
],
"offsets": [
[
0,
22
]
],
"normalized": []
},
{
"id": "73895",
"type": "Participant_Condition",
"text": [
"interferon therapy of breast cancer ."
],
"offsets": [
[
39,
76
]
],
"normalized": []
}
] | [] | [] | [] |
73896 | 2865615 | [
{
"id": "73897",
"type": "document",
"text": [
"Use of transdermal glyceryl trinitrate to reduce failure of intravenous infusion due to phlebitis and extravasation . Self-adhesive patches which release glyceryl trinitrate at a slow continuous rate or placebo patches were applied to the skin of patients distal to intravenous infusion sites in a double-blind manner . The frequency of infusion failure was three times lower with the glyceryl trinitrate than with placebo patches . The decrease was of similar magnitude whether failure was due to extravasation or phlebitis . Headaches were more common in patients with active patches but were relieved by simple analgesics ."
],
"offsets": [
[
0,
626
]
]
}
] | [
{
"id": "73898",
"type": "Intervention_Pharmacological",
"text": [
"transdermal glyceryl trinitrate"
],
"offsets": [
[
7,
38
]
],
"normalized": []
},
{
"id": "73899",
"type": "Intervention_Pharmacological",
"text": [
"glyceryl trinitrate"
],
"offsets": [
[
19,
38
]
],
"normalized": []
},
{
"id": "73900",
"type": "Intervention_Control",
"text": [
"placebo patches"
],
"offsets": [
[
203,
218
]
],
"normalized": []
},
{
"id": "73901",
"type": "Intervention_Pharmacological",
"text": [
"glyceryl trinitrate"
],
"offsets": [
[
19,
38
]
],
"normalized": []
},
{
"id": "73902",
"type": "Intervention_Control",
"text": [
"placebo patches"
],
"offsets": [
[
203,
218
]
],
"normalized": []
},
{
"id": "73903",
"type": "Intervention_Pharmacological",
"text": [
"analgesics"
],
"offsets": [
[
614,
624
]
],
"normalized": []
},
{
"id": "73904",
"type": "Outcome_Physical",
"text": [
"failure of intravenous infusion"
],
"offsets": [
[
49,
80
]
],
"normalized": []
},
{
"id": "73905",
"type": "Outcome_Physical",
"text": [
"Headaches"
],
"offsets": [
[
527,
536
]
],
"normalized": []
},
{
"id": "73906",
"type": "Participant_Condition",
"text": [
"phlebitis and extravasation"
],
"offsets": [
[
88,
115
]
],
"normalized": []
}
] | [] | [] | [] |
73907 | 2868645 | [
{
"id": "73908",
"type": "document",
"text": [
"Comparison of the efficacy and safety of esmolol , a short-acting beta blocker , with placebo in the treatment of supraventricular tachyarrhythmias . The Esmolol vs Placebo Multicenter Study Group . The efficacy and safety of esmolol , a short-acting intravenous beta-adrenergic-blocking agent , and placebo were compared in patients with supraventricular tachyarrhythmias ( heart rate greater than 120 bpm ) in a multicenter , double-blind , partial-crossover study . Seventy-one patients were randomized to receive either esmolol ( n = 36 ) or placebo ( n = 35 ) as initial treatment . Therapeutic failures were crossed over to the other study medication . Therapeutic response was defined as greater than or equal to 20 % reduction in heart rate , heart rate less than 100 bpm , or conversion to normal sinus rhythm . The therapeutic response to esmolol during the initial treatment period ( 72 % ) was similar to that obtained when esmolol was given as a second agent . The average esmolol dosage producing a therapeutic response was 97.5 micrograms/kg/min . Four patients ( 6 % ) converted to normal sinus rhythm during esmolol infusion . In the majority of patients ( 80 % ) , therapeutic response was lost within 30 minutes following discontinuation of esmolol infusion , a finding indicative of rapid reversal of beta-adrenoceptor blockade . The most prevalent adverse effect during esmolol infusion was hypotension which occurred in eight patients ( 12 % ) . Hypotension and associated symptoms resolved within 30 minutes after discontinuation of esmolol infusion , which is consistent with the short duration of action of esmolol ( elimination half-life of 9.2 minutes ) ."
],
"offsets": [
[
0,
1682
]
]
}
] | [
{
"id": "73909",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73910",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
86,
93
]
],
"normalized": []
},
{
"id": "73911",
"type": "Intervention_Pharmacological",
"text": [
"Esmolol"
],
"offsets": [
[
154,
161
]
],
"normalized": []
},
{
"id": "73912",
"type": "Intervention_Pharmacological",
"text": [
"Placebo"
],
"offsets": [
[
165,
172
]
],
"normalized": []
},
{
"id": "73913",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73914",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
86,
93
]
],
"normalized": []
},
{
"id": "73915",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73916",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
86,
93
]
],
"normalized": []
},
{
"id": "73917",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73918",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73919",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73920",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73921",
"type": "Intervention_Pharmacological",
"text": [
"esmolol"
],
"offsets": [
[
41,
48
]
],
"normalized": []
},
{
"id": "73922",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "73923",
"type": "Outcome_Other",
"text": [
"safety"
],
"offsets": [
[
31,
37
]
],
"normalized": []
},
{
"id": "73924",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "73925",
"type": "Outcome_Other",
"text": [
"safety"
],
"offsets": [
[
31,
37
]
],
"normalized": []
},
{
"id": "73926",
"type": "Outcome_Physical",
"text": [
"Therapeutic response"
],
"offsets": [
[
659,
679
]
],
"normalized": []
},
{
"id": "73927",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
375,
385
]
],
"normalized": []
},
{
"id": "73928",
"type": "Outcome_Physical",
"text": [
"heart rate less than 100 bpm"
],
"offsets": [
[
751,
779
]
],
"normalized": []
},
{
"id": "73929",
"type": "Outcome_Physical",
"text": [
"conversion to normal sinus rhythm"
],
"offsets": [
[
785,
818
]
],
"normalized": []
},
{
"id": "73930",
"type": "Outcome_Other",
"text": [
"The therapeutic response"
],
"offsets": [
[
821,
845
]
],
"normalized": []
},
{
"id": "73931",
"type": "Outcome_Physical",
"text": [
"normal sinus rhythm"
],
"offsets": [
[
799,
818
]
],
"normalized": []
},
{
"id": "73932",
"type": "Outcome_Other",
"text": [
"therapeutic response"
],
"offsets": [
[
825,
845
]
],
"normalized": []
},
{
"id": "73933",
"type": "Outcome_Adverse-effects",
"text": [
"adverse effect"
],
"offsets": [
[
1369,
1383
]
],
"normalized": []
},
{
"id": "73934",
"type": "Outcome_Adverse-effects",
"text": [
"hypotension"
],
"offsets": [
[
1412,
1423
]
],
"normalized": []
},
{
"id": "73935",
"type": "Outcome_Adverse-effects",
"text": [
"Hypotension and associated symptoms"
],
"offsets": [
[
1468,
1503
]
],
"normalized": []
},
{
"id": "73936",
"type": "Participant_Condition",
"text": [
"supraventricular tachyarrhythmias ."
],
"offsets": [
[
114,
149
]
],
"normalized": []
},
{
"id": "73937",
"type": "Participant_Condition",
"text": [
"supraventricular tachyarrhythmias"
],
"offsets": [
[
114,
147
]
],
"normalized": []
},
{
"id": "73938",
"type": "Participant_Sample-size",
"text": [
"Seventy-one"
],
"offsets": [
[
469,
480
]
],
"normalized": []
}
] | [] | [] | [] |
73939 | 2869714 | [
{
"id": "73940",
"type": "document",
"text": [
"[ Potentiation of the effect of non-depolarizing muscle relaxants by acylaminopenicillins . Studies on the example of vecuronium ] . In a prospective controlled clinical study interactions between nondepolarizing muscle relaxants and acylaminopenicillins were investigated electromyographically . Six patients in each group received either apalcillin , azlocillin , mezlocillin or piperacillin during the operation . Muscle relaxation was maintained using the short acting nondepolarizing relaxant vecuronium , which shows no cumulative effect within clinical dosages . The intra-individual comparison with the control period ( 100 % ) showed a significant prolongation of the duration of action after a fixed dose of vecuronium . The mean increase was +26 % following apalcillin , +46 % after piperacillin , +38 % following mezlocillin and +55 % following azlocillin . The shortest time of the control periods was 8.6 min and the maximum time was 32.6 min . We also found a significant depression of the EMG-response . No significant differences could be detected between the four antibiotics . The method described here has proven to be sensitive enough to detect clinically relevant interactions with muscle relaxants . As a result of our study , caution seems to be necessary if acylaminopenicillins are administered in the early postoperative period ."
],
"offsets": [
[
0,
1356
]
]
}
] | [
{
"id": "73941",
"type": "Intervention_Pharmacological",
"text": [
"acylaminopenicillins"
],
"offsets": [
[
69,
89
]
],
"normalized": []
},
{
"id": "73942",
"type": "Intervention_Pharmacological",
"text": [
"nondepolarizing muscle relaxants"
],
"offsets": [
[
197,
229
]
],
"normalized": []
},
{
"id": "73943",
"type": "Intervention_Pharmacological",
"text": [
"acylaminopenicillins"
],
"offsets": [
[
69,
89
]
],
"normalized": []
},
{
"id": "73944",
"type": "Intervention_Pharmacological",
"text": [
"apalcillin , azlocillin , mezlocillin or piperacillin"
],
"offsets": [
[
340,
393
]
],
"normalized": []
},
{
"id": "73945",
"type": "Intervention_Pharmacological",
"text": [
"acylaminopenicillins"
],
"offsets": [
[
69,
89
]
],
"normalized": []
},
{
"id": "73946",
"type": "Outcome_Pain",
"text": [
"Muscle relaxation"
],
"offsets": [
[
417,
434
]
],
"normalized": []
},
{
"id": "73947",
"type": "Outcome_Other",
"text": [
"prolongation of the duration of action"
],
"offsets": [
[
657,
695
]
],
"normalized": []
},
{
"id": "73948",
"type": "Outcome_Other",
"text": [
"mean increase"
],
"offsets": [
[
735,
748
]
],
"normalized": []
},
{
"id": "73949",
"type": "Outcome_Other",
"text": [
"shortest time"
],
"offsets": [
[
874,
887
]
],
"normalized": []
},
{
"id": "73950",
"type": "Outcome_Mental",
"text": [
"depression"
],
"offsets": [
[
987,
997
]
],
"normalized": []
},
{
"id": "73951",
"type": "Outcome_Physical",
"text": [
"EMG-response"
],
"offsets": [
[
1005,
1017
]
],
"normalized": []
},
{
"id": "73952",
"type": "Outcome_Pain",
"text": [
"clinically relevant interactions"
],
"offsets": [
[
1166,
1198
]
],
"normalized": []
},
{
"id": "73953",
"type": "Outcome_Pain",
"text": [
"muscle relaxants"
],
"offsets": [
[
49,
65
]
],
"normalized": []
},
{
"id": "73954",
"type": "Participant_Condition",
"text": [
"Six"
],
"offsets": [
[
297,
300
]
],
"normalized": []
}
] | [] | [] | [] |
73955 | 2871744 | [
{
"id": "73956",
"type": "document",
"text": [
"Propranolol in acute myocardial infarction : the MILIS experience . The results of the propranolol limb of the Multicenter Investigation of the Limitation of Infarct Size are reviewed . A total of 269 patients , who presented with symptoms and electrocardiographic signs suggesting acute myocardial infarction were randomized to acute intravenous and subsequent oral therapy with propranolol ( n = 134 ) or placebo ( n = 135 ) . Eligibility for acute beta-blocker therapy was determined on the basis of readily available , noninvasive tests . Therapy was started at an average time of 8.5 hours after onset of symptoms . The full induction dose of intravenous propranolol ( 0.1 mg/kg ) was tolerated by 90 % of treated patients , and oral maintenance therapy was being continued in 82 % of treated patients on the second hospital day . There was a significant reduction in heart rate throughout maintenance therapy with propranolol , which continued through the tenth hospital day . There was no significant difference in the incidence of congestive heart failure between propranolol- and placebo-treated groups . There was also no significant difference between the 2 groups in infarct size estimated by measurement of serum CK-MB , planimetry of infarct area on technetium pyrophosphate myocardial scintigrams or R-wave measurements in patients with transmural anterior and inferior infarcts . There was no significant difference in mortality between the 2 groups during an average of 36 months ' follow-up . Although propranolol can be administered safely to patients with acute myocardial infarction who are selected on the basis of simple clinical criteria , there is no evidence of reduction of infarct size when beta blockade is begun 8.5 hours after the onset of symptoms ."
],
"offsets": [
[
0,
1781
]
]
}
] | [
{
"id": "73957",
"type": "Intervention_Pharmacological",
"text": [
"Propranolol"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "73958",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
87,
98
]
],
"normalized": []
},
{
"id": "73959",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
87,
98
]
],
"normalized": []
},
{
"id": "73960",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
407,
414
]
],
"normalized": []
},
{
"id": "73961",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
87,
98
]
],
"normalized": []
},
{
"id": "73962",
"type": "Intervention_Pharmacological",
"text": [
"propranolol-"
],
"offsets": [
[
1072,
1084
]
],
"normalized": []
},
{
"id": "73963",
"type": "Intervention_Control",
"text": [
"placebo-treated"
],
"offsets": [
[
1089,
1104
]
],
"normalized": []
},
{
"id": "73964",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
87,
98
]
],
"normalized": []
},
{
"id": "73965",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
873,
883
]
],
"normalized": []
},
{
"id": "73966",
"type": "Outcome_Physical",
"text": [
"incidence of congestive heart failure"
],
"offsets": [
[
1026,
1063
]
],
"normalized": []
},
{
"id": "73967",
"type": "Outcome_Physical",
"text": [
"infarct size"
],
"offsets": [
[
1179,
1191
]
],
"normalized": []
},
{
"id": "73968",
"type": "Outcome_Physical",
"text": [
"serum CK-MB , planimetry of infarct area on technetium pyrophosphate myocardial scintigrams or R-wave measurements"
],
"offsets": [
[
1220,
1334
]
],
"normalized": []
},
{
"id": "73969",
"type": "Outcome_Mortality",
"text": [
"mortality"
],
"offsets": [
[
1435,
1444
]
],
"normalized": []
},
{
"id": "73970",
"type": "Outcome_Physical",
"text": [
"infarct size"
],
"offsets": [
[
1179,
1191
]
],
"normalized": []
},
{
"id": "73971",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction :"
],
"offsets": [
[
15,
44
]
],
"normalized": []
},
{
"id": "73972",
"type": "Participant_Sample-size",
"text": [
"269"
],
"offsets": [
[
197,
200
]
],
"normalized": []
},
{
"id": "73973",
"type": "Participant_Condition",
"text": [
"symptoms and electrocardiographic signs suggesting acute myocardial infarction"
],
"offsets": [
[
231,
309
]
],
"normalized": []
},
{
"id": "73974",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction"
],
"offsets": [
[
15,
42
]
],
"normalized": []
}
] | [] | [] | [] |
73975 | 2871945 | [
{
"id": "73976",
"type": "document",
"text": [
"Protective effect of high-dose medroxyprogesterone acetate ( HD-MPA ) on hematological toxicity induced by chemotherapy for advanced solid tumors : a multicentric controlled clinical trial . MPA-Hematology Italian Cooperative Group . A multicenter , randomized , controlled trial was conducted comparing active treatment with placebo in 227 patients with breast , colorectal , lung and other solid forms of cancer . Combination therapy , ( CT ) conventionally employed for the various types of tumor involved , was associated with MPA ( 117 patients ) or placebo ( 110 patients ) . MPA was given orally as tablets , as a dose of 500 mg b.i.d . for 6 months . The results were , briefly , as follows : The incidence of leukopenia was significantly lower in the groups receiving MPA in patients with breast and colorectal cancer ( P less than 0.02 ) . Tumors of the lung and other solid forms showed no such difference . The incidence of thrombocytopenia was the same in all disease groups . Objective responses ( CR + PR ) were observed in 23/46 ( 50 % ) of breast cancer patients treated with CT + MPA , and in 13/47 ( 28 % ) of those given CT + placebo . The difference was significant ( P less than 0.02 ) . Subjective parameters also showed more improvement in the MPA group than in the patients given CT alone . No significant differences were found for the other types of tumor , but the numbers in this population were very limited . In a group of 45 patients , antithrombin III a ( % ) , antithrombin III R : Ag ( % ) , plasminogen ( mg/dl ) , alpha-2 macroglobulin ( % ) , factor VIII C ( % ) , factor VIII R : Ag ( % ) and factor IX C ( % ) were determined . The most interesting post-treatment findings were an increase in anti-thrombin III ( activity and antigen level ) and in plasminogen . This suggests that MPA does not increase the risk of thrombosis , and might even , to some extent , impede tumor-induced thrombophilia . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1975
]
]
}
] | [
{
"id": "73977",
"type": "Intervention_Pharmacological",
"text": [
"high-dose medroxyprogesterone acetate ( HD-MPA )"
],
"offsets": [
[
21,
69
]
],
"normalized": []
},
{
"id": "73978",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
107,
119
]
],
"normalized": []
},
{
"id": "73979",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
326,
333
]
],
"normalized": []
},
{
"id": "73980",
"type": "Intervention_Physical",
"text": [
"Combination therapy , ( CT )"
],
"offsets": [
[
416,
444
]
],
"normalized": []
},
{
"id": "73981",
"type": "Intervention_Pharmacological",
"text": [
"MPA"
],
"offsets": [
[
64,
67
]
],
"normalized": []
},
{
"id": "73982",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
326,
333
]
],
"normalized": []
},
{
"id": "73983",
"type": "Intervention_Pharmacological",
"text": [
"MPA"
],
"offsets": [
[
64,
67
]
],
"normalized": []
},
{
"id": "73984",
"type": "Intervention_Physical",
"text": [
"CT + MPA"
],
"offsets": [
[
1093,
1101
]
],
"normalized": []
},
{
"id": "73985",
"type": "Intervention_Control",
"text": [
"CT + placebo"
],
"offsets": [
[
1141,
1153
]
],
"normalized": []
},
{
"id": "73986",
"type": "Intervention_Physical",
"text": [
"MPA"
],
"offsets": [
[
64,
67
]
],
"normalized": []
},
{
"id": "73987",
"type": "Outcome_Physical",
"text": [
"hematological toxicity"
],
"offsets": [
[
73,
95
]
],
"normalized": []
},
{
"id": "73988",
"type": "Outcome_Physical",
"text": [
"incidence of leukopenia"
],
"offsets": [
[
705,
728
]
],
"normalized": []
},
{
"id": "73989",
"type": "Outcome_Physical",
"text": [
"Tumors of the lung and other solid forms"
],
"offsets": [
[
850,
890
]
],
"normalized": []
},
{
"id": "73990",
"type": "Outcome_Physical",
"text": [
"incidence of thrombocytopenia"
],
"offsets": [
[
923,
952
]
],
"normalized": []
},
{
"id": "73991",
"type": "Outcome_Physical",
"text": [
"Objective responses ( CR + PR )"
],
"offsets": [
[
990,
1021
]
],
"normalized": []
},
{
"id": "73992",
"type": "Outcome_Other",
"text": [
"Subjective parameters"
],
"offsets": [
[
1210,
1231
]
],
"normalized": []
},
{
"id": "73993",
"type": "Outcome_Physical",
"text": [
"antithrombin III a ( % ) , antithrombin III R : Ag ( % ) , plasminogen ( mg/dl ) , alpha-2 macroglobulin ( % ) , factor VIII C ( % ) , factor VIII R : Ag ( % ) and factor IX C ( % )"
],
"offsets": [
[
1468,
1649
]
],
"normalized": []
},
{
"id": "73994",
"type": "Outcome_Physical",
"text": [
"anti-thrombin III ( activity and antigen level ) and in plasminogen"
],
"offsets": [
[
1733,
1800
]
],
"normalized": []
}
] | [] | [] | [] |
73995 | 2881132 | [
{
"id": "73996",
"type": "document",
"text": [
"Antibiotic elimination of group-B streptococci in urine in prevention of preterm labour . The presence of group-B streptococci in the urine of pregnant women seems to be associated with preterm labour . Urine samples from 4122 women at 27-31 weeks ' gestation were examined for bacteria . Group-B streptococci were found in the urine of 69 women . In a double-blind , controlled study these patients were given either penicillin ( 10 ( 6 ) IU three times daily for 6 days ; 37 patients ) or placebo ( 32 patients ) . The rates of primary rupture of the membranes ( 11 % v 53 % ; p less than 0.001 ) and preterm labour ( 5.4 % v 38 % ; p less than 0.002 ) were significantly lower in the penicillin group than in the placebo group . These results suggest that treatment and follow-up to prevent recolonisation in pregnant women with group-B streptococci in the urine may reduce the frequency of preterm labour in these patients ."
],
"offsets": [
[
0,
928
]
]
}
] | [
{
"id": "73997",
"type": "Intervention_Pharmacological",
"text": [
"penicillin"
],
"offsets": [
[
418,
428
]
],
"normalized": []
},
{
"id": "73998",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
491,
498
]
],
"normalized": []
},
{
"id": "73999",
"type": "Intervention_Pharmacological",
"text": [
"penicillin"
],
"offsets": [
[
418,
428
]
],
"normalized": []
},
{
"id": "74000",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
491,
498
]
],
"normalized": []
},
{
"id": "74001",
"type": "Outcome_Physical",
"text": [
"preterm labour"
],
"offsets": [
[
73,
87
]
],
"normalized": []
},
{
"id": "74002",
"type": "Outcome_Physical",
"text": [
"primary rupture of the membranes"
],
"offsets": [
[
530,
562
]
],
"normalized": []
},
{
"id": "74003",
"type": "Outcome_Physical",
"text": [
"preterm labour"
],
"offsets": [
[
73,
87
]
],
"normalized": []
},
{
"id": "74004",
"type": "Outcome_Physical",
"text": [
"frequency of preterm labour"
],
"offsets": [
[
881,
908
]
],
"normalized": []
},
{
"id": "74005",
"type": "Participant_Condition",
"text": [
"preterm labour"
],
"offsets": [
[
73,
87
]
],
"normalized": []
},
{
"id": "74006",
"type": "Participant_Condition",
"text": [
"pregnant"
],
"offsets": [
[
143,
151
]
],
"normalized": []
},
{
"id": "74007",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
152,
157
]
],
"normalized": []
},
{
"id": "74008",
"type": "Participant_Sample-size",
"text": [
"4122"
],
"offsets": [
[
222,
226
]
],
"normalized": []
},
{
"id": "74009",
"type": "Participant_Sample-size",
"text": [
"69"
],
"offsets": [
[
337,
339
]
],
"normalized": []
},
{
"id": "74010",
"type": "Participant_Condition",
"text": [
"pregnant"
],
"offsets": [
[
143,
151
]
],
"normalized": []
},
{
"id": "74011",
"type": "Participant_Condition",
"text": [
"group-B streptococci"
],
"offsets": [
[
26,
46
]
],
"normalized": []
}
] | [] | [] | [] |
74012 | 288173 | [
{
"id": "74013",
"type": "document",
"text": [
"Bronchial carcinoma . II . Quantitative measurements of the quality of survival . A prospective randomized study of the result of therapy in inoperable patients with advanced disease . Forty-eight bronchial carcinoma patients in clinicoanatomical stage 4 of the disease ( advanced disease ) were randomly assigned to groups for radiotherapy , chemotherapy ( cyclophosphamide ) and placebo treatment , respectively . The results were assessed by the survival time and quality of survival . The median survival time was 4.7 months for radiotherapy , 4.7 months for cyclophosphamide and 1.7 months for placebo . The median total sum of vitagram points was 28.1 for radiotherapy , 20.7 for cyclophosphamide and 6.8 for placebo . When calculated per month , the median sum of vitagram points was 5.9 for radiotherapy , 5.7 for cyclophosphamide and 4.8 for placebo . Statistically the results give no reason to believe that placebo is better than radiotherapy , but it can not be excluded that radiotherapy patients could have a much longer survival . As for cyclophosphamide versus radiotherapy , the differences are to uncertain for any conclusion to be drawn ."
],
"offsets": [
[
0,
1157
]
]
}
] | [
{
"id": "74014",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74015",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy ( cyclophosphamide )"
],
"offsets": [
[
343,
376
]
],
"normalized": []
},
{
"id": "74016",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "74017",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74018",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
358,
374
]
],
"normalized": []
},
{
"id": "74019",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "74020",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74021",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
358,
374
]
],
"normalized": []
},
{
"id": "74022",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "74023",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74024",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
358,
374
]
],
"normalized": []
},
{
"id": "74025",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "74026",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "74027",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74028",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74029",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
358,
374
]
],
"normalized": []
},
{
"id": "74030",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
328,
340
]
],
"normalized": []
},
{
"id": "74031",
"type": "Outcome_Mortality",
"text": [
"quality of survival"
],
"offsets": [
[
60,
79
]
],
"normalized": []
},
{
"id": "74032",
"type": "Outcome_Mortality",
"text": [
"survival time"
],
"offsets": [
[
449,
462
]
],
"normalized": []
},
{
"id": "74033",
"type": "Outcome_Mortality",
"text": [
"quality of survival"
],
"offsets": [
[
60,
79
]
],
"normalized": []
},
{
"id": "74034",
"type": "Outcome_Mortality",
"text": [
"median survival time"
],
"offsets": [
[
493,
513
]
],
"normalized": []
},
{
"id": "74035",
"type": "Outcome_Other",
"text": [
"median total sum of vitagram points"
],
"offsets": [
[
613,
648
]
],
"normalized": []
},
{
"id": "74036",
"type": "Outcome_Other",
"text": [
"median sum of vitagram points"
],
"offsets": [
[
757,
786
]
],
"normalized": []
},
{
"id": "74037",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
71,
79
]
],
"normalized": []
},
{
"id": "74038",
"type": "Participant_Condition",
"text": [
"Bronchial carcinoma"
],
"offsets": [
[
0,
19
]
],
"normalized": []
},
{
"id": "74039",
"type": "Participant_Sample-size",
"text": [
"Forty-eight"
],
"offsets": [
[
185,
196
]
],
"normalized": []
},
{
"id": "74040",
"type": "Participant_Condition",
"text": [
"bronchial carcinoma"
],
"offsets": [
[
197,
216
]
],
"normalized": []
}
] | [] | [] | [] |
74041 | 2882234 | [
{
"id": "74042",
"type": "document",
"text": [
"Comparison of endotracheal and peripheral intravenous adrenaline in cardiac arrest . Is the endotracheal route reliable ? Twelve patients presenting to an accident and emergency department in asystolic cardiac arrest were randomly allocated to treatment with endotracheal adrenaline ( five patients ) or peripheral intravenous adrenaline ( seven patients ) . Femoral-artery blood samples were taken for assay of adrenaline and noradrenaline . After intravenous adrenaline there was a good clinical and biochemical response , but after endotracheal adrenaline there was no change in serum adrenaline and no measurable clinical response . The endotracheal route of adrenaline administration is not reliable in out-of-hospital cardiac arrest ."
],
"offsets": [
[
0,
740
]
]
}
] | [
{
"id": "74043",
"type": "Intervention_Pharmacological",
"text": [
"endotracheal and peripheral intravenous adrenaline"
],
"offsets": [
[
14,
64
]
],
"normalized": []
},
{
"id": "74044",
"type": "Intervention_Pharmacological",
"text": [
"endotracheal adrenaline"
],
"offsets": [
[
259,
282
]
],
"normalized": []
},
{
"id": "74045",
"type": "Intervention_Pharmacological",
"text": [
"peripheral intravenous adrenaline"
],
"offsets": [
[
31,
64
]
],
"normalized": []
},
{
"id": "74046",
"type": "Intervention_Pharmacological",
"text": [
"adrenaline"
],
"offsets": [
[
54,
64
]
],
"normalized": []
},
{
"id": "74047",
"type": "Intervention_Pharmacological",
"text": [
"noradrenaline"
],
"offsets": [
[
427,
440
]
],
"normalized": []
},
{
"id": "74048",
"type": "Intervention_Pharmacological",
"text": [
"adrenaline"
],
"offsets": [
[
54,
64
]
],
"normalized": []
},
{
"id": "74049",
"type": "Intervention_Pharmacological",
"text": [
"adrenaline"
],
"offsets": [
[
54,
64
]
],
"normalized": []
},
{
"id": "74050",
"type": "Outcome_Physical",
"text": [
"clinical and biochemical response"
],
"offsets": [
[
489,
522
]
],
"normalized": []
},
{
"id": "74051",
"type": "Outcome_Physical",
"text": [
"no change in serum adrenaline"
],
"offsets": [
[
569,
598
]
],
"normalized": []
},
{
"id": "74052",
"type": "Outcome_Physical",
"text": [
"measurable clinical response"
],
"offsets": [
[
606,
634
]
],
"normalized": []
},
{
"id": "74053",
"type": "Participant_Condition",
"text": [
"cardiac arrest ."
],
"offsets": [
[
68,
84
]
],
"normalized": []
},
{
"id": "74054",
"type": "Participant_Sample-size",
"text": [
"Twelve"
],
"offsets": [
[
122,
128
]
],
"normalized": []
}
] | [] | [] | [] |
74055 | 288486 | [
{
"id": "74056",
"type": "document",
"text": [
"Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia . Twenty-seven patients receiving a standard cytosine arabinoside and daunorubicin regimen as induction of reinduction therapy of acute myelogenous leukemia were randomly assigned to receive lithium carbonate , 300 mg t.i.d. , or no lithium . Treatment groups were comparable with respect to age and baseline granulocyte counts . All patients developed granulocyte nadirs below 100/cu mm . By actuarial analysis , the median duration of granulocytopenia , less than 1000/cu mm , was 16.0 days in the lithium group and 24.6 days in the no-lithium group , p = 0.013 . The median duration of granulocytes less than 500/cu mm also favored the lithium group but only approached statistical significance : 14.0 days versus 20.5 days , p = 0.054 . Lithium levels between 0.5 and 1.0 meq/liter were easily maintained in 11 of 12 patients receiving lithium , 300 mg t.i.d. , and toxicity directly attributable to lithium was not observed . Despite the shortened duration of neutropenia , the incidence of infections and the rate of remission were not affected ."
],
"offsets": [
[
0,
1136
]
]
}
] | [
{
"id": "74057",
"type": "Intervention_Pharmacological",
"text": [
"Lithium"
],
"offsets": [
[
0,
7
]
],
"normalized": []
},
{
"id": "74058",
"type": "Intervention_Pharmacological",
"text": [
"standard cytosine arabinoside"
],
"offsets": [
[
120,
149
]
],
"normalized": []
},
{
"id": "74059",
"type": "Intervention_Pharmacological",
"text": [
"daunorubicin regimen"
],
"offsets": [
[
154,
174
]
],
"normalized": []
},
{
"id": "74060",
"type": "Intervention_Pharmacological",
"text": [
"lithium carbonate , 300 mg t.i.d."
],
"offsets": [
[
275,
308
]
],
"normalized": []
},
{
"id": "74061",
"type": "Intervention_Pharmacological",
"text": [
"no lithium"
],
"offsets": [
[
314,
324
]
],
"normalized": []
},
{
"id": "74062",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
275,
282
]
],
"normalized": []
},
{
"id": "74063",
"type": "Intervention_Pharmacological",
"text": [
"no-lithium"
],
"offsets": [
[
619,
629
]
],
"normalized": []
},
{
"id": "74064",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
275,
282
]
],
"normalized": []
},
{
"id": "74065",
"type": "Intervention_Pharmacological",
"text": [
"Lithium"
],
"offsets": [
[
0,
7
]
],
"normalized": []
},
{
"id": "74066",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
275,
282
]
],
"normalized": []
},
{
"id": "74067",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
275,
282
]
],
"normalized": []
},
{
"id": "74068",
"type": "Outcome_Physical",
"text": [
"granulocyte nadirs"
],
"offsets": [
[
437,
455
]
],
"normalized": []
},
{
"id": "74069",
"type": "Outcome_Physical",
"text": [
"median duration of granulocytopenia"
],
"offsets": [
[
502,
537
]
],
"normalized": []
},
{
"id": "74070",
"type": "Outcome_Physical",
"text": [
"median duration of granulocytes"
],
"offsets": [
[
654,
685
]
],
"normalized": []
},
{
"id": "74071",
"type": "Outcome_Physical",
"text": [
"Lithium levels between 0.5 and 1.0 meq/liter"
],
"offsets": [
[
825,
869
]
],
"normalized": []
},
{
"id": "74072",
"type": "Outcome_Other",
"text": [
"toxicity"
],
"offsets": [
[
954,
962
]
],
"normalized": []
},
{
"id": "74073",
"type": "Outcome_Physical",
"text": [
"shortened duration of neutropenia"
],
"offsets": [
[
1027,
1060
]
],
"normalized": []
},
{
"id": "74074",
"type": "Participant_Condition",
"text": [
"acute myelogenous leukemia ."
],
"offsets": [
[
57,
85
]
],
"normalized": []
}
] | [] | [] | [] |
74075 | 2885607 | [
{
"id": "74076",
"type": "document",
"text": [
"Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer ."
],
"offsets": [
[
0,
100
]
]
}
] | [
{
"id": "74077",
"type": "Intervention_Physical",
"text": [
"perioperative chemotherapy"
],
"offsets": [
[
48,
74
]
],
"normalized": []
},
{
"id": "74078",
"type": "Outcome_Physical",
"text": [
"toxic interaction"
],
"offsets": [
[
27,
44
]
],
"normalized": []
},
{
"id": "74079",
"type": "Participant_Condition",
"text": [
"perioperative chemotherapy for early breast cancer"
],
"offsets": [
[
48,
98
]
],
"normalized": []
}
] | [] | [] | [] |
74080 | 2885887 | [
{
"id": "74081",
"type": "document",
"text": [
"Noradrenergic mechanisms in akathisia : treatment with propranolol and clonidine ."
],
"offsets": [
[
0,
82
]
]
}
] | [
{
"id": "74082",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
55,
66
]
],
"normalized": []
},
{
"id": "74083",
"type": "Intervention_Pharmacological",
"text": [
"clonidine"
],
"offsets": [
[
71,
80
]
],
"normalized": []
},
{
"id": "74084",
"type": "Participant_Condition",
"text": [
"akathisia"
],
"offsets": [
[
28,
37
]
],
"normalized": []
},
{
"id": "74085",
"type": "Participant_Condition",
"text": [
"propranolol and clonidine"
],
"offsets": [
[
55,
80
]
],
"normalized": []
}
] | [] | [] | [] |
74086 | 2890442 | [
{
"id": "74087",
"type": "document",
"text": [
"Cardiovascular effects of non-depolarizing neuromuscular blockers in patients with aortic valve disease . To compare haemodynamic responses associated with equipotent doses of neuromuscular blockers and high-dose fentanyl ( 50 micrograms.kg-1 ) , 40 patients with aortic valve stenosis ( AS ) and 20 patients with aortic insufficiency ( AI ) were randomized to four study groups to receive the following : ( 1 ) pancuronium 0.12 mg.kg-1 , ( 2 ) vecuronium 0.12 mg.kg-1 , ( 3 ) atracurium 0.4 mg.kg-1 , or ( 4 ) pancuronium-metocurine mixture ( 0.4 mg + 1.6 mg/ml ) : 1 ml/10 kg ) . Neuromuscular blockers were injected at the same time with the fentanyl ; haemodynamics were recorded with the patients awake ( baseline ) , at two minutes post-induction , and at two and five minutes after intubation . In patients with AS , pancuronium increased heart rate more than vecuronium or atracurium ; heart rates were also higher with the pancuronium-metocurine mixture than with vecuronium . Although there were no ECG signs of ischaemia , one patient given pancuronium developed severe hypotension associated with tachycardia . Reductions in SVR after atracurium allowed small but significant ( p less than 0.01 ) decreases in MAP which were well tolerated ; one patient , however , did develop severe hypotension . Intubation resulted in significant ( p less than 0.01 ) increases in MAP in the pancuronium-metocurine mixture group . Vecuronium permitted the most stable overall haemodynamic course at all measurement times . In contrast , patients with AI showed stable haemodynamics after vecuronium , pancuronium and the pancuronium-metocurine mixture ; one patient became tachycardic following vecuronium . Atracurium caused unexplained elevations in diastolic and mean arterial pressures which were significant when compared to vecuronium ( p less than 0.01 ) . These results in increases in PCWP ; mean PA pressures and CVP were also increased . These effects of atracurium inpatients with Al need further evaluation ."
],
"offsets": [
[
0,
2020
]
]
}
] | [
{
"id": "74088",
"type": "Intervention_Pharmacological",
"text": [
"non-depolarizing neuromuscular blockers"
],
"offsets": [
[
26,
65
]
],
"normalized": []
},
{
"id": "74089",
"type": "Intervention_Pharmacological",
"text": [
"neuromuscular blockers"
],
"offsets": [
[
43,
65
]
],
"normalized": []
},
{
"id": "74090",
"type": "Intervention_Pharmacological",
"text": [
"fentanyl"
],
"offsets": [
[
213,
221
]
],
"normalized": []
},
{
"id": "74091",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium 0.12 mg.kg-1 , ( 2 ) vecuronium 0.12 mg.kg-1"
],
"offsets": [
[
412,
468
]
],
"normalized": []
},
{
"id": "74092",
"type": "Intervention_Pharmacological",
"text": [
"( 3 ) atracurium 0.4 mg.kg-1"
],
"offsets": [
[
471,
499
]
],
"normalized": []
},
{
"id": "74093",
"type": "Intervention_Pharmacological",
"text": [
"( 4 ) pancuronium-metocurine mixture"
],
"offsets": [
[
505,
541
]
],
"normalized": []
},
{
"id": "74094",
"type": "Intervention_Pharmacological",
"text": [
"Neuromuscular blockers"
],
"offsets": [
[
582,
604
]
],
"normalized": []
},
{
"id": "74095",
"type": "Intervention_Pharmacological",
"text": [
"fentanyl"
],
"offsets": [
[
213,
221
]
],
"normalized": []
},
{
"id": "74096",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium"
],
"offsets": [
[
412,
423
]
],
"normalized": []
},
{
"id": "74097",
"type": "Intervention_Pharmacological",
"text": [
"vecuronium"
],
"offsets": [
[
445,
455
]
],
"normalized": []
},
{
"id": "74098",
"type": "Intervention_Pharmacological",
"text": [
"atracurium"
],
"offsets": [
[
477,
487
]
],
"normalized": []
},
{
"id": "74099",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium-metocurine mixture"
],
"offsets": [
[
511,
541
]
],
"normalized": []
},
{
"id": "74100",
"type": "Intervention_Pharmacological",
"text": [
"vecuronium"
],
"offsets": [
[
445,
455
]
],
"normalized": []
},
{
"id": "74101",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium-metocurine"
],
"offsets": [
[
511,
533
]
],
"normalized": []
},
{
"id": "74102",
"type": "Intervention_Pharmacological",
"text": [
"Vecuronium"
],
"offsets": [
[
1430,
1440
]
],
"normalized": []
},
{
"id": "74103",
"type": "Intervention_Pharmacological",
"text": [
"vecuronium"
],
"offsets": [
[
445,
455
]
],
"normalized": []
},
{
"id": "74104",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium"
],
"offsets": [
[
412,
423
]
],
"normalized": []
},
{
"id": "74105",
"type": "Intervention_Pharmacological",
"text": [
"pancuronium-metocurine mixture"
],
"offsets": [
[
511,
541
]
],
"normalized": []
},
{
"id": "74106",
"type": "Intervention_Pharmacological",
"text": [
"vecuronium"
],
"offsets": [
[
445,
455
]
],
"normalized": []
},
{
"id": "74107",
"type": "Intervention_Pharmacological",
"text": [
"Atracurium"
],
"offsets": [
[
1707,
1717
]
],
"normalized": []
},
{
"id": "74108",
"type": "Intervention_Pharmacological",
"text": [
"vecuronium"
],
"offsets": [
[
445,
455
]
],
"normalized": []
},
{
"id": "74109",
"type": "Intervention_Pharmacological",
"text": [
"atracurium"
],
"offsets": [
[
477,
487
]
],
"normalized": []
},
{
"id": "74110",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
846,
856
]
],
"normalized": []
},
{
"id": "74111",
"type": "Outcome_Physical",
"text": [
"heart rates"
],
"offsets": [
[
894,
905
]
],
"normalized": []
},
{
"id": "74112",
"type": "Outcome_Physical",
"text": [
"ECG signs of ischaemia"
],
"offsets": [
[
1009,
1031
]
],
"normalized": []
},
{
"id": "74113",
"type": "Outcome_Physical",
"text": [
"severe hypotension associated with tachycardia"
],
"offsets": [
[
1074,
1120
]
],
"normalized": []
},
{
"id": "74114",
"type": "Outcome_Physical",
"text": [
"SVR"
],
"offsets": [
[
1137,
1140
]
],
"normalized": []
},
{
"id": "74115",
"type": "Outcome_Physical",
"text": [
"MAP"
],
"offsets": [
[
1222,
1225
]
],
"normalized": []
},
{
"id": "74116",
"type": "Outcome_Other",
"text": [
"well tolerated"
],
"offsets": [
[
1237,
1251
]
],
"normalized": []
},
{
"id": "74117",
"type": "Outcome_Physical",
"text": [
"severe hypotension"
],
"offsets": [
[
1074,
1092
]
],
"normalized": []
},
{
"id": "74118",
"type": "Outcome_Physical",
"text": [
"MAP"
],
"offsets": [
[
1222,
1225
]
],
"normalized": []
},
{
"id": "74119",
"type": "Outcome_Physical",
"text": [
"overall haemodynamic course"
],
"offsets": [
[
1467,
1494
]
],
"normalized": []
},
{
"id": "74120",
"type": "Outcome_Physical",
"text": [
"stable haemodynamics"
],
"offsets": [
[
1560,
1580
]
],
"normalized": []
},
{
"id": "74121",
"type": "Outcome_Physical",
"text": [
"tachycardic"
],
"offsets": [
[
1672,
1683
]
],
"normalized": []
},
{
"id": "74122",
"type": "Outcome_Physical",
"text": [
"elevations in diastolic and mean arterial pressures"
],
"offsets": [
[
1737,
1788
]
],
"normalized": []
},
{
"id": "74123",
"type": "Outcome_Physical",
"text": [
"PCWP"
],
"offsets": [
[
1893,
1897
]
],
"normalized": []
},
{
"id": "74124",
"type": "Outcome_Physical",
"text": [
"mean PA pressures"
],
"offsets": [
[
1900,
1917
]
],
"normalized": []
},
{
"id": "74125",
"type": "Outcome_Physical",
"text": [
"CVP"
],
"offsets": [
[
1922,
1925
]
],
"normalized": []
},
{
"id": "74126",
"type": "Outcome_Other",
"text": [
"increased"
],
"offsets": [
[
836,
845
]
],
"normalized": []
}
] | [] | [] | [] |
74127 | 2891940 | [
{
"id": "74128",
"type": "document",
"text": [
"Mexiletine for treatment of chronic painful diabetic neuropathy . Sixteen of nineteen patients completed a randomised double-blind crossover trial to assess the effect of oral mexiletine ( 10 mg/kg bodyweight daily ) on the symptoms and signs of chronic painful diabetic neuropathy . The median age of the sixteen patients was 50 years ( range 30-64 ) . Assessment with a five-item clinical symptom scale showed significant improvement during the mexiletine phase compared with the placebo phase . Pain was reduced during mexiletine but not during placebo , as assessed by a visual analogue rating scale . Mexiletine treatment had no effect on tendon reflexes , vibration threshold levels , beat-to-beat variation in heart rate during deep breathing , and postural blood pressure response . Mild side-effects were seen in three of the sixteen patients during mexiletine treatment ."
],
"offsets": [
[
0,
881
]
]
}
] | [
{
"id": "74129",
"type": "Intervention_Pharmacological",
"text": [
"Mexiletine"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "74130",
"type": "Intervention_Pharmacological",
"text": [
"oral mexiletine"
],
"offsets": [
[
171,
186
]
],
"normalized": []
},
{
"id": "74131",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
482,
489
]
],
"normalized": []
},
{
"id": "74132",
"type": "Intervention_Pharmacological",
"text": [
"mexiletine"
],
"offsets": [
[
176,
186
]
],
"normalized": []
},
{
"id": "74133",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
482,
489
]
],
"normalized": []
},
{
"id": "74134",
"type": "Intervention_Pharmacological",
"text": [
"Mexiletine"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "74135",
"type": "Outcome_Other",
"text": [
"five-item clinical symptom scale"
],
"offsets": [
[
372,
404
]
],
"normalized": []
},
{
"id": "74136",
"type": "Outcome_Pain",
"text": [
"Pain"
],
"offsets": [
[
498,
502
]
],
"normalized": []
},
{
"id": "74137",
"type": "Outcome_Physical",
"text": [
"tendon reflexes"
],
"offsets": [
[
644,
659
]
],
"normalized": []
},
{
"id": "74138",
"type": "Outcome_Physical",
"text": [
"vibration threshold levels"
],
"offsets": [
[
662,
688
]
],
"normalized": []
},
{
"id": "74139",
"type": "Outcome_Physical",
"text": [
"beat-to-beat variation in heart rate during deep breathing"
],
"offsets": [
[
691,
749
]
],
"normalized": []
},
{
"id": "74140",
"type": "Outcome_Physical",
"text": [
"postural blood pressure response"
],
"offsets": [
[
756,
788
]
],
"normalized": []
},
{
"id": "74141",
"type": "Outcome_Adverse-effects",
"text": [
"Mild side-effects"
],
"offsets": [
[
791,
808
]
],
"normalized": []
}
] | [] | [] | [] |
74142 | 2895910 | [
{
"id": "74143",
"type": "document",
"text": [
"Multicenter trial of cryotherapy for retinopathy of prematurity : preliminary results . Cryotherapy for Retinopathy of Prematurity Cooperative Group . We report the preliminary 3-month outcome of a multicenter randomized trial of cryotherapy for treatment of retinopathy of prematurity ( ROP ) . Transscleral cryotherapy to the avascular retina was applied to one randomly selected eye when there was threshold disease ( defined as five or more contiguous or eight cumulative 30 degree sectors [ clock hours ] of stage 3 ROP in zone 1 or 2 in the presence of \" plus \" disease ) . An unfavorable outcome was defined as posterior retinal detachment , retinal fold involving the macula , or retrolental tissue . At this writing , 172 infants had been examined 3 months after randomization . An unfavorable outcome was significantly less frequent in the eyes undergoing cryotherapy ( 21.8 % ) compared with the untreated eyes ( 43 % ) . While the surgery was stressful , no unexpected complications occurred during or following treatment . These data support the efficacy of cryotherapy in reducing by approximately one half the risk of unfavorable retinal outcome from threshold ROP ."
],
"offsets": [
[
0,
1181
]
]
}
] | [
{
"id": "74144",
"type": "Intervention_Physical",
"text": [
"cryotherapy"
],
"offsets": [
[
21,
32
]
],
"normalized": []
},
{
"id": "74145",
"type": "Intervention_Physical",
"text": [
"Cryotherapy"
],
"offsets": [
[
88,
99
]
],
"normalized": []
},
{
"id": "74146",
"type": "Intervention_Physical",
"text": [
"cryotherapy"
],
"offsets": [
[
21,
32
]
],
"normalized": []
},
{
"id": "74147",
"type": "Intervention_Physical",
"text": [
"Transscleral cryotherapy"
],
"offsets": [
[
296,
320
]
],
"normalized": []
},
{
"id": "74148",
"type": "Intervention_Physical",
"text": [
"cryotherapy"
],
"offsets": [
[
21,
32
]
],
"normalized": []
},
{
"id": "74149",
"type": "Intervention_Physical",
"text": [
"cryotherapy"
],
"offsets": [
[
21,
32
]
],
"normalized": []
},
{
"id": "74150",
"type": "Outcome_Physical",
"text": [
"posterior retinal detachment"
],
"offsets": [
[
618,
646
]
],
"normalized": []
},
{
"id": "74151",
"type": "Outcome_Physical",
"text": [
"retinal fold involving the macula"
],
"offsets": [
[
649,
682
]
],
"normalized": []
},
{
"id": "74152",
"type": "Outcome_Physical",
"text": [
"retrolental tissue"
],
"offsets": [
[
688,
706
]
],
"normalized": []
},
{
"id": "74153",
"type": "Outcome_Adverse-effects",
"text": [
"unexpected complications"
],
"offsets": [
[
970,
994
]
],
"normalized": []
},
{
"id": "74154",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
1059,
1067
]
],
"normalized": []
},
{
"id": "74155",
"type": "Participant_Condition",
"text": [
"retinopathy of prematurity :"
],
"offsets": [
[
37,
65
]
],
"normalized": []
}
] | [] | [] | [] |
74156 | 2915887 | [
{
"id": "74157",
"type": "document",
"text": [
"5-Fluorouracil , adriamycin , cyclophosphamide ( FAC ) vs. 5-fluorouracil , epirubicin , cyclophosphamide ( FEC ) in metastatic breast cancer . 94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fluorouracil , adriamycin , and cyclophosphamide ( FAC ) or 5-fluorouracil , epirubicin , and cyclophosphamide ( FEC ) , with cycles repeated every 3 weeks . The objective response rate to FAC was 46 % versus 44 % to FEC . There was no significant difference in the median duration of response and median survival for the two regimens . Toxicity was more frequent and more pronounced in patients receiving FAC . Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm ."
],
"offsets": [
[
0,
741
]
]
}
] | [
{
"id": "74158",
"type": "Intervention_Pharmacological",
"text": [
"5-Fluorouracil , adriamycin , cyclophosphamide ( FAC )"
],
"offsets": [
[
0,
54
]
],
"normalized": []
},
{
"id": "74159",
"type": "Intervention_Pharmacological",
"text": [
"5-fluorouracil , epirubicin , cyclophosphamide ( FEC )"
],
"offsets": [
[
59,
113
]
],
"normalized": []
},
{
"id": "74160",
"type": "Intervention_Pharmacological",
"text": [
"5-fluorouracil , adriamycin , and cyclophosphamide ( FAC ) or 5-fluorouracil , epirubicin , and cyclophosphamide ( FEC )"
],
"offsets": [
[
222,
342
]
],
"normalized": []
},
{
"id": "74161",
"type": "Intervention_Pharmacological",
"text": [
"FAC"
],
"offsets": [
[
49,
52
]
],
"normalized": []
},
{
"id": "74162",
"type": "Intervention_Pharmacological",
"text": [
"FEC"
],
"offsets": [
[
108,
111
]
],
"normalized": []
},
{
"id": "74163",
"type": "Intervention_Pharmacological",
"text": [
"FAC"
],
"offsets": [
[
49,
52
]
],
"normalized": []
},
{
"id": "74164",
"type": "Outcome_Physical",
"text": [
"objective response rate"
],
"offsets": [
[
386,
409
]
],
"normalized": []
},
{
"id": "74165",
"type": "Outcome_Physical",
"text": [
"median duration of response and"
],
"offsets": [
[
490,
521
]
],
"normalized": []
},
{
"id": "74166",
"type": "Outcome_Mortality",
"text": [
"median survival"
],
"offsets": [
[
522,
537
]
],
"normalized": []
},
{
"id": "74167",
"type": "Outcome_Adverse-effects",
"text": [
"Toxicity"
],
"offsets": [
[
561,
569
]
],
"normalized": []
},
{
"id": "74168",
"type": "Participant_Condition",
"text": [
"metastatic breast cancer"
],
"offsets": [
[
117,
141
]
],
"normalized": []
},
{
"id": "74169",
"type": "Participant_Condition",
"text": [
"94 evaluable patients with metastatic breast cancer"
],
"offsets": [
[
144,
195
]
],
"normalized": []
}
] | [] | [] | [] |
74170 | 2928074 | [
{
"id": "74171",
"type": "document",
"text": [
"Motion aftereffects with horizontally moving sound sources in the free field . A horizontally moving sound was presented to an observer seated in the center of an anechoic chamber . The sound , either a 500-Hz low-pass noise or a 6300-Hz high-pass noise , repeatedly traversed a semicircular arc in the observer 's front hemifield at ear level ( distance : 1.5 m ) . At 10-sec intervals this adaptor was interrupted , and a 750-msec moving probe ( a 500-Hz low-pass noise ) was presented from a horizontal arc 1.6 m in front of the observer . During a run , the adaptor was presented at a constant velocity ( -200 degrees to +200 degrees/sec ) , while probes with velocities varying from -10 degrees to +10 degrees/sec were presented in a random order . Observers judged the direction of motion ( left or right ) of each probe . As in the case of stimuli presented over headphones ( Grantham & Wightman , 1979 ) , an auditory motion aftereffect ( MAE ) occurred : subjects responded \" left \" to probes more often when the adaptor moved right than when it moved left . When the adaptor and probe were spectrally the same , the MAE was greater than when they were from different spectral regions ; the magnitude of this difference depended on adaptor speed and was subject-dependent . It is proposed that there are two components underlying the auditory MAE : ( 1 ) a generalized bias to respond that probes move in the direction opposite to that of the adaptor , independent of their spectra ; and ( 2 ) a loss of sensitivity to the velocity of moving sounds after prolonged exposure to moving sounds having the same spectral content ."
],
"offsets": [
[
0,
1634
]
]
}
] | [
{
"id": "74172",
"type": "Intervention_Other",
"text": [
"horizontally moving sound"
],
"offsets": [
[
25,
50
]
],
"normalized": []
},
{
"id": "74173",
"type": "Intervention_Other",
"text": [
"500-Hz low-pass noise"
],
"offsets": [
[
203,
224
]
],
"normalized": []
},
{
"id": "74174",
"type": "Intervention_Other",
"text": [
"6300-Hz high-pass noise"
],
"offsets": [
[
230,
253
]
],
"normalized": []
},
{
"id": "74175",
"type": "Intervention_Other",
"text": [
"moving probe"
],
"offsets": [
[
433,
445
]
],
"normalized": []
},
{
"id": "74176",
"type": "Outcome_Physical",
"text": [
"auditory motion aftereffect ( MAE )"
],
"offsets": [
[
917,
952
]
],
"normalized": []
},
{
"id": "74177",
"type": "Outcome_Physical",
"text": [
"MAE"
],
"offsets": [
[
947,
950
]
],
"normalized": []
},
{
"id": "74178",
"type": "Outcome_Physical",
"text": [
"MAE"
],
"offsets": [
[
947,
950
]
],
"normalized": []
}
] | [] | [] | [] |
74179 | 2932908 | [
{
"id": "74180",
"type": "document",
"text": [
"Chemotherapy of large bowel carcinoma -- fluorouracil ( FU ) + hydroxyurea ( HU ) vs. methyl-CCNU , oncovin , fluorouracil , and streptozotocin ( MOF-Strep ) . An Eastern Cooperative Oncology Group study . In this prospective randomized study of initial chemotherapy for advanced measurable metastatic large bowel carcinoma , the response rate was 6/32 ( 19 % ) for FU + HU and 5/32 ( 16 % ) for MOF-Strep ; the estimated median survival is 43 weeks for both treatments . Patients who received MOF-Strep experienced substantially greater vomiting and hematologic toxicity than patients who received FU + HU ( p less than 0.001 ) ."
],
"offsets": [
[
0,
630
]
]
}
] | [
{
"id": "74181",
"type": "Intervention_Pharmacological",
"text": [
"fluorouracil ( FU ) + hydroxyurea ( HU )"
],
"offsets": [
[
41,
81
]
],
"normalized": []
},
{
"id": "74182",
"type": "Intervention_Pharmacological",
"text": [
"methyl-CCNU , oncovin , fluorouracil , and streptozotocin ( MOF-Strep )"
],
"offsets": [
[
86,
157
]
],
"normalized": []
},
{
"id": "74183",
"type": "Outcome_Physical",
"text": [
"bowel carcinoma"
],
"offsets": [
[
22,
37
]
],
"normalized": []
},
{
"id": "74184",
"type": "Outcome_Physical",
"text": [
"response rate"
],
"offsets": [
[
330,
343
]
],
"normalized": []
},
{
"id": "74185",
"type": "Outcome_Mortality",
"text": [
"median survival"
],
"offsets": [
[
422,
437
]
],
"normalized": []
},
{
"id": "74186",
"type": "Outcome_Adverse-effects",
"text": [
"vomiting and hematologic toxicity"
],
"offsets": [
[
538,
571
]
],
"normalized": []
},
{
"id": "74187",
"type": "Participant_Condition",
"text": [
"large bowel carcinoma"
],
"offsets": [
[
16,
37
]
],
"normalized": []
},
{
"id": "74188",
"type": "Participant_Condition",
"text": [
"advanced measurable metastatic large bowel carcinoma"
],
"offsets": [
[
271,
323
]
],
"normalized": []
}
] | [] | [] | [] |
74189 | 2936772 | [
{
"id": "74190",
"type": "document",
"text": [
"Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris . A double-blind study . The efficacy of erythromycin base ( E-Mycin tablets , 333 mg ) and the efficacy of tetracycline hydrochloride ( Panmycin tablets ) were compared in this double-blind , randomized study . Two hundred patients with moderate to moderately severe acne vulgaris were randomly assigned to the study . One hundred patients received 1 gm of erythromycin base by mouth per day for 4 weeks , followed by 333 mg/day for 8 weeks , plus placebo for tetracycline . The second group of patients received 1 gm of tetracycline by mouth per day for 4 weeks , followed by 500 mg/day for 8 weeks , plus placebo for erythromycin . Both drugs reduced acne severity to the same extent . Pustules , papules , and open comedo counts decreased significantly over the 12-week period . Seventy-seven percent of the erythromycin-treated patients and 89 % of the tetracycline-treated patients stated that their acne was markedly improved or improved by week 12 . Most of the side effects in patients treated with erythromycin were gastrointestinal symptoms . Among the side effects in patients treated with tetracycline were Candida vaginitis in one patient and pseudotumor cerebri in one patient ."
],
"offsets": [
[
0,
1294
]
]
}
] | [
{
"id": "74191",
"type": "Intervention_Pharmacological",
"text": [
"oral erythromycin"
],
"offsets": [
[
24,
41
]
],
"normalized": []
},
{
"id": "74192",
"type": "Intervention_Pharmacological",
"text": [
"oral tetracycline"
],
"offsets": [
[
49,
66
]
],
"normalized": []
},
{
"id": "74193",
"type": "Intervention_Pharmacological",
"text": [
"erythromycin base"
],
"offsets": [
[
142,
159
]
],
"normalized": []
},
{
"id": "74194",
"type": "Intervention_Pharmacological",
"text": [
"tetracycline hydrochloride"
],
"offsets": [
[
209,
235
]
],
"normalized": []
},
{
"id": "74195",
"type": "Intervention_Pharmacological",
"text": [
"1 gm of erythromycin base"
],
"offsets": [
[
451,
476
]
],
"normalized": []
},
{
"id": "74196",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
550,
557
]
],
"normalized": []
},
{
"id": "74197",
"type": "Intervention_Pharmacological",
"text": [
"tetracycline"
],
"offsets": [
[
54,
66
]
],
"normalized": []
},
{
"id": "74198",
"type": "Intervention_Pharmacological",
"text": [
"tetracycline"
],
"offsets": [
[
54,
66
]
],
"normalized": []
},
{
"id": "74199",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
550,
557
]
],
"normalized": []
},
{
"id": "74200",
"type": "Intervention_Pharmacological",
"text": [
"erythromycin"
],
"offsets": [
[
29,
41
]
],
"normalized": []
},
{
"id": "74201",
"type": "Outcome_Physical",
"text": [
"acne vulgaris ."
],
"offsets": [
[
87,
102
]
],
"normalized": []
},
{
"id": "74202",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
12,
20
]
],
"normalized": []
},
{
"id": "74203",
"type": "Outcome_Physical",
"text": [
"erythromycin base ( E-Mycin tablets , 333 mg )"
],
"offsets": [
[
142,
188
]
],
"normalized": []
},
{
"id": "74204",
"type": "Outcome_Physical",
"text": [
"efficacy"
],
"offsets": [
[
12,
20
]
],
"normalized": []
},
{
"id": "74205",
"type": "Outcome_Physical",
"text": [
"tetracycline hydrochloride"
],
"offsets": [
[
209,
235
]
],
"normalized": []
},
{
"id": "74206",
"type": "Outcome_Physical",
"text": [
"acne severity"
],
"offsets": [
[
755,
768
]
],
"normalized": []
},
{
"id": "74207",
"type": "Outcome_Physical",
"text": [
"Pustules , papules , and open comedo counts"
],
"offsets": [
[
790,
833
]
],
"normalized": []
},
{
"id": "74208",
"type": "Outcome_Physical",
"text": [
"acne"
],
"offsets": [
[
87,
91
]
],
"normalized": []
},
{
"id": "74209",
"type": "Outcome_Adverse-effects",
"text": [
"gastrointestinal symptoms ."
],
"offsets": [
[
1127,
1154
]
],
"normalized": []
},
{
"id": "74210",
"type": "Outcome_Adverse-effects",
"text": [
"Candida vaginitis"
],
"offsets": [
[
1221,
1238
]
],
"normalized": []
},
{
"id": "74211",
"type": "Outcome_Adverse-effects",
"text": [
"pseudotumor cerebri"
],
"offsets": [
[
1258,
1277
]
],
"normalized": []
},
{
"id": "74212",
"type": "Participant_Sample-size",
"text": [
"Two hundred patients"
],
"offsets": [
[
313,
333
]
],
"normalized": []
},
{
"id": "74213",
"type": "Participant_Condition",
"text": [
"moderate to moderately severe acne vulgaris"
],
"offsets": [
[
339,
382
]
],
"normalized": []
}
] | [] | [] | [] |
74214 | 2939214 | [
{
"id": "74215",
"type": "document",
"text": [
"Comparison of ketanserin and pindolol in hypertension . The antihypertensive effects of ketanserin ( 40 mg twice daily ) and pindolol ( 5 mg twice daily ) as monotherapy were compared in a crossover , double-blind trial in 17 patients with essential hypertension . Both ketanserin and pindolol decreased supine systolic and diastolic blood pressure significantly ( P less than 0.01 for systolic and P less than 0.001 for diastolic ) when evaluated at the end of the 2-month treatment periods . There was no significant difference between the two drugs . No significant changes in heart rate were observed on either drug . Both drugs were well tolerated ."
],
"offsets": [
[
0,
654
]
]
}
] | [
{
"id": "74216",
"type": "Intervention_Pharmacological",
"text": [
"ketanserin"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "74217",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
29,
37
]
],
"normalized": []
},
{
"id": "74218",
"type": "Intervention_Pharmacological",
"text": [
"ketanserin"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "74219",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
29,
37
]
],
"normalized": []
},
{
"id": "74220",
"type": "Intervention_Pharmacological",
"text": [
"ketanserin"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "74221",
"type": "Intervention_Pharmacological",
"text": [
"pindolol"
],
"offsets": [
[
29,
37
]
],
"normalized": []
},
{
"id": "74222",
"type": "Outcome_Physical",
"text": [
"supine systolic and diastolic blood pressure"
],
"offsets": [
[
304,
348
]
],
"normalized": []
},
{
"id": "74223",
"type": "Outcome_Physical",
"text": [
"systolic and P"
],
"offsets": [
[
386,
400
]
],
"normalized": []
},
{
"id": "74224",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
580,
590
]
],
"normalized": []
},
{
"id": "74225",
"type": "Participant_Condition",
"text": [
"hypertension ."
],
"offsets": [
[
41,
55
]
],
"normalized": []
},
{
"id": "74226",
"type": "Participant_Sample-size",
"text": [
"17"
],
"offsets": [
[
223,
225
]
],
"normalized": []
}
] | [] | [] | [] |
74227 | 2943781 | [
{
"id": "74228",
"type": "document",
"text": [
"Prevention of subsequent exercise-induced periinfarct ischemia by emergency coronary angioplasty in acute myocardial infarction : comparison with intracoronary streptokinase . To compare the efficacy of emergency percutaneous transluminal coronary angioplasty and intracoronary streptokinase in preventing exercise-induced periinfarct ischemia , 28 patients presenting within 12 hours of the onset of symptoms of acute myocardial infarction were prospectively randomized . Of these , 14 patients were treated with emergency angioplasty and 14 patients received intracoronary streptokinase . Recatheterization and submaximal exercise thallium-201 single photon emission computed tomography were performed before hospital discharge . Periinfarct ischemia was defined as a reversible thallium defect adjacent to a fixed defect assessed qualitatively . Successful reperfusion was achieved in 86 % of patients treated with emergency angioplasty and 86 % of patients treated with intracoronary streptokinase ( p = NS ) . Residual stenosis of the infarct-related coronary artery shown at predischarge angiography was 43.8 +/- 31.4 % for the angioplasty group and 75.0 +/- 15.6 % for the streptokinase group ( p less than 0.05 ) . Of the angioplasty group , 9 % developed exercise-induced periinfarct ischemia compared with 60 % of the streptokinase group ( p less than 0.05 ) . Thus , patients with acute myocardial infarction treated with emergency angioplasty had significantly less severe residual coronary stenosis and exercise-induced periinfarct ischemia than did those treated with intracoronary streptokinase . These results suggest further application of coronary angioplasty in the management of acute myocardial infarction ."
],
"offsets": [
[
0,
1728
]
]
}
] | [
{
"id": "74229",
"type": "Intervention_Physical",
"text": [
"emergency coronary angioplasty"
],
"offsets": [
[
66,
96
]
],
"normalized": []
},
{
"id": "74230",
"type": "Intervention_Physical",
"text": [
"intracoronary streptokinase"
],
"offsets": [
[
146,
173
]
],
"normalized": []
},
{
"id": "74231",
"type": "Intervention_Surgical",
"text": [
"emergency percutaneous transluminal coronary angioplasty"
],
"offsets": [
[
203,
259
]
],
"normalized": []
},
{
"id": "74232",
"type": "Intervention_Physical",
"text": [
"intracoronary streptokinase"
],
"offsets": [
[
146,
173
]
],
"normalized": []
},
{
"id": "74233",
"type": "Intervention_Physical",
"text": [
"emergency angioplasty"
],
"offsets": [
[
514,
535
]
],
"normalized": []
},
{
"id": "74234",
"type": "Intervention_Physical",
"text": [
"intracoronary streptokinase"
],
"offsets": [
[
146,
173
]
],
"normalized": []
},
{
"id": "74235",
"type": "Intervention_Physical",
"text": [
"Recatheterization and submaximal exercise thallium-201 single photon emission computed tomography"
],
"offsets": [
[
591,
688
]
],
"normalized": []
},
{
"id": "74236",
"type": "Intervention_Physical",
"text": [
"emergency angioplasty"
],
"offsets": [
[
514,
535
]
],
"normalized": []
},
{
"id": "74237",
"type": "Intervention_Physical",
"text": [
"streptokinase"
],
"offsets": [
[
160,
173
]
],
"normalized": []
},
{
"id": "74238",
"type": "Intervention_Physical",
"text": [
"streptokinase"
],
"offsets": [
[
160,
173
]
],
"normalized": []
},
{
"id": "74239",
"type": "Intervention_Physical",
"text": [
"coronary angioplasty"
],
"offsets": [
[
76,
96
]
],
"normalized": []
},
{
"id": "74240",
"type": "Outcome_Physical",
"text": [
"exercise-induced periinfarct ischemia"
],
"offsets": [
[
25,
62
]
],
"normalized": []
},
{
"id": "74241",
"type": "Outcome_Physical",
"text": [
"Periinfarct ischemia"
],
"offsets": [
[
732,
752
]
],
"normalized": []
},
{
"id": "74242",
"type": "Outcome_Physical",
"text": [
"Successful reperfusion"
],
"offsets": [
[
849,
871
]
],
"normalized": []
},
{
"id": "74243",
"type": "Outcome_Physical",
"text": [
"Residual stenosis of the infarct-related coronary artery shown at predischarge angiography"
],
"offsets": [
[
1015,
1105
]
],
"normalized": []
},
{
"id": "74244",
"type": "Outcome_Physical",
"text": [
"exercise-induced periinfarct ischemia"
],
"offsets": [
[
25,
62
]
],
"normalized": []
},
{
"id": "74245",
"type": "Outcome_Physical",
"text": [
"severe residual coronary stenosis"
],
"offsets": [
[
1478,
1511
]
],
"normalized": []
},
{
"id": "74246",
"type": "Outcome_Physical",
"text": [
"exercise-induced periinfarct ischemia"
],
"offsets": [
[
25,
62
]
],
"normalized": []
},
{
"id": "74247",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction :"
],
"offsets": [
[
100,
129
]
],
"normalized": []
},
{
"id": "74248",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction"
],
"offsets": [
[
100,
127
]
],
"normalized": []
},
{
"id": "74249",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction"
],
"offsets": [
[
100,
127
]
],
"normalized": []
},
{
"id": "74250",
"type": "Participant_Condition",
"text": [
"acute myocardial infarction"
],
"offsets": [
[
100,
127
]
],
"normalized": []
}
] | [] | [] | [] |
74251 | 2947151 | [
{
"id": "74252",
"type": "document",
"text": [
"[ Therapeutic value of a combination of trimetazidine with a calcium inhibitor in the treatment of chronic coronary insufficiency ] . This double-blind , placebo-controlled study sought to examine the short-term benefit of adding 60 mg of trimetazidine to the daily therapeutic regimen of 29 male patients with coronary insufficiency who had persistent ST depression on exercise tolerance test ( greater than or equal to 1 mm ) , despite treatment with nifedipine 40 mg per day . As compared with the placebo group , after only 14 days , the patients treated with trimetazidine showed statistically significant increases in the maximum workload level attained before ST depression occurred ( 31 % versus - 6 % ; P = 0.009 ) , the total work performed ( 31 % versus 2 % ; P = 0.024 ) and a significant decrease in the systolic tension time ( double product ) /workload ratio ( -5 % versus +11 % ; P = 0.005 ) . Throughout the study the clinical acceptability was excellent , with no side effects attributable to trimetazidine being recorded . This study shows that the addition of trimetazidine to a calcium antagonist brings a valuable improvement in therapeutic results ."
],
"offsets": [
[
0,
1172
]
]
}
] | [
{
"id": "74253",
"type": "Intervention_Pharmacological",
"text": [
"trimetazidine"
],
"offsets": [
[
40,
53
]
],
"normalized": []
},
{
"id": "74254",
"type": "Intervention_Pharmacological",
"text": [
"trimetazidine"
],
"offsets": [
[
40,
53
]
],
"normalized": []
},
{
"id": "74255",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
453,
463
]
],
"normalized": []
},
{
"id": "74256",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
154,
161
]
],
"normalized": []
},
{
"id": "74257",
"type": "Outcome_Physical",
"text": [
"maximum workload level attained before ST depression"
],
"offsets": [
[
628,
680
]
],
"normalized": []
},
{
"id": "74258",
"type": "Outcome_Physical",
"text": [
"the total work performed"
],
"offsets": [
[
726,
750
]
],
"normalized": []
},
{
"id": "74259",
"type": "Outcome_Physical",
"text": [
"systolic tension time"
],
"offsets": [
[
817,
838
]
],
"normalized": []
},
{
"id": "74260",
"type": "Participant_Condition",
"text": [
"chronic coronary insufficiency ]"
],
"offsets": [
[
99,
131
]
],
"normalized": []
},
{
"id": "74261",
"type": "Participant_Sample-size",
"text": [
"29"
],
"offsets": [
[
289,
291
]
],
"normalized": []
},
{
"id": "74262",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
292,
296
]
],
"normalized": []
},
{
"id": "74263",
"type": "Participant_Condition",
"text": [
"coronary insufficiency"
],
"offsets": [
[
107,
129
]
],
"normalized": []
},
{
"id": "74264",
"type": "Participant_Condition",
"text": [
"persistent ST depression"
],
"offsets": [
[
342,
366
]
],
"normalized": []
}
] | [] | [] | [] |
74265 | 2949396 | [
{
"id": "74266",
"type": "document",
"text": [
"No effect of acetylsalicylic acid on B-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischaemic attacks . We studied the effect of acetylsalicylic acid ( ASA ) versus placebo on B-thromboglobulin ( B-TG ) and platelet factor 4 ( PF4 ) plasma levels and ADP-induced platelet aggregation in 25 male patients with transient ischaemic attacks ( TIA ) . The patients were allocated randomly to two groups : 14 patients received oral treatment with ASA 500 mg b.i.d . for 14 days , 11 patients placebo b.i.d . for the same period . B-TG and PF4 plasma levels and ADP-induced platelet aggregation were determined in basal conditions , and two hours , and seven and fourteen days after starting with ASA or placebo . In addition , the same parameters were studied in a group of 20 healthy males of matched age . Basal levels of plasma B-TG and PF4 and the maximal amplitude of ADP-induced platelet aggregation were abnormally high in TIA patients . ASA caused a significant reduction of B-TG plasma levels in TIA patients 2 hours after the first administration , but no effect was observed at the 7th and 14th day of treatment . PF4 plasma levels were unaffected by ASA treatment . It is concluded that ASA , at the dose conventionally used in clinical trials , does not affect the release of two alpha-granule proteins ."
],
"offsets": [
[
0,
1345
]
]
}
] | [
{
"id": "74267",
"type": "Intervention_Pharmacological",
"text": [
"acetylsalicylic acid"
],
"offsets": [
[
13,
33
]
],
"normalized": []
},
{
"id": "74268",
"type": "Intervention_Pharmacological",
"text": [
"acetylsalicylic acid ( ASA )"
],
"offsets": [
[
163,
191
]
],
"normalized": []
},
{
"id": "74269",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
199,
206
]
],
"normalized": []
},
{
"id": "74270",
"type": "Intervention_Pharmacological",
"text": [
"ASA"
],
"offsets": [
[
186,
189
]
],
"normalized": []
},
{
"id": "74271",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
199,
206
]
],
"normalized": []
},
{
"id": "74272",
"type": "Outcome_Physical",
"text": [
"B-thromboglobulin and platelet factor 4 plasma levels"
],
"offsets": [
[
37,
90
]
],
"normalized": []
},
{
"id": "74273",
"type": "Outcome_Physical",
"text": [
"B-thromboglobulin ( B-TG ) and platelet factor 4 ( PF4 ) plasma levels and ADP-induced platelet aggregation"
],
"offsets": [
[
210,
317
]
],
"normalized": []
},
{
"id": "74274",
"type": "Outcome_Physical",
"text": [
"B-TG and PF4 plasma levels and ADP-induced platelet aggregation"
],
"offsets": [
[
558,
621
]
],
"normalized": []
},
{
"id": "74275",
"type": "Outcome_Physical",
"text": [
"Basal levels of plasma B-TG and PF4"
],
"offsets": [
[
836,
871
]
],
"normalized": []
},
{
"id": "74276",
"type": "Outcome_Physical",
"text": [
"amplitude of ADP-induced platelet aggregation"
],
"offsets": [
[
888,
933
]
],
"normalized": []
},
{
"id": "74277",
"type": "Outcome_Physical",
"text": [
"B-TG plasma levels"
],
"offsets": [
[
1011,
1029
]
],
"normalized": []
},
{
"id": "74278",
"type": "Outcome_Physical",
"text": [
"PF4 plasma levels"
],
"offsets": [
[
567,
584
]
],
"normalized": []
},
{
"id": "74279",
"type": "Participant_Condition",
"text": [
"transient ischaemic attacks"
],
"offsets": [
[
108,
135
]
],
"normalized": []
},
{
"id": "74280",
"type": "Participant_Sample-size",
"text": [
"25"
],
"offsets": [
[
321,
323
]
],
"normalized": []
},
{
"id": "74281",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
324,
328
]
],
"normalized": []
},
{
"id": "74282",
"type": "Participant_Condition",
"text": [
"transient ischaemic attacks ( TIA )"
],
"offsets": [
[
343,
378
]
],
"normalized": []
},
{
"id": "74283",
"type": "Participant_Sample-size",
"text": [
"20"
],
"offsets": [
[
802,
804
]
],
"normalized": []
},
{
"id": "74284",
"type": "Participant_Sex",
"text": [
"males"
],
"offsets": [
[
813,
818
]
],
"normalized": []
}
] | [] | [] | [] |
74285 | 2956874 | [
{
"id": "74286",
"type": "document",
"text": [
"Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation . Seventeen patients with stable congestive heart failure ( class II and III New York Heart Association ) received intravenous and oral enoximone in a 2-part study . Hemodynamic data were first obtained after intravenous administration of 0.75 mg/kg of enoximone ; data were again obtained after 12 weeks of therapy with either oral enoximone ( 150 mg 3 times daily ) or placebo . The efficacy and safety of oral enoximone were also studied in a 12-week , double-blind randomized format . In the intravenous study , enoximone was delivered over 5 minutes and hemodynamic data were measured for up to 12 hours after . Cardiac index increased 2.76 +/- 0.63 to 3.42 +/- 0.72 liters/min/m2 ) , pulmonary wedge pressure decreased ( 19.5 +/- 8.8 to 14.6 +/- 8.0 mm Hg ) as did mean arterial blood pressure ( 101 +/- 14.8 to 85 +/- 13.7 mm Hg ) and systemic vascular resistance ( 1,880 +/- 573 to 1,254 +/- 383 dynes s cm-5 ) . Heart rate increased slightly ( 82 +/- 17 to 86 +/- 14 beats/min ) . All these changes were maximal 1 to 2 hours after infusion and lasted 8 hours at least . Patients were then randomized double-blind to oral treatment . Baseline values showed that the 7 patients who received placebo had more severe CHF . Therefore , comparison might be biased . Patient overall assessment showed a continuous benefit in both groups . Ejection fraction improved from 30.1 +/- 6.8 % to 33.9 +/- 9.9 % in the enoximone group while it remained unchanged with placebo ( 23.4 +/- 6.5 % to 23.4 +/- 1.5 % ) . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1673
]
]
}
] | [
{
"id": "74287",
"type": "Intervention_Pharmacological",
"text": [
"oral enoximone"
],
"offsets": [
[
28,
42
]
],
"normalized": []
},
{
"id": "74288",
"type": "Intervention_Pharmacological",
"text": [
"enoximone"
],
"offsets": [
[
33,
42
]
],
"normalized": []
},
{
"id": "74289",
"type": "Intervention_Pharmacological",
"text": [
"0.75 mg/kg of enoximone"
],
"offsets": [
[
368,
391
]
],
"normalized": []
},
{
"id": "74290",
"type": "Intervention_Pharmacological",
"text": [
"oral enoximone"
],
"offsets": [
[
28,
42
]
],
"normalized": []
},
{
"id": "74291",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
500,
507
]
],
"normalized": []
},
{
"id": "74292",
"type": "Intervention_Pharmacological",
"text": [
"oral enoximone"
],
"offsets": [
[
28,
42
]
],
"normalized": []
},
{
"id": "74293",
"type": "Intervention_Pharmacological",
"text": [
"enoximone"
],
"offsets": [
[
33,
42
]
],
"normalized": []
},
{
"id": "74294",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
500,
507
]
],
"normalized": []
},
{
"id": "74295",
"type": "Outcome_Other",
"text": [
"initial and final intravenous hemodynamic evaluation"
],
"offsets": [
[
76,
128
]
],
"normalized": []
},
{
"id": "74296",
"type": "Outcome_Other",
"text": [
"Hemodynamic data"
],
"offsets": [
[
295,
311
]
],
"normalized": []
},
{
"id": "74297",
"type": "Outcome_Physical",
"text": [
"Cardiac index"
],
"offsets": [
[
746,
759
]
],
"normalized": []
},
{
"id": "74298",
"type": "Outcome_Physical",
"text": [
"pulmonary wedge pressure"
],
"offsets": [
[
819,
843
]
],
"normalized": []
},
{
"id": "74299",
"type": "Outcome_Physical",
"text": [
"mean arterial blood pressure"
],
"offsets": [
[
900,
928
]
],
"normalized": []
},
{
"id": "74300",
"type": "Outcome_Physical",
"text": [
"systemic vascular resistance"
],
"offsets": [
[
971,
999
]
],
"normalized": []
},
{
"id": "74301",
"type": "Outcome_Physical",
"text": [
"Heart rate"
],
"offsets": [
[
1050,
1060
]
],
"normalized": []
},
{
"id": "74302",
"type": "Outcome_Physical",
"text": [
"CHF"
],
"offsets": [
[
1351,
1354
]
],
"normalized": []
},
{
"id": "74303",
"type": "Participant_Sample-size",
"text": [
"Seventeen patients"
],
"offsets": [
[
131,
149
]
],
"normalized": []
},
{
"id": "74304",
"type": "Participant_Condition",
"text": [
"stable congestive heart failure ( class II and III New York Heart Association )"
],
"offsets": [
[
155,
234
]
],
"normalized": []
}
] | [] | [] | [] |
74305 | 2959901 | [
{
"id": "74306",
"type": "document",
"text": [
"Bronchodilator effect of fenoterol and ipratropium bromide in infants with acute wheezing : use of MDI with a spacer device . Twenty-eight infants admitted to Exequiel González Cortes Children 's Hospital because of acute wheezing ( AW ) were randomly assigned to three study groups . Fenoterol ( FNT ) , ipratropium bromide ( IB ) , and placebo were administered respectively to children in the different groups by means of metered dose inhalers ( MDI ) with spacers , using doses of 3 puffs every hour , for 4 hours . The degree of bronchial obstruction was assessed clinically and scored with the single-blind method every hour prior to each treatment . The criterion of a bronchodilator effect was a significant decrease in the degree of bronchial obstruction at subsequent scorings . The scores of the three groups were compared using the Student 's t test for matched samples . The same test was also applied to the independent samples for determining the superiority of one treatment , FNT or IB , over the other . The results indicated a significant decrease in the scores of the groups receiving FNT and IB ( P less than 0.05 ) ; this did not occur in the group in which placebo was used . FNT produced a more rapid and sustained effect than IB ( P less than 0.05 ) . Significant bronchodilator effect was obtained in infants with AW when repeated doses of FNT or IB were administered with MDI and spacers . This effect was significantly greater in the group treated with FNT ."
],
"offsets": [
[
0,
1486
]
]
}
] | [
{
"id": "74307",
"type": "Intervention_Pharmacological",
"text": [
"fenoterol"
],
"offsets": [
[
25,
34
]
],
"normalized": []
},
{
"id": "74308",
"type": "Intervention_Pharmacological",
"text": [
"ipratropium bromide"
],
"offsets": [
[
39,
58
]
],
"normalized": []
},
{
"id": "74309",
"type": "Intervention_Pharmacological",
"text": [
"Fenoterol ( FNT )"
],
"offsets": [
[
285,
302
]
],
"normalized": []
},
{
"id": "74310",
"type": "Intervention_Pharmacological",
"text": [
"ipratropium bromide ( IB )"
],
"offsets": [
[
305,
331
]
],
"normalized": []
},
{
"id": "74311",
"type": "Outcome_Physical",
"text": [
"a bronchodilator effect"
],
"offsets": [
[
674,
697
]
],
"normalized": []
}
] | [] | [] | [] |
74312 | 2963645 | [
{
"id": "74313",
"type": "document",
"text": [
"Flow-cytometric studies with eleutherococcus senticosus extract as an immunomodulatory agent . A placebo-controlled study of the effect of an Eleutherococcus senticosus extract ( Eleukokk ) on the immune system was performed with 36 healthy volunteers utilising quantitative multi-parameter flow cytometry with monoclonal antibodies directed against specific surface markers of human lymphocyte subsets . Volunteers in the verum group received 10 ml of an ethanolic ( vincamine free ) eleutherococcus senticosus preparation , 3 times daily for 4 weeks . In the placebo , the eleutherococcus extract was substituted by additional wine , resulting in identical final concentrations of ethanol in both preparations . The purpose of the double-blind study was the demonstration of possible effects on the cellular immune status , as determined by quantitative flow cytometry . The most salient feature in the verum group was a drastic increase in the absolute number of immunocompetent cells , with an especially pronounced effect on T lymphocytes , predominantly of the helper/inducer type , but also on cytotoxic and natural killer cells . In addition , a general enhancement of the activation state of T lymphocytes was observed . No side effects were observed during the trial or afterwards ( observation period 6 months ) ."
],
"offsets": [
[
0,
1324
]
]
}
] | [
{
"id": "74314",
"type": "Intervention_Educational",
"text": [
"eleutherococcus senticosus extract"
],
"offsets": [
[
29,
63
]
],
"normalized": []
},
{
"id": "74315",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
97,
115
]
],
"normalized": []
},
{
"id": "74316",
"type": "Intervention_Educational",
"text": [
"Eleutherococcus senticosus extract ( Eleukokk )"
],
"offsets": [
[
142,
189
]
],
"normalized": []
},
{
"id": "74317",
"type": "Intervention_Control",
"text": [
"placebo , the eleutherococcus extract was substituted by additional wine , resulting in identical final concentrations of ethanol in both preparations"
],
"offsets": [
[
561,
711
]
],
"normalized": []
},
{
"id": "74318",
"type": "Outcome_Physical",
"text": [
"cellular immune status"
],
"offsets": [
[
801,
823
]
],
"normalized": []
},
{
"id": "74319",
"type": "Outcome_Other",
"text": [
"quantitative flow cytometry"
],
"offsets": [
[
843,
870
]
],
"normalized": []
},
{
"id": "74320",
"type": "Outcome_Physical",
"text": [
"absolute number of immunocompetent cells"
],
"offsets": [
[
947,
987
]
],
"normalized": []
},
{
"id": "74321",
"type": "Outcome_Physical",
"text": [
"T lymphocytes"
],
"offsets": [
[
1030,
1043
]
],
"normalized": []
},
{
"id": "74322",
"type": "Outcome_Physical",
"text": [
"helper/inducer type"
],
"offsets": [
[
1067,
1086
]
],
"normalized": []
},
{
"id": "74323",
"type": "Outcome_Physical",
"text": [
"cytotoxic and natural killer cells ."
],
"offsets": [
[
1101,
1137
]
],
"normalized": []
},
{
"id": "74324",
"type": "Outcome_Physical",
"text": [
"activation state of T lymphocytes"
],
"offsets": [
[
1181,
1214
]
],
"normalized": []
},
{
"id": "74325",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
1233,
1245
]
],
"normalized": []
},
{
"id": "74326",
"type": "Participant_Condition",
"text": [
"immune system"
],
"offsets": [
[
197,
210
]
],
"normalized": []
},
{
"id": "74327",
"type": "Participant_Sample-size",
"text": [
"36"
],
"offsets": [
[
230,
232
]
],
"normalized": []
}
] | [] | [] | [] |
74328 | 2968595 | [
{
"id": "74329",
"type": "document",
"text": [
"[ Effects of simvastatin on plasma lipids , lipoproteins and apoproteins ( A1 and B ) . 24 cases of major primary hypercholesterolemia ] . We studied the effects of simvastatin ( MK 733 ) , a new competitive inhibitor of HMG CoA reductase , alone and in combination with a bile acid sequestrant , cholestyramine , on serum levels of lipoproteins and apoproteins A1 and B , in 24 patients with familial hypercholesterolemia . After simvastatin treatment ( 40 mg/day ) alone for 12 weeks , serum total and low density lipoprotein cholesterol decreased by 31 and 36 percent respectively . With the addition of cholestyramine , there was a 41 per cent total decrease in serum cholesterol from the control value and a 50 percent decrease in low density lipoprotein cholesterol . After cholestyramine treatment alone for 12 weeks , serum total and low density lipoprotein cholesterol decreased by 20 percent and 29 percent respectively . With the addition of simvastatin ( 20 mg per day ) , there was a 32 percent total decrease in serum cholesterol from the control value and a 43 percent decrease in low density lipoprotein cholesterol . High density lipoprotein cholesterol remained unchanged . No major adverse effect was observed . If long term safety can be confirmed , the simvastatin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia ."
],
"offsets": [
[
0,
1373
]
]
}
] | [
{
"id": "74330",
"type": "Intervention_Pharmacological",
"text": [
"simvastatin"
],
"offsets": [
[
13,
24
]
],
"normalized": []
},
{
"id": "74331",
"type": "Intervention_Pharmacological",
"text": [
"simvastatin ( MK 733"
],
"offsets": [
[
165,
185
]
],
"normalized": []
},
{
"id": "74332",
"type": "Intervention_Pharmacological",
"text": [
"bile acid sequestrant , cholestyramine"
],
"offsets": [
[
273,
311
]
],
"normalized": []
},
{
"id": "74333",
"type": "Intervention_Pharmacological",
"text": [
"simvastatin treatment"
],
"offsets": [
[
431,
452
]
],
"normalized": []
},
{
"id": "74334",
"type": "Intervention_Pharmacological",
"text": [
"cholestyramine"
],
"offsets": [
[
297,
311
]
],
"normalized": []
},
{
"id": "74335",
"type": "Intervention_Pharmacological",
"text": [
"cholestyramine treatment"
],
"offsets": [
[
780,
804
]
],
"normalized": []
},
{
"id": "74336",
"type": "Intervention_Pharmacological",
"text": [
"simvastatin"
],
"offsets": [
[
13,
24
]
],
"normalized": []
},
{
"id": "74337",
"type": "Intervention_Pharmacological",
"text": [
"simvastatin-cholestyramine regimen"
],
"offsets": [
[
1274,
1308
]
],
"normalized": []
},
{
"id": "74338",
"type": "Outcome_Physical",
"text": [
"plasma lipids"
],
"offsets": [
[
28,
41
]
],
"normalized": []
},
{
"id": "74339",
"type": "Outcome_Physical",
"text": [
"lipoproteins"
],
"offsets": [
[
44,
56
]
],
"normalized": []
},
{
"id": "74340",
"type": "Outcome_Physical",
"text": [
"apoproteins"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74341",
"type": "Outcome_Physical",
"text": [
"low density lipoprotein cholesterol"
],
"offsets": [
[
504,
539
]
],
"normalized": []
},
{
"id": "74342",
"type": "Outcome_Physical",
"text": [
"serum cholesterol"
],
"offsets": [
[
666,
683
]
],
"normalized": []
},
{
"id": "74343",
"type": "Outcome_Other",
"text": [
"low density lipoprotein cholesterol"
],
"offsets": [
[
504,
539
]
],
"normalized": []
},
{
"id": "74344",
"type": "Outcome_Mental",
"text": [
"."
],
"offsets": [
[
86,
87
]
],
"normalized": []
},
{
"id": "74345",
"type": "Outcome_Physical",
"text": [
"serum total"
],
"offsets": [
[
488,
499
]
],
"normalized": []
},
{
"id": "74346",
"type": "Outcome_Other",
"text": [
"and low density lipoprotein cholesterol"
],
"offsets": [
[
500,
539
]
],
"normalized": []
},
{
"id": "74347",
"type": "Outcome_Physical",
"text": [
"serum cholesterol"
],
"offsets": [
[
666,
683
]
],
"normalized": []
},
{
"id": "74348",
"type": "Outcome_Mental",
"text": [
"density lipoprotein cholesterol"
],
"offsets": [
[
508,
539
]
],
"normalized": []
},
{
"id": "74349",
"type": "Outcome_Other",
"text": [
"High density lipoprotein cholesterol"
],
"offsets": [
[
1134,
1170
]
],
"normalized": []
},
{
"id": "74350",
"type": "Outcome_Adverse-effects",
"text": [
"major adverse effect"
],
"offsets": [
[
1195,
1215
]
],
"normalized": []
},
{
"id": "74351",
"type": "Participant_Condition",
"text": [
"hypercholesterolemia"
],
"offsets": [
[
114,
134
]
],
"normalized": []
},
{
"id": "74352",
"type": "Participant_Sample-size",
"text": [
"24"
],
"offsets": [
[
88,
90
]
],
"normalized": []
},
{
"id": "74353",
"type": "Participant_Condition",
"text": [
"familial hypercholesterolemia"
],
"offsets": [
[
393,
422
]
],
"normalized": []
},
{
"id": "74354",
"type": "Participant_Condition",
"text": [
"heterozygous familial hypercholesterolemia"
],
"offsets": [
[
1329,
1371
]
],
"normalized": []
}
] | [] | [] | [] |
74355 | 2973215 | [
{
"id": "74356",
"type": "document",
"text": [
"Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction . Left ventricular ( LV ) hypertrophy is known to be an independent risk factor for cardiac death , but its significance in non-Q-wave acute myocardial infarction ( AMI ) has not been assessed previously . In a randomized diltiazem-placebo-controlled therapeutic trial of non-Q-wave AMI confirmed by creatine kinase-MB ( CK-MB ) , 126 of 544 patients ( 23 % ) exhibited LV hypertrophy using standard voltage criteria . Compared to patients without LV hypertrophy , patients with LV hypertrophy were significantly older ( 65 vs 60 years , p less than 0.0001 ) and had smaller peak adjusted CK levels ( 490 +/- 376 vs 666 +/- 726 IU/liter , p less than 0.001 ) than patients without LV hypertrophy . Patients with and without LV hypertrophy did not differ significantly in acute mortality during hospitalization , progression to Q waves , reinfarction by CK-MB criteria or angina associated with transient electrocardiographic changes . Compared with patients without LV hypertrophy , those patients with non-Q-wave AMI and LV hypertrophy had a 2-fold higher incidence of reinfarction ( 24 vs 12 % , p less than 0.005 ) and death ( 19 vs 9 % , p = 0.044 ) during the first year of follow-up . Multivariate regression analysis revealed that the relative risk of death and reinfarction during the initial year after AMI was increased by a factor of 1.7 and 2.1 among patients with LV hypertrophy , respectively . It was therefore concluded that , although patients with LV hypertrophy and non-Q-wave AMI have smaller enzymatic infarcts and the same short-term prognosis as do patients without LV hypertrophy , their reinfarction and mortality rates are significantly increased during the first year of follow-up . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1867
]
]
}
] | [
{
"id": "74357",
"type": "Intervention_Control",
"text": [
"diltiazem-placebo-controlled"
],
"offsets": [
[
344,
372
]
],
"normalized": []
},
{
"id": "74358",
"type": "Outcome_Mortality",
"text": [
"mortality"
],
"offsets": [
[
899,
908
]
],
"normalized": []
},
{
"id": "74359",
"type": "Outcome_Other",
"text": [
"hospitalization"
],
"offsets": [
[
916,
931
]
],
"normalized": []
},
{
"id": "74360",
"type": "Outcome_Physical",
"text": [
"progression to Q waves"
],
"offsets": [
[
934,
956
]
],
"normalized": []
},
{
"id": "74361",
"type": "Outcome_Physical",
"text": [
"reinfarction by CK-MB criteria"
],
"offsets": [
[
959,
989
]
],
"normalized": []
},
{
"id": "74362",
"type": "Outcome_Physical",
"text": [
"angina"
],
"offsets": [
[
993,
999
]
],
"normalized": []
},
{
"id": "74363",
"type": "Outcome_Physical",
"text": [
"reinfarction"
],
"offsets": [
[
959,
971
]
],
"normalized": []
},
{
"id": "74364",
"type": "Outcome_Mortality",
"text": [
"risk of death"
],
"offsets": [
[
1373,
1386
]
],
"normalized": []
},
{
"id": "74365",
"type": "Outcome_Physical",
"text": [
"reinfarction"
],
"offsets": [
[
959,
971
]
],
"normalized": []
},
{
"id": "74366",
"type": "Participant_Condition",
"text": [
"non-Q-wave acute myocardial infarction"
],
"offsets": [
[
83,
121
]
],
"normalized": []
},
{
"id": "74367",
"type": "Participant_Condition",
"text": [
"non-Q-wave acute myocardial infarction ( AMI )"
],
"offsets": [
[
246,
292
]
],
"normalized": []
}
] | [] | [] | [] |
74368 | 2975949 | [
{
"id": "74369",
"type": "document",
"text": [
"Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty . Between September 1985 and April 1987 , 110 consecutive patients who had successful coronary angioplasty were included in a randomised prospective controlled evaluation of the effects of warfarin on restenosis . The warfarin ( n = 56 ) and the control ( n = 54 ) groups were not different in terms of age , sex , previous coronary bypass surgery or coronary balloon angioplasty , severity of symptoms , and frequency of multivessel disease or of total coronary occlusions . Warfarin was started on the day of the procedure and the dosage was adjusted to maintain the thromboplastin international normalised ratio greater than or equal to 2.5 . One hundred and five ( 96 % ) of the patients were given verapamil and other antianginal drugs were prescribed as needed . Low molecular weight dextran and heparin were given during the procedure and heparin was continued for 24 hours in all patients . One hundred and eight ( 98 % ) of patients were followed up clinically after a median of five months ( range 1-20 ) . Eighty five ( 77 % ) had follow up angiography at five months . In the warfarin group symptoms improved in 46 ( 85 % ) patients by at least 1 angina class and 31 ( 57 % ) were symptom free ; the exercise test remained positive in 20 ( 36 % ) patients and the angiographic restenosis rate was 25 % per lesion and 29 % per patient . There were no major bleeding complications . In the control group 46 ( 85 % ) patients were improved by at least 1 angina class and 31 ( 57 % ) were symptom free ; the exercise test was positive in 11 ( 21 % ) patients and the angiographic restenosis rate was 33 % per lesion and 37 % per patient . Although the incidence of angiographic restenosis tended to be lower with warfarin , none of these differences was significant . These data suggest that the combination of verapamil and warfarin , in the absence of aspirin , is not significantly better than verapamil alone in preventing symptom recurrence or angiographic restenosis after coronary angioplasty ."
],
"offsets": [
[
0,
2117
]
]
}
] | [
{
"id": "74370",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74371",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74372",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74373",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
257,
264
]
],
"normalized": []
},
{
"id": "74374",
"type": "Intervention_Pharmacological",
"text": [
"Warfarin"
],
"offsets": [
[
584,
592
]
],
"normalized": []
},
{
"id": "74375",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
811,
820
]
],
"normalized": []
},
{
"id": "74376",
"type": "Intervention_Pharmacological",
"text": [
"other antianginal drugs"
],
"offsets": [
[
825,
848
]
],
"normalized": []
},
{
"id": "74377",
"type": "Intervention_Pharmacological",
"text": [
"Low molecular weight dextran and heparin"
],
"offsets": [
[
877,
917
]
],
"normalized": []
},
{
"id": "74378",
"type": "Intervention_Pharmacological",
"text": [
"heparin"
],
"offsets": [
[
910,
917
]
],
"normalized": []
},
{
"id": "74379",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74380",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74381",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
811,
820
]
],
"normalized": []
},
{
"id": "74382",
"type": "Intervention_Pharmacological",
"text": [
"warfarin"
],
"offsets": [
[
18,
26
]
],
"normalized": []
},
{
"id": "74383",
"type": "Intervention_Pharmacological",
"text": [
"aspirin"
],
"offsets": [
[
1970,
1977
]
],
"normalized": []
},
{
"id": "74384",
"type": "Outcome_Physical",
"text": [
"restenosis rate"
],
"offsets": [
[
34,
49
]
],
"normalized": []
},
{
"id": "74385",
"type": "Outcome_Physical",
"text": [
"symptoms"
],
"offsets": [
[
502,
510
]
],
"normalized": []
},
{
"id": "74386",
"type": "Outcome_Other",
"text": [
"symptom free"
],
"offsets": [
[
1301,
1313
]
],
"normalized": []
},
{
"id": "74387",
"type": "Outcome_Physical",
"text": [
"angiographic restenosis rate"
],
"offsets": [
[
1384,
1412
]
],
"normalized": []
},
{
"id": "74388",
"type": "Outcome_Adverse-effects",
"text": [
"major bleeding complications"
],
"offsets": [
[
1470,
1498
]
],
"normalized": []
},
{
"id": "74389",
"type": "Outcome_Other",
"text": [
"exercise test"
],
"offsets": [
[
1320,
1333
]
],
"normalized": []
},
{
"id": "74390",
"type": "Outcome_Physical",
"text": [
"angiographic restenosis rate"
],
"offsets": [
[
1384,
1412
]
],
"normalized": []
},
{
"id": "74391",
"type": "Outcome_Physical",
"text": [
"angiographic restenosis"
],
"offsets": [
[
1384,
1407
]
],
"normalized": []
},
{
"id": "74392",
"type": "Participant_Condition",
"text": [
"Between September 1985 and April 1987 , 110 consecutive patients who had successful coronary angioplasty"
],
"offsets": [
[
110,
214
]
],
"normalized": []
}
] | [] | [] | [] |
74393 | 2975995 | [
{
"id": "74394",
"type": "document",
"text": [
"Arginine vasopressin dissociates the diuresis and natriuresis due to atrial natriuretic factor in man . The possible interaction between arginine vasopressin ( AVP ) and atrial natriuretic factor ( ANF ) in the control of urinary sodium and water excretion was investigated in man . Nine healthy male volunteers undergoing stable maximal water diuresis were studied on four separate occasions . Atrial natriuretic factor 15 pmol kg-1 min-1 or placebo ( P ) was concomitantly administered against a background infusion of either AVP 0.003 pmol kg-1 min-1 or P ; thus the combinations P + P , AVP + P , P + ANF and AVP + ANF were studied . Atrial natriuretic factor caused a significant increase in sodium excretion ( UNaV ) [ +56 % ] , urinary flow rate ( V ) [ +17 % ] and free water clearance ( CH2O ) [ +23 % ] ; creatinine clearance ( Ccr ) did not change . Arginine vasopressin reduced V ( -58 % ) and CH2O ( -68 % ) but did not alter UNaV or Ccr . On the AVP + ANF study day , UNaV increased ( +64 % ) as with P + ANF , but V ( -44 % ) and CH2O ( -52 % ) continued to decrease below baseline levels ; analysis of variance showed this antidiuresis reflected the prevalent effect of AVP rather than any specific interaction . These results show that AVP is able to dissociate the natriuretic and diuretic effects of ANF ."
],
"offsets": [
[
0,
1324
]
]
}
] | [
{
"id": "74395",
"type": "Intervention_Pharmacological",
"text": [
"Arginine vasopressin"
],
"offsets": [
[
0,
20
]
],
"normalized": []
},
{
"id": "74396",
"type": "Intervention_Pharmacological",
"text": [
"arginine vasopressin ( AVP )"
],
"offsets": [
[
137,
165
]
],
"normalized": []
},
{
"id": "74397",
"type": "Intervention_Pharmacological",
"text": [
"Atrial natriuretic factor"
],
"offsets": [
[
395,
420
]
],
"normalized": []
},
{
"id": "74398",
"type": "Intervention_Pharmacological",
"text": [
"placebo"
],
"offsets": [
[
443,
450
]
],
"normalized": []
},
{
"id": "74399",
"type": "Intervention_Pharmacological",
"text": [
"AVP"
],
"offsets": [
[
160,
163
]
],
"normalized": []
},
{
"id": "74400",
"type": "Intervention_Pharmacological",
"text": [
"P"
],
"offsets": [
[
162,
163
]
],
"normalized": []
},
{
"id": "74401",
"type": "Intervention_Pharmacological",
"text": [
"ANF"
],
"offsets": [
[
198,
201
]
],
"normalized": []
},
{
"id": "74402",
"type": "Intervention_Pharmacological",
"text": [
"Atrial natriuretic factor"
],
"offsets": [
[
395,
420
]
],
"normalized": []
},
{
"id": "74403",
"type": "Intervention_Pharmacological",
"text": [
"Arginine vasopressin"
],
"offsets": [
[
0,
20
]
],
"normalized": []
},
{
"id": "74404",
"type": "Intervention_Pharmacological",
"text": [
"AVP"
],
"offsets": [
[
160,
163
]
],
"normalized": []
},
{
"id": "74405",
"type": "Intervention_Pharmacological",
"text": [
"ANF"
],
"offsets": [
[
198,
201
]
],
"normalized": []
},
{
"id": "74406",
"type": "Outcome_Physical",
"text": [
"diuresis and natriuresis"
],
"offsets": [
[
37,
61
]
],
"normalized": []
},
{
"id": "74407",
"type": "Outcome_Physical",
"text": [
"sodium excretion ( UNaV )"
],
"offsets": [
[
697,
722
]
],
"normalized": []
},
{
"id": "74408",
"type": "Outcome_Physical",
"text": [
"urinary flow rate ( V )"
],
"offsets": [
[
735,
758
]
],
"normalized": []
},
{
"id": "74409",
"type": "Outcome_Physical",
"text": [
"free water clearance ( CH2O )"
],
"offsets": [
[
773,
802
]
],
"normalized": []
},
{
"id": "74410",
"type": "Outcome_Physical",
"text": [
"creatinine clearance ( Ccr )"
],
"offsets": [
[
815,
843
]
],
"normalized": []
},
{
"id": "74411",
"type": "Outcome_Physical",
"text": [
"V"
],
"offsets": [
[
161,
162
]
],
"normalized": []
},
{
"id": "74412",
"type": "Outcome_Physical",
"text": [
"CH2O"
],
"offsets": [
[
796,
800
]
],
"normalized": []
},
{
"id": "74413",
"type": "Outcome_Physical",
"text": [
"UNaV or Ccr"
],
"offsets": [
[
939,
950
]
],
"normalized": []
},
{
"id": "74414",
"type": "Outcome_Physical",
"text": [
"UNaV"
],
"offsets": [
[
716,
720
]
],
"normalized": []
},
{
"id": "74415",
"type": "Outcome_Physical",
"text": [
"P + ANF"
],
"offsets": [
[
601,
608
]
],
"normalized": []
},
{
"id": "74416",
"type": "Outcome_Physical",
"text": [
"V"
],
"offsets": [
[
161,
162
]
],
"normalized": []
},
{
"id": "74417",
"type": "Outcome_Physical",
"text": [
"CH2O"
],
"offsets": [
[
796,
800
]
],
"normalized": []
},
{
"id": "74418",
"type": "Outcome_Physical",
"text": [
"natriuretic and diuretic effects"
],
"offsets": [
[
1283,
1315
]
],
"normalized": []
},
{
"id": "74419",
"type": "Participant_Sex",
"text": [
"man ."
],
"offsets": [
[
98,
103
]
],
"normalized": []
},
{
"id": "74420",
"type": "Participant_Sex",
"text": [
"man ."
],
"offsets": [
[
98,
103
]
],
"normalized": []
}
] | [] | [] | [] |
74421 | 2990708 | [
{
"id": "74422",
"type": "document",
"text": [
"Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung . The role of intensive induction chemotherapy in small cell cancer of the lung remains unclear . Twenty-eight newly diagnosed patients with small cell lung cancer were randomized to receive either high-dose or standard-dose cyclophosphamide , vincristine , and semustine in a trial where the dose of induction chemotherapy was the sole treatment variable . Complete responses ( CR ) were achieved in 57 % of patients receiving high-dose therapy as compared to 21 % of patients receiving standard-dose therapy ( P less than 0.05 ) . There was a higher rate of severe toxicity in the high-dose group ( P less than 0.01 ) . The overall median survival was not improved ( 36 weeks for the high-dose group vs 43 weeks for the standard-dose group ) ; however , the median survival in patients achieving CR was prolonged ( 92 weeks for the high-dose group vs 50 weeks for the standard-dose group ) . These effects were most pronounced in patients with extensive disease ; a CR after induction was achieved in five of nine patients treated with high doses but not in any of those treated with standard doses ( P less than 0.05 ) . A small group of patients appear to benefit by achieving a long-term remission with intensive induction chemotherapy , but this effect may be offset by increased morbidity ."
],
"offsets": [
[
0,
1378
]
]
}
] | [
{
"id": "74423",
"type": "Intervention_Physical",
"text": [
"Intensive induction chemotherapy"
],
"offsets": [
[
0,
32
]
],
"normalized": []
},
{
"id": "74424",
"type": "Intervention_Pharmacological",
"text": [
"intensive induction chemotherapy"
],
"offsets": [
[
95,
127
]
],
"normalized": []
},
{
"id": "74425",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
306,
322
]
],
"normalized": []
},
{
"id": "74426",
"type": "Intervention_Pharmacological",
"text": [
"vincristine"
],
"offsets": [
[
325,
336
]
],
"normalized": []
},
{
"id": "74427",
"type": "Intervention_Pharmacological",
"text": [
"semustine"
],
"offsets": [
[
343,
352
]
],
"normalized": []
},
{
"id": "74428",
"type": "Outcome_Physical",
"text": [
"Complete responses ( CR )"
],
"offsets": [
[
439,
464
]
],
"normalized": []
},
{
"id": "74429",
"type": "Outcome_Physical",
"text": [
"severe toxicity"
],
"offsets": [
[
641,
656
]
],
"normalized": []
},
{
"id": "74430",
"type": "Outcome_Mortality",
"text": [
"overall median survival"
],
"offsets": [
[
707,
730
]
],
"normalized": []
},
{
"id": "74431",
"type": "Outcome_Mortality",
"text": [
"median survival"
],
"offsets": [
[
715,
730
]
],
"normalized": []
},
{
"id": "74432",
"type": "Outcome_Physical",
"text": [
"CR"
],
"offsets": [
[
460,
462
]
],
"normalized": []
},
{
"id": "74433",
"type": "Participant_Sample-size",
"text": [
"Twenty-eight"
],
"offsets": [
[
179,
191
]
],
"normalized": []
},
{
"id": "74434",
"type": "Participant_Condition",
"text": [
"small cell lung cancer"
],
"offsets": [
[
222,
244
]
],
"normalized": []
}
] | [] | [] | [] |
74435 | 3001523 | [
{
"id": "74436",
"type": "document",
"text": [
"Treatment of varicella-zoster virus infection in severely immunocompromised patients . A randomized comparison of acyclovir and vidarabine . In a prospective , randomized trial , we compared intravenous acyclovir and vidarabine in the treatment of varicella-zoster virus infection in severely immunocompromised patients who presented within 72 hours of onset of the infection . Eleven patients were treated in each group . Cutaneous dissemination of infection occurred in none of the 10 acyclovir recipients and in 5 of the 10 vidarabine recipients who had presented with localized dermatomal disease ( P = 0.016 ) . As compared with vidarabine , acyclovir treatment shortened the median periods during which cultures were positive for the virus ( four vs. seven days , P = 0.004 ) and new lesions formed ( three vs. six days , P = 0.03 ) . Acyclovir also shortened the median interval until the first decrease in pain ( 4 vs. 7 days , P = 0.005 ) , the pustulation of all lesions ( 4 vs. 7 days , P = 0.0004 ) , the crusting of all lesions ( 7 vs. 17 days , P = 0.0003 ) , and the complete healing of lesions ( 17 vs. 28 days , P = 0.003 ) . In addition , acyclovir reduced the incidence of fever ( two vs. eight patients , P = 0.015 ) . We conclude that acyclovir is better than vidarabine for the treatment of varicella-zoster infection in immunocompromised patients ."
],
"offsets": [
[
0,
1371
]
]
}
] | [
{
"id": "74437",
"type": "Intervention_Pharmacological",
"text": [
"acyclovir"
],
"offsets": [
[
114,
123
]
],
"normalized": []
},
{
"id": "74438",
"type": "Intervention_Pharmacological",
"text": [
"vidarabine"
],
"offsets": [
[
128,
138
]
],
"normalized": []
},
{
"id": "74439",
"type": "Intervention_Pharmacological",
"text": [
"intravenous acyclovir"
],
"offsets": [
[
191,
212
]
],
"normalized": []
},
{
"id": "74440",
"type": "Intervention_Pharmacological",
"text": [
"vidarabine"
],
"offsets": [
[
128,
138
]
],
"normalized": []
},
{
"id": "74441",
"type": "Intervention_Pharmacological",
"text": [
"acyclovir"
],
"offsets": [
[
114,
123
]
],
"normalized": []
},
{
"id": "74442",
"type": "Intervention_Pharmacological",
"text": [
"vidarabine"
],
"offsets": [
[
128,
138
]
],
"normalized": []
},
{
"id": "74443",
"type": "Intervention_Pharmacological",
"text": [
"Acyclovir"
],
"offsets": [
[
841,
850
]
],
"normalized": []
},
{
"id": "74444",
"type": "Intervention_Pharmacological",
"text": [
"acyclovir"
],
"offsets": [
[
114,
123
]
],
"normalized": []
},
{
"id": "74445",
"type": "Intervention_Pharmacological",
"text": [
"acyclovir"
],
"offsets": [
[
114,
123
]
],
"normalized": []
},
{
"id": "74446",
"type": "Intervention_Pharmacological",
"text": [
"vidarabine"
],
"offsets": [
[
128,
138
]
],
"normalized": []
},
{
"id": "74447",
"type": "Outcome_Physical",
"text": [
"Cutaneous dissemination of infection"
],
"offsets": [
[
423,
459
]
],
"normalized": []
},
{
"id": "74448",
"type": "Outcome_Physical",
"text": [
"median periods during which cultures were positive for the virus"
],
"offsets": [
[
681,
745
]
],
"normalized": []
},
{
"id": "74449",
"type": "Outcome_Physical",
"text": [
"new lesions"
],
"offsets": [
[
786,
797
]
],
"normalized": []
},
{
"id": "74450",
"type": "Outcome_Pain",
"text": [
"interval until the first decrease in pain"
],
"offsets": [
[
877,
918
]
],
"normalized": []
},
{
"id": "74451",
"type": "Outcome_Physical",
"text": [
"pustulation of all lesions"
],
"offsets": [
[
954,
980
]
],
"normalized": []
},
{
"id": "74452",
"type": "Outcome_Physical",
"text": [
"crusting of all lesions"
],
"offsets": [
[
1017,
1040
]
],
"normalized": []
},
{
"id": "74453",
"type": "Outcome_Physical",
"text": [
"fever"
],
"offsets": [
[
1192,
1197
]
],
"normalized": []
}
] | [] | [] | [] |
74454 | 3010510 | [
{
"id": "74455",
"type": "document",
"text": [
"Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation . In an attempt to reduce the incidence of lethal cytomegalovirus ( CMV ) interstitial pneumonitis after allogenic bone marrow transplantation 49 patients were randomized in a multicenter controlled study to receive either CMV-hyperimmune globulin or a control immune globulin with low anticytomegalovirus titer . Immune globulin was administered intravenously 6 times with 20 days interval , starting on day 7 before transplantation . Patients receiving CMV hyperimmune globulin or control immune globulin were comparable with regard to age , diagnosis , pretransplant anti-CMV titer , incidence of graft-versus-host disease and transfusions . In each group , the incidence of histologically proven CMV interstitial pneumonitis during the first 110 days post BMT was recorded . Six of 23 patients in the control group versus 1 of 26 in the CMV hyperimmune globulin group died of CMV interstitial pneumonitis ( p less than 0.05 ) . No significant effect on idiopathic pneumonitis or survival was observed ."
],
"offsets": [
[
0,
1144
]
]
}
] | [
{
"id": "74456",
"type": "Intervention_Pharmacological",
"text": [
"Intravenous hyperimmune globulin prophylaxis"
],
"offsets": [
[
0,
44
]
],
"normalized": []
},
{
"id": "74457",
"type": "Intervention_Physical",
"text": [
"allogenic bone marrow transplantation"
],
"offsets": [
[
100,
137
]
],
"normalized": []
},
{
"id": "74458",
"type": "Intervention_Pharmacological",
"text": [
"CMV-hyperimmune globulin"
],
"offsets": [
[
361,
385
]
],
"normalized": []
},
{
"id": "74459",
"type": "Intervention_Control",
"text": [
"control immune globulin with low anticytomegalovirus titer ."
],
"offsets": [
[
391,
451
]
],
"normalized": []
},
{
"id": "74460",
"type": "Intervention_Pharmacological",
"text": [
"Immune globulin"
],
"offsets": [
[
452,
467
]
],
"normalized": []
},
{
"id": "74461",
"type": "Intervention_Pharmacological",
"text": [
"CMV hyperimmune globulin"
],
"offsets": [
[
593,
617
]
],
"normalized": []
},
{
"id": "74462",
"type": "Intervention_Control",
"text": [
"control immune globulin"
],
"offsets": [
[
391,
414
]
],
"normalized": []
},
{
"id": "74463",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
326,
333
]
],
"normalized": []
},
{
"id": "74464",
"type": "Intervention_Pharmacological",
"text": [
"CMV hyperimmune globulin"
],
"offsets": [
[
593,
617
]
],
"normalized": []
},
{
"id": "74465",
"type": "Outcome_Physical",
"text": [
"cytomegalovirus ( CMV ) interstitial pneumonitis"
],
"offsets": [
[
188,
236
]
],
"normalized": []
},
{
"id": "74466",
"type": "Outcome_Adverse-effects",
"text": [
"CMV interstitial pneumonitis"
],
"offsets": [
[
838,
866
]
],
"normalized": []
},
{
"id": "74467",
"type": "Outcome_Mortality",
"text": [
"died of CMV interstitial pneumonitis"
],
"offsets": [
[
1010,
1046
]
],
"normalized": []
},
{
"id": "74468",
"type": "Outcome_Mortality",
"text": [
"idiopathic pneumonitis"
],
"offsets": [
[
1095,
1117
]
],
"normalized": []
},
{
"id": "74469",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
1121,
1129
]
],
"normalized": []
},
{
"id": "74470",
"type": "Participant_Condition",
"text": [
"allogenic bone marrow transplantation ."
],
"offsets": [
[
100,
139
]
],
"normalized": []
}
] | [] | [] | [] |
74471 | 3030386 | [
{
"id": "74472",
"type": "document",
"text": [
"Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide . This study was designed to investigate the validity of the then current recommendations for initiation of therapy with enalapril in hypertensive patients on treatment with a diuretic . Enalapril in single doses of 10 and 20 mg was given to 13 hypertensive patients on treatment with bendrofluazide 5 mg daily in a randomised , crossover , placebo controlled study . The mean maximal reduction in blood pressure was similar with both doses ( 35/20 mmHg supine , 38/20 mmHg standing ) , occurred on average within 6 h of tablet ingestion , and was not accompanied by any significant change in heart rate . Three patients experienced symptomatic hypotension . In one patient this was incapacitating after 10 mg and precluded exposure to 20 mg . This study shows that in hypertensive patients receiving treatment with diuretics , the addition of enalapril should be undertaken with caution . An optimal starting dose of enalapril in such patients remains to be confirmed ."
],
"offsets": [
[
0,
1076
]
]
}
] | [
{
"id": "74473",
"type": "Intervention_Pharmacological",
"text": [
"enalapril"
],
"offsets": [
[
43,
52
]
],
"normalized": []
},
{
"id": "74474",
"type": "Intervention_Pharmacological",
"text": [
"bendrofluazide"
],
"offsets": [
[
91,
105
]
],
"normalized": []
},
{
"id": "74475",
"type": "Intervention_Pharmacological",
"text": [
"enalapril"
],
"offsets": [
[
43,
52
]
],
"normalized": []
},
{
"id": "74476",
"type": "Intervention_Pharmacological",
"text": [
"Enalapril"
],
"offsets": [
[
293,
302
]
],
"normalized": []
},
{
"id": "74477",
"type": "Intervention_Pharmacological",
"text": [
"bendrofluazide"
],
"offsets": [
[
91,
105
]
],
"normalized": []
},
{
"id": "74478",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
447,
454
]
],
"normalized": []
},
{
"id": "74479",
"type": "Outcome_Physical",
"text": [
"Antihypertensive effect"
],
"offsets": [
[
0,
23
]
],
"normalized": []
},
{
"id": "74480",
"type": "Outcome_Physical",
"text": [
"The mean maximal reduction in blood pressure"
],
"offsets": [
[
474,
518
]
],
"normalized": []
},
{
"id": "74481",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
699,
709
]
],
"normalized": []
},
{
"id": "74482",
"type": "Outcome_Physical",
"text": [
"symptomatic hypotension"
],
"offsets": [
[
739,
762
]
],
"normalized": []
},
{
"id": "74483",
"type": "Outcome_Adverse-effects",
"text": [
"incapacitating"
],
"offsets": [
[
789,
803
]
],
"normalized": []
},
{
"id": "74484",
"type": "Participant_Condition",
"text": [
"hypertensive patients"
],
"offsets": [
[
56,
77
]
],
"normalized": []
},
{
"id": "74485",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
4,
16
]
],
"normalized": []
},
{
"id": "74486",
"type": "Participant_Sample-size",
"text": [
"13"
],
"offsets": [
[
348,
350
]
],
"normalized": []
}
] | [] | [] | [] |
74487 | 3056498 | [
{
"id": "74488",
"type": "document",
"text": [
"Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints . Sixty women with climacteric complaints who had not menstruated for at least 1 year were randomly allocated to receive one of four hormonal replacement regimens . All four formulations were administered daily and continuously and each contained 2 mg of micronized oestradiol-17 beta in combination with either norethisterone acetate 1 mg ( group A ) or 0.5 mg ( group B ) or megestrol acetate 5 mg ( group C ) or 2.5 mg ( group D ) . The clinical efficacy was the same although the alleviation of vasomotor symptoms was somewhat slower in those women receiving preparation A . The endometrium was atrophied in nearly all biopsies . Irregular uterine bleeding was almost entirely confined to the earlier phase of the study and was substantially less with the formulation containing 1 mg norethisterone acetate . It is concluded that a continuous oestradiol-progestogen combination can be used for long-term treatment of climacteric complaints in postmenopausal women and that after 4 months the clinical efficacy is the same irrespective of the type and dose of progestogen administered ."
],
"offsets": [
[
0,
1202
]
]
}
] | [
{
"id": "74489",
"type": "Intervention_Pharmacological",
"text": [
"progestogen plus oestradiol"
],
"offsets": [
[
45,
72
]
],
"normalized": []
},
{
"id": "74490",
"type": "Intervention_Pharmacological",
"text": [
"micronized oestradiol-17 beta in combination with either norethisterone acetate 1 mg"
],
"offsets": [
[
368,
452
]
],
"normalized": []
},
{
"id": "74491",
"type": "Intervention_Pharmacological",
"text": [
"or megestrol acetate 5 mg"
],
"offsets": [
[
487,
512
]
],
"normalized": []
},
{
"id": "74492",
"type": "Intervention_Pharmacological",
"text": [
"norethisterone acetate"
],
"offsets": [
[
425,
447
]
],
"normalized": []
},
{
"id": "74493",
"type": "Intervention_Pharmacological",
"text": [
"oestradiol-progestogen combination"
],
"offsets": [
[
960,
994
]
],
"normalized": []
},
{
"id": "74494",
"type": "Intervention_Pharmacological",
"text": [
"progestogen"
],
"offsets": [
[
45,
56
]
],
"normalized": []
},
{
"id": "74495",
"type": "Outcome_Other",
"text": [
"climacteric complaints ."
],
"offsets": [
[
90,
114
]
],
"normalized": []
},
{
"id": "74496",
"type": "Outcome_Other",
"text": [
"clinical efficacy"
],
"offsets": [
[
553,
570
]
],
"normalized": []
},
{
"id": "74497",
"type": "Outcome_Physical",
"text": [
"vasomotor symptoms"
],
"offsets": [
[
612,
630
]
],
"normalized": []
},
{
"id": "74498",
"type": "Outcome_Physical",
"text": [
"endometrium"
],
"offsets": [
[
696,
707
]
],
"normalized": []
},
{
"id": "74499",
"type": "Outcome_Physical",
"text": [
"biopsies ."
],
"offsets": [
[
736,
746
]
],
"normalized": []
},
{
"id": "74500",
"type": "Outcome_Other",
"text": [
"Irregular"
],
"offsets": [
[
747,
756
]
],
"normalized": []
},
{
"id": "74501",
"type": "Outcome_Physical",
"text": [
"uterine"
],
"offsets": [
[
757,
764
]
],
"normalized": []
},
{
"id": "74502",
"type": "Outcome_Other",
"text": [
"bleeding"
],
"offsets": [
[
765,
773
]
],
"normalized": []
},
{
"id": "74503",
"type": "Outcome_Physical",
"text": [
"climacteric complaints"
],
"offsets": [
[
90,
112
]
],
"normalized": []
},
{
"id": "74504",
"type": "Outcome_Physical",
"text": [
"clinical efficacy"
],
"offsets": [
[
553,
570
]
],
"normalized": []
},
{
"id": "74505",
"type": "Participant_Sample-size",
"text": [
"Sixty"
],
"offsets": [
[
115,
120
]
],
"normalized": []
},
{
"id": "74506",
"type": "Participant_Condition",
"text": [
"not menstruated"
],
"offsets": [
[
163,
178
]
],
"normalized": []
}
] | [] | [] | [] |
74507 | 305873 | [
{
"id": "74508",
"type": "document",
"text": [
"[ Whole gut irrigation with isotonic mannitol solution in the treatment of gastrointestinal bleeding due to cirrhosis : a controlled study ( author 's transl ) ] ."
],
"offsets": [
[
0,
163
]
]
}
] | [
{
"id": "74509",
"type": "Intervention_Pharmacological",
"text": [
"[ Whole gut irrigation with isotonic mannitol solution"
],
"offsets": [
[
0,
54
]
],
"normalized": []
},
{
"id": "74510",
"type": "Outcome_Physical",
"text": [
"gastrointestinal bleeding"
],
"offsets": [
[
75,
100
]
],
"normalized": []
},
{
"id": "74511",
"type": "Participant_Condition",
"text": [
"gastrointestinal bleeding due to cirrhosis :"
],
"offsets": [
[
75,
119
]
],
"normalized": []
}
] | [] | [] | [] |
74512 | 3059450 | [
{
"id": "74513",
"type": "document",
"text": [
"Comparison of 5-aminosalicylic acid ( 3 g ) and prednisolone phosphate sodium enemas ( 30 mg ) in the treatment of distal ulcerative colitis . A prospective , randomized , double-blind trial . Twenty-nine patients with attacks of distal ulcerative colitis were treated randomly with 3 g 5-aminosalicylic acid ( 5-ASA ) or 30 mg of prednisolone phosphate sodium ( PP ) enemas ( 40 ml ) . Endoscopic , clinical , and histologic improvement were comparable in the two treatment groups . Our study showed that topical treatment with 5-ASA is as efficacious as PP in improving distal ulcerative colitis ."
],
"offsets": [
[
0,
599
]
]
}
] | [
{
"id": "74514",
"type": "Intervention_Pharmacological",
"text": [
"5-aminosalicylic acid"
],
"offsets": [
[
14,
35
]
],
"normalized": []
},
{
"id": "74515",
"type": "Intervention_Pharmacological",
"text": [
"prednisolone phosphate sodium"
],
"offsets": [
[
48,
77
]
],
"normalized": []
},
{
"id": "74516",
"type": "Intervention_Pharmacological",
"text": [
"5-aminosalicylic acid ( 5-ASA )"
],
"offsets": [
[
287,
318
]
],
"normalized": []
},
{
"id": "74517",
"type": "Intervention_Pharmacological",
"text": [
"prednisolone phosphate sodium ( PP )"
],
"offsets": [
[
331,
367
]
],
"normalized": []
},
{
"id": "74518",
"type": "Intervention_Pharmacological",
"text": [
"5-ASA"
],
"offsets": [
[
311,
316
]
],
"normalized": []
},
{
"id": "74519",
"type": "Intervention_Pharmacological",
"text": [
"PP"
],
"offsets": [
[
363,
365
]
],
"normalized": []
},
{
"id": "74520",
"type": "Outcome_Physical",
"text": [
"distal ulcerative colitis"
],
"offsets": [
[
115,
140
]
],
"normalized": []
},
{
"id": "74521",
"type": "Outcome_Physical",
"text": [
"Endoscopic , clinical , and histologic improvement"
],
"offsets": [
[
387,
437
]
],
"normalized": []
},
{
"id": "74522",
"type": "Outcome_Physical",
"text": [
"distal ulcerative colitis"
],
"offsets": [
[
115,
140
]
],
"normalized": []
},
{
"id": "74523",
"type": "Participant_Condition",
"text": [
"distal ulcerative colitis"
],
"offsets": [
[
115,
140
]
],
"normalized": []
},
{
"id": "74524",
"type": "Participant_Sample-size",
"text": [
"Twenty-nine patients"
],
"offsets": [
[
193,
213
]
],
"normalized": []
},
{
"id": "74525",
"type": "Participant_Condition",
"text": [
"attacks of distal ulcerative colitis"
],
"offsets": [
[
219,
255
]
],
"normalized": []
},
{
"id": "74526",
"type": "Participant_Condition",
"text": [
"distal ulcerative colitis"
],
"offsets": [
[
115,
140
]
],
"normalized": []
}
] | [] | [] | [] |
74527 | 3063541 | [
{
"id": "74528",
"type": "document",
"text": [
"Comparison of endocrine and radiation therapy in locally advanced prostatic cancer . 151 patients with locally advanced prostatic cancer ( T3-4 M0 ) , representing 38 % of the 404 cancer patients in a Finnish multicenter study , were randomly assigned to one of three treatment arms : orchiectomy , estrogens or radiotherapy . During the 4-year follow-up period there were no significant differences in the progression rates ( appearance of metastases in bone scan ) between the therapy groups . The frequency of thromboembolic and other cardiovascular complications was highest in the estrogen group ( 13/50 patients ) . In the radiotherapy group , 19 of 45 patients had bowel or bladder complications . On the other hand , orchiectomy has few , if any , complications . The high risk of complications associated with estrogens and radiotherapy has to be taken into consideration in the selection of treatment ."
],
"offsets": [
[
0,
912
]
]
}
] | [
{
"id": "74529",
"type": "Intervention_Pharmacological",
"text": [
"endocrine"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "74530",
"type": "Intervention_Physical",
"text": [
"radiation therapy"
],
"offsets": [
[
28,
45
]
],
"normalized": []
},
{
"id": "74531",
"type": "Intervention_Surgical",
"text": [
"orchiectomy"
],
"offsets": [
[
285,
296
]
],
"normalized": []
},
{
"id": "74532",
"type": "Intervention_Pharmacological",
"text": [
"estrogens"
],
"offsets": [
[
299,
308
]
],
"normalized": []
},
{
"id": "74533",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
312,
324
]
],
"normalized": []
},
{
"id": "74534",
"type": "Outcome_Other",
"text": [
"progression rates"
],
"offsets": [
[
407,
424
]
],
"normalized": []
},
{
"id": "74535",
"type": "Outcome_Physical",
"text": [
"( appearance of metastases in bone scan )"
],
"offsets": [
[
425,
466
]
],
"normalized": []
},
{
"id": "74536",
"type": "Outcome_Adverse-effects",
"text": [
"frequency of thromboembolic and other cardiovascular complications"
],
"offsets": [
[
500,
566
]
],
"normalized": []
},
{
"id": "74537",
"type": "Outcome_Adverse-effects",
"text": [
"bowel or bladder complications"
],
"offsets": [
[
672,
702
]
],
"normalized": []
},
{
"id": "74538",
"type": "Participant_Condition",
"text": [
"locally advanced prostatic cancer ."
],
"offsets": [
[
49,
84
]
],
"normalized": []
},
{
"id": "74539",
"type": "Participant_Sample-size",
"text": [
"151"
],
"offsets": [
[
85,
88
]
],
"normalized": []
},
{
"id": "74540",
"type": "Participant_Condition",
"text": [
"( T3-4 M0 )"
],
"offsets": [
[
137,
148
]
],
"normalized": []
},
{
"id": "74541",
"type": "Participant_Condition",
"text": [
"representing 38 % of the 404 cancer patients in a Finnish multicenter study"
],
"offsets": [
[
151,
226
]
],
"normalized": []
}
] | [] | [] | [] |
74542 | 3065176 | [
{
"id": "74543",
"type": "document",
"text": [
"[ Vulvovaginal Candida mycoses -- treatment with clotrimazole . Comparison of single-dose treatment with 6-day therapy ] ."
],
"offsets": [
[
0,
122
]
]
}
] | [
{
"id": "74544",
"type": "Intervention_Pharmacological",
"text": [
"clotrimazole"
],
"offsets": [
[
49,
61
]
],
"normalized": []
},
{
"id": "74545",
"type": "Participant_Condition",
"text": [
"[ Vulvovaginal Candida mycoses -- treatment"
],
"offsets": [
[
0,
43
]
],
"normalized": []
}
] | [] | [] | [] |
74546 | 3073441 | [
{
"id": "74547",
"type": "document",
"text": [
"[ Controlled study of the quinidine-amiodarone combination in the reversal of auricular fibrillation ] ."
],
"offsets": [
[
0,
104
]
]
}
] | [
{
"id": "74548",
"type": "Intervention_Pharmacological",
"text": [
"quinidine-amiodarone combination"
],
"offsets": [
[
26,
58
]
],
"normalized": []
},
{
"id": "74549",
"type": "Outcome_Physical",
"text": [
"reversal of auricular fibrillation ]"
],
"offsets": [
[
66,
102
]
],
"normalized": []
},
{
"id": "74550",
"type": "Participant_Condition",
"text": [
"auricular fibrillation ]"
],
"offsets": [
[
78,
102
]
],
"normalized": []
}
] | [] | [] | [] |
74551 | 3075724 | [
{
"id": "74552",
"type": "document",
"text": [
"Plasma 3,4-dihydroxyphenylethyleneglycol and 3-methoxy-4-hydroxyphenylethyleneglycol as indicators of central noradrenergic activity . A comparative study on control subjects and depressed patients . Animal studies have suggested interspecies differences in brain norepinephrine ( NE ) metabolism , especially with regard to the relative proportions of 3,4-dihydroxyphenylethyleneglycol ( DOPEG ) compared to 3-methoxy-4-hydroxyphenylethyleneglycol ( MOPEG ) . In order to question the value of both glycol metabolites as peripheral indices of central noradrenergic activity , a comparative study of plasma DOPEG and MOPEG ( measured by HPLC ) related to depression , sex , age and diagnostic categories ( DSM-III ) was carried out on depressed and control subjects . In addition , two groups of 8 patients were randomly submitted to a desipramine 150 mg/day , or a metapramine 450 mg/day antidepressant treatment influencing the formation of DOPEG and MOPEG in a different way . The study did not demonstrate any difference between DOPEG and MOPEG for most of the experimental factors . We found also a significant positive correlation between plasma levels of DOPEG and MOPEG . Our results support the idea that each of these two biological indices can be used in the assessment of central noradrenergic activity ."
],
"offsets": [
[
0,
1316
]
]
}
] | [
{
"id": "74553",
"type": "Intervention_Pharmacological",
"text": [
"desipramine 150 mg/day"
],
"offsets": [
[
836,
858
]
],
"normalized": []
},
{
"id": "74554",
"type": "Intervention_Pharmacological",
"text": [
"a metapramine 450 mg/day antidepressant treatment"
],
"offsets": [
[
864,
913
]
],
"normalized": []
},
{
"id": "74555",
"type": "Outcome_Physical",
"text": [
"central noradrenergic activity"
],
"offsets": [
[
102,
132
]
],
"normalized": []
},
{
"id": "74556",
"type": "Outcome_Physical",
"text": [
"positive correlation between plasma levels of DOPEG and MOPEG"
],
"offsets": [
[
1116,
1177
]
],
"normalized": []
},
{
"id": "74557",
"type": "Outcome_Physical",
"text": [
"central noradrenergic activity"
],
"offsets": [
[
102,
132
]
],
"normalized": []
},
{
"id": "74558",
"type": "Participant_Condition",
"text": [
"depressed"
],
"offsets": [
[
179,
188
]
],
"normalized": []
},
{
"id": "74559",
"type": "Participant_Sample-size",
"text": [
"8"
],
"offsets": [
[
796,
797
]
],
"normalized": []
}
] | [] | [] | [] |
74560 | 3076138 | [
{
"id": "74561",
"type": "document",
"text": [
"Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension ."
],
"offsets": [
[
0,
91
]
]
}
] | [
{
"id": "74562",
"type": "Intervention_Pharmacological",
"text": [
"pinacidil"
],
"offsets": [
[
23,
32
]
],
"normalized": []
},
{
"id": "74563",
"type": "Intervention_Pharmacological",
"text": [
"nifedipine"
],
"offsets": [
[
37,
47
]
],
"normalized": []
},
{
"id": "74564",
"type": "Participant_Condition",
"text": [
"arterial hypertension ."
],
"offsets": [
[
68,
91
]
],
"normalized": []
}
] | [] | [] | [] |
74565 | 3081148 | [
{
"id": "74566",
"type": "document",
"text": [
"Combined use of vasopressin and synthetic hypothalamic releasing factors as a new test of anterior pituitary function . Nine normal volunteers and 15 patients with pituitary disorders were given a combined test of anterior pituitary function using four hypothalamic releasing factors and arginine vasopressin . Rapid sequential intravenous infusions of human corticotrophin releasing factor 100 micrograms , growth hormone releasing factor 100 micrograms , luteinising hormone releasing hormone 100 micrograms , and thyrotrophin releasing hormone 200 micrograms were administered . Arginine vasopressin ( 10 pressor units ) was given intramuscularly at the same time . Plasma or serum samples were assayed for concentrations of cortisol , growth hormone , luteinising hormone , follicle stimulating hormone , prolactin , and thyroid stimulating hormone at multiple times for 120 minutes . No troublesome side effects occurred . The results of the releasing factor combined test with arginine vasopressin were compared in the same subjects with a conventional combined test using insulin together with thyrotrophin releasing hormone and luteinising hormone releasing hormone . No difference was observed in the basal and peak concentrations of luteinising hormone , follicle stimulating hormone , thyroid stimulating hormone , and prolactin . Both cortisol and growth hormone responses to the releasing factors with arginine vasopressin were much greater than those seen with insulin induced hypoglycaemia or the combined releasing factors without arginine vasopressin . Patients with pituitary hypo-function were similarly recognised in both studies . There was a rapid increase in all hormone values with a peak usually by 60 minutes . In most people adequate assessment of individual hormone reserves may be achieved using basal , 30 minute , and 60 minute samples . This new combined releasing factor test appears to be a safe , rapid , and useful test of anterior pituitary function ."
],
"offsets": [
[
0,
1988
]
]
}
] | [
{
"id": "74567",
"type": "Intervention_Pharmacological",
"text": [
"vasopressin"
],
"offsets": [
[
16,
27
]
],
"normalized": []
},
{
"id": "74568",
"type": "Intervention_Pharmacological",
"text": [
"synthetic hypothalamic releasing factors"
],
"offsets": [
[
32,
72
]
],
"normalized": []
},
{
"id": "74569",
"type": "Intervention_Pharmacological",
"text": [
"arginine vasopressin ."
],
"offsets": [
[
288,
310
]
],
"normalized": []
},
{
"id": "74570",
"type": "Intervention_Pharmacological",
"text": [
"human corticotrophin"
],
"offsets": [
[
353,
373
]
],
"normalized": []
},
{
"id": "74571",
"type": "Intervention_Pharmacological",
"text": [
"growth hormone"
],
"offsets": [
[
408,
422
]
],
"normalized": []
},
{
"id": "74572",
"type": "Intervention_Pharmacological",
"text": [
"luteinising hormone"
],
"offsets": [
[
457,
476
]
],
"normalized": []
},
{
"id": "74573",
"type": "Intervention_Pharmacological",
"text": [
"thyrotrophin"
],
"offsets": [
[
516,
528
]
],
"normalized": []
},
{
"id": "74574",
"type": "Intervention_Pharmacological",
"text": [
"Arginine vasopressin"
],
"offsets": [
[
582,
602
]
],
"normalized": []
},
{
"id": "74575",
"type": "Outcome_Physical",
"text": [
"side effects"
],
"offsets": [
[
904,
916
]
],
"normalized": []
},
{
"id": "74576",
"type": "Outcome_Physical",
"text": [
"basal and peak concentrations of luteinising hormone , follicle stimulating hormone , thyroid stimulating hormone , and prolactin ."
],
"offsets": [
[
1210,
1341
]
],
"normalized": []
},
{
"id": "74577",
"type": "Outcome_Physical",
"text": [
"cortisol and growth hormone responses"
],
"offsets": [
[
1347,
1384
]
],
"normalized": []
},
{
"id": "74578",
"type": "Outcome_Physical",
"text": [
"pituitary hypo-function"
],
"offsets": [
[
1584,
1607
]
],
"normalized": []
},
{
"id": "74579",
"type": "Outcome_Physical",
"text": [
"hormone values"
],
"offsets": [
[
1686,
1700
]
],
"normalized": []
},
{
"id": "74580",
"type": "Participant_Condition",
"text": [
"Nine normal volunteers and 15 patients with pituitary disorders"
],
"offsets": [
[
120,
183
]
],
"normalized": []
}
] | [] | [] | [] |
74581 | 3085131 | [
{
"id": "74582",
"type": "document",
"text": [
"Effects of mecamylamine on human cigarette smoking and subjective ratings . Multiple measures of cigarette smoking , subjective effect and physiological effect were collected during 90-min test sessions in normal volunteers . Before sessions subjects received oral doses of mecamylamine ( 2.5 , 5.0 , 10 , 20 mg ) or placebo . Each dose and placebo was given three times in a randomized block sequence . Mecamylamine increased several measures of cigarette smoking , including number of cigarettes , number of puffs per cigarette , and expired air carbon monoxide level . Mecamylamine also produced modest , dose-related decreases in standing blood pressure and increases in standing heart rate . The subjective effects produced by mecamylamine were not characteristic of those of psychoactive drugs . Mecamylamine appears to have increased cigarette smoking by decreasing the effective dose level of nicotine available from cigarette smoking ."
],
"offsets": [
[
0,
944
]
]
}
] | [
{
"id": "74583",
"type": "Intervention_Pharmacological",
"text": [
"mecamylamine"
],
"offsets": [
[
11,
23
]
],
"normalized": []
},
{
"id": "74584",
"type": "Intervention_Pharmacological",
"text": [
"oral doses of mecamylamine ( 2.5 , 5.0 , 10 , 20 mg ) or placebo"
],
"offsets": [
[
260,
324
]
],
"normalized": []
},
{
"id": "74585",
"type": "Intervention_Pharmacological",
"text": [
"placebo"
],
"offsets": [
[
317,
324
]
],
"normalized": []
},
{
"id": "74586",
"type": "Intervention_Pharmacological",
"text": [
"Mecamylamine"
],
"offsets": [
[
404,
416
]
],
"normalized": []
},
{
"id": "74587",
"type": "Intervention_Pharmacological",
"text": [
"Mecamylamine"
],
"offsets": [
[
404,
416
]
],
"normalized": []
},
{
"id": "74588",
"type": "Intervention_Pharmacological",
"text": [
"mecamylamine"
],
"offsets": [
[
11,
23
]
],
"normalized": []
},
{
"id": "74589",
"type": "Intervention_Pharmacological",
"text": [
"Mecamylamine"
],
"offsets": [
[
404,
416
]
],
"normalized": []
},
{
"id": "74590",
"type": "Outcome_Physical",
"text": [
"number of cigarettes"
],
"offsets": [
[
477,
497
]
],
"normalized": []
},
{
"id": "74591",
"type": "Outcome_Physical",
"text": [
"number of puffs per cigarette"
],
"offsets": [
[
500,
529
]
],
"normalized": []
},
{
"id": "74592",
"type": "Outcome_Physical",
"text": [
"expired air carbon monoxide level"
],
"offsets": [
[
536,
569
]
],
"normalized": []
},
{
"id": "74593",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
643,
657
]
],
"normalized": []
},
{
"id": "74594",
"type": "Outcome_Physical",
"text": [
"standing heart rate"
],
"offsets": [
[
675,
694
]
],
"normalized": []
},
{
"id": "74595",
"type": "Participant_Condition",
"text": [
"cigarette smoking"
],
"offsets": [
[
33,
50
]
],
"normalized": []
},
{
"id": "74596",
"type": "Participant_Condition",
"text": [
"normal"
],
"offsets": [
[
206,
212
]
],
"normalized": []
}
] | [] | [] | [] |
74597 | 3089050 | [
{
"id": "74598",
"type": "document",
"text": [
"Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon ."
],
"offsets": [
[
0,
1066
]
]
}
] | [
{
"id": "74599",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74600",
"type": "Intervention_Pharmacological",
"text": [
"diamorphine"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "74601",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74602",
"type": "Intervention_Pharmacological",
"text": [
"diamorphine"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "74603",
"type": "Intervention_Pharmacological",
"text": [
"caudal injection"
],
"offsets": [
[
219,
235
]
],
"normalized": []
},
{
"id": "74604",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74605",
"type": "Intervention_Pharmacological",
"text": [
"diamorphine"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "74606",
"type": "Intervention_Pharmacological",
"text": [
"diamorphine"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "74607",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74608",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
61,
72
]
],
"normalized": []
},
{
"id": "74609",
"type": "Intervention_Pharmacological",
"text": [
"diamorphine"
],
"offsets": [
[
77,
88
]
],
"normalized": []
},
{
"id": "74610",
"type": "Outcome_Physical",
"text": [
"analgesia"
],
"offsets": [
[
7,
16
]
],
"normalized": []
},
{
"id": "74611",
"type": "Outcome_Physical",
"text": [
"analgesia"
],
"offsets": [
[
7,
16
]
],
"normalized": []
},
{
"id": "74612",
"type": "Outcome_Adverse-effects",
"text": [
"Side effects"
],
"offsets": [
[
662,
674
]
],
"normalized": []
},
{
"id": "74613",
"type": "Outcome_Adverse-effects",
"text": [
"some degree of urinary retention"
],
"offsets": [
[
816,
848
]
],
"normalized": []
},
{
"id": "74614",
"type": "Outcome_Adverse-effects",
"text": [
"temporary catheterisation"
],
"offsets": [
[
874,
899
]
],
"normalized": []
},
{
"id": "74615",
"type": "Outcome_Physical",
"text": [
"."
],
"offsets": [
[
38,
39
]
],
"normalized": []
},
{
"id": "74616",
"type": "Participant_Sample-size",
"text": [
"Seventy-three"
],
"offsets": [
[
91,
104
]
],
"normalized": []
},
{
"id": "74617",
"type": "Participant_Condition",
"text": [
"elective perianal surgery"
],
"offsets": [
[
125,
150
]
],
"normalized": []
}
] | [] | [] | [] |
74618 | 3089263 | [
{
"id": "74619",
"type": "document",
"text": [
"Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter ( interim report ) ."
],
"offsets": [
[
0,
130
]
]
}
] | [
{
"id": "74620",
"type": "Intervention_Pharmacological",
"text": [
"amiodarone and disopyramide"
],
"offsets": [
[
14,
41
]
],
"normalized": []
},
{
"id": "74621",
"type": "Outcome_Physical",
"text": [
"control of paroxysmal atrial fibrillation and atrial flutter"
],
"offsets": [
[
49,
109
]
],
"normalized": []
},
{
"id": "74622",
"type": "Participant_Condition",
"text": [
"control of paroxysmal atrial fibrillation and atrial flutter"
],
"offsets": [
[
49,
109
]
],
"normalized": []
}
] | [] | [] | [] |
74623 | 3098341 | [
{
"id": "74624",
"type": "document",
"text": [
"Dose dependent response of symptoms , pituitary , and bone to transdermal oestrogen in postmenopausal women . The effect of the plasma oestradiol concentration on climacteric symptoms , gonadotrophin release , and bone resorption was studied in three groups of postmenopausal women given 0.025 mg , 0.05 mg , or 0.1 mg transdermal oestradiol daily . There was a dose related reduction in symptoms , plasma follicle stimulating hormone concentration , and urinary calcium and hydroxyproline excretion . The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l ( 41 pg/ml ) . Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely to increase the risk of side effects without conferring any additional benefit ."
],
"offsets": [
[
0,
920
]
]
}
] | [
{
"id": "74625",
"type": "Intervention_Pharmacological",
"text": [
"transdermal oestradiol"
],
"offsets": [
[
319,
341
]
],
"normalized": []
},
{
"id": "74626",
"type": "Intervention_Pharmacological",
"text": [
"oestradiol"
],
"offsets": [
[
135,
145
]
],
"normalized": []
},
{
"id": "74627",
"type": "Outcome_Physical",
"text": [
"climacteric symptoms"
],
"offsets": [
[
163,
183
]
],
"normalized": []
},
{
"id": "74628",
"type": "Outcome_Physical",
"text": [
"gonadotrophin release"
],
"offsets": [
[
186,
207
]
],
"normalized": []
},
{
"id": "74629",
"type": "Outcome_Physical",
"text": [
"bone resorption"
],
"offsets": [
[
214,
229
]
],
"normalized": []
},
{
"id": "74630",
"type": "Outcome_Physical",
"text": [
"reduction in symptoms"
],
"offsets": [
[
375,
396
]
],
"normalized": []
},
{
"id": "74631",
"type": "Outcome_Physical",
"text": [
"plasma follicle stimulating hormone concentration"
],
"offsets": [
[
399,
448
]
],
"normalized": []
},
{
"id": "74632",
"type": "Outcome_Physical",
"text": [
"urinary calcium and hydroxyproline excretion"
],
"offsets": [
[
455,
499
]
],
"normalized": []
},
{
"id": "74633",
"type": "Outcome_Physical",
"text": [
"relation of the response to plasma oestradiol values"
],
"offsets": [
[
506,
558
]
],
"normalized": []
},
{
"id": "74634",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
864,
876
]
],
"normalized": []
},
{
"id": "74635",
"type": "Outcome_Other",
"text": [
"additional benefit"
],
"offsets": [
[
900,
918
]
],
"normalized": []
},
{
"id": "74636",
"type": "Participant_Condition",
"text": [
"postmenopausal women ."
],
"offsets": [
[
87,
109
]
],
"normalized": []
}
] | [] | [] | [] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.